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Abstract 
Background: Glioblastoma multiforme is a rapidly fatal disease. Despite 
recent understanding of their molecular basis and advances in standard therapy, most 
patients die within 2 years of diagnosis of their disease. Apoptosis is a safe way to 
eliminate cancer cells without systemic inflammation or local cytotoxicity. We 
hypothesize that amplication of apoptotic cell death could be observed i f both intrinsic 
and extrinsic pathways are triggered simultaneously. Lovastatin and Tumor Necrosis 
Nactor Related Apoptosis-Inducing Ligand (TRAIL) were used in our study. 
3-hydroxy-S-methyIgutaryl Co A reductase inhibitors, commonly known as HMG-Co 
A reductase inhibitors or statin, is a widely used cholesterol-lowering agent for the 
prevention of atherosclerotic cardiovascular diseases. HMG-Co A reductase 
inhibitors have been reported for their pleiotropic properties as anticancer agents 
based on preclinical evidence of their pro-apoptotic effects through intrinsic pathway. 
Tumor necrosis factor related apoptosis-inducing ligand (TRAIL), is a member of the 
tumor necrosis factor alpha family with preferential induction of cancer cell death 
through the extrinsic pathway. By combining these two low-cytotoxic agents, a new 
stragety for glioblastoma treatment may form. 
Objectives: There were two objectives in this study: 1. To investigate the effects of 
Lovastatin-induced apoptosis and analyze lovastatin-modulated gene expression 
profiles in GBM cell lines. 2. To test the validity of our hypothesis by using 
lovastatin and TRAIL. 
Methods: We first examined anti-proliferation effects by lovastatin using MTT 
> 
assay. Apoptotic cell death and necrosis were determined by Annexin V and 
Propidium Iodide (PI) staining using flow cytometry. PI staining was employed for 
cell cycle analysis. Codelink microarray chips were used to determined gene 
I 
expression profiles modulated by lovastatin. Synergistic effects by lovastatin and 
TRAIL were examined by various assays: MTT assay for synergistic anti-proliferation, 
synergistic apoptotic cell death by flow cytometry, synergistic DNA-fragmentation 
using ELISA kit, and TRAIL receptor expression using RT-PCR. 
Results: At 5uM, 20uM and 40uM concentrations, lovastatin showed significant 
anti-proliferation effects in human glioblastoma cell lines A172, M059J and M059K; 
the major mode of cell death was apoptosis at 72 hours. Cells arrested in G q - G i phase 
were significantly increased by 20uM lovastatin after 48 hours incubation time. 
There were large number of genes regulated by 20uM lovastatin at 12 and 36 hours 
incubation time but only few of them were modulated simultaneously. The distinct 
genes were NDRGl , KLF2, ARHB, DSIPI, TIMP3 (up-regulation with more than 
three folds, simultaneously), and CTGF, CYR61, BDNF, SNK (down-regulation with 
more than three folds, simultaneously). M059J and M059K are resistant to 
TRAIL-induced cell death, however, lovastatin successfully sensitized glioblastoma 
to TRAIL-induced cell death. Lovastatin and TRAIL worked synergistically on 
human glioblastoma cells, in the aspect of both anti-proliferation and apoptotic injury. 
DNA fragmentation was also observed in these glioblastoma cells with synergistic 
effects. RT-PCR revealed that lovastatin unevenly up-regulated the expression of 
TRAIL receptor 2，suggested that lovastatin sensitized glioblastoma independent to 
TRAIL-induced apoptosis because serum free control also showed up-regulation of 
TRAIL receptor 2 while glioblastoma cells remained resistant to TRAIL-induced cell 
death.-» 
• Conclusion: Lovastatin significantly induced apoptosis and preformed 
anti-proliferation effects in these glioblastoma cells. The observed synergism 
supported our hypothesis as a novel treatment strategy in human glioblastoma. The 
II 
modulated genes may reveal the mechanism how lovastatin sensitized glioblastoma 
cells to TRAIL-induced apoptosis and provide informations to elucidate the apoptotic 









腫瘤細胞通過內在途徑(intrinsic pathway)及外在途徑(extrinsic pathway)誘發腫瘤 
細胞调亡，進而達到治療的效果。羅伐史達丁（Lovastatin)及腫瘤壞死因子相關 
调亡誘導配體(Tumor necrosis factor related apoptosis-inducing ligand, TRAIL)是用於 
這次硏究的媒體，羅伐史達丁是刺激細胞调亡內在途徑的媒體；而腫瘤壞死因子 
相關调亡誘導配體則用於刺激細胞调亡外在途徑。羅伐史達丁是一種還原酶抑制 
劑（HMG CoA reductase inhibitors)，其學名稱爲三經基三甲基戊二酸單酰輔酶A 
還原酶抑製劑（3-hydroxy-3-methylgutaryl Co A reductase inhibitors)；廣泛地用於抑 











實驗方法：使用細胞增殖及細胞毒性檢測試劑（MTT Cell Proliferation and 
Cytotoxicity Assay)測試羅伐史達丁對多型性神經膠母細胞瘤細胞的抑制作用。 
流式細胞術雙標記(AnnexinV/P.I.)法檢測則用於細胞调亡及細胞壞死的分類。碑 
化丙D定(propidium iodide, P.I.)染色法用於細胞週期檢定。使用生物芯片技術 
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X I V 
Chapter One: Introduction and Literature Review 
1.1 Cancer in General 
Cancer is a disease entity characterized by uncontrolled cell proliferation, which 
grows continuously and divides without restraint, eventually spreading throughout 
the body and interfering with the function of normal tissues and organs, and 
progressively leading to death. In the year 2000, cancer was diagnosed in 10 
million people worldwide and caused 6.2 million deaths, an increase of about 22% 
since 1990. Cancer causes 10% of all deaths worldwide and is second only to 
cardiovascular disease as the main cause of death in developed countries (Parkin et 
al. 2001). Cancer does not represent a single disease but a huge collection of 
pathologic varieties with as many different manifestations as there are tissues and 
cell types in human body. Tumorigenesis is a multistep process, which reflects 
genetic alterations that provoke progressive transformation from normal cells to 
highly malignant states. During tumorigenesis, individual cells loses of growth 
control and acquires capabilities to escape from our body systematic control. 
There are several strategies that cancer cells must acquired at least one of them 
including self-sufficiency in growth signals, insensivity to antigrowth signals, 
1 
evading apoptosis, sustained angiogenesis, limitless replicative potential, tissue 
invasion and metastasis (Hanahan and Weinberg 2000). The distinctions among 
the various kinds of cancer are of great practical importance, not only there are 
numerous types of cancer, but individual cancers of the same type sometimes behave 





Gliomas are a group of central nervous system (CNS) neoplasms with distinct 
histologic characteristics, comprising almost sixty percent of total human CNS 
malignancies with a peak incidence at around age 60. In international comparisons, 
glioma rates among whites in Canada, the United States, Europe, the United 
Kingdom, and Australia are relatively similar, and rates are low in Asian populations. 
In Chinese populations, the incidence is 30 and 15 persons per hundred thousands 
people in male and female, respectively. Despite the fact that gliomas are derived 
from astrocytes, oligodendrocytes, or ependymal cells, significant variations exist 
between them that may indicate the genes involved in their genesis (Naomi Allen et 
al. 2005). Figure 1-2-1 and 1-2-2 showed CNS cancer incidences worldwide and 
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Figure 1. 1 CNS Cnacer incidence worldwide 
CNS cancer incidence rate per 100,000 worldwide (Globocan 2002). 
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1.2.1 Types of Glioma 
There are generally three types of glial tumors which are named after their putative 
cell type of their origin: Astrocytomas, oligodendrogliomas and ependymomas. Al l 
of these glial tumors can be either low grade or high grade. Glial tumors are 
graded pathologically, on the basis of the most malignant area identified, according 
to either the World Health Organization (WHO) system or the St. Anne-Mayo 
system, both of which are based on the presence or absence of nuclear atypia, 
mitosis, microvascular proliferation, and necrosis (Kleihues et al. 2002). Precise 
pathological grading is important because it defines treatment and prognosis. The 
histologic features of the tumor and the patient's age and performance status are 
major prognostic factors and have more influence than any specific therapy on the 
outcome (Scott et al. 1999). 
1.2.1.1 Astrocytomas 
Astrocytomas that account for the majority of brain tumors can be either low grade 
or high grade. High-grade cases affect the ubiquitous star-shaped cells that provide 
extensive structural and physiological support of neurons in the central nervous 
6 
system (CNS). Astrocytomas are tumors found in young adulthood, with a peak 
incidence in the third to fourth decade of life (DeAngelis 2001). While malignant 
astrocytoma, including anaplastic astrocytoma and glioblastoma multiforme, are the 
most common glial tumors and the peak age at onset for anaplastic astrocytomas is 
the fourth or fifth decade, whereas glioblastomas usually present in the sixth or 
seventh decade. These type of glioma comprise a wide range of neoplasm that 
differ in their location within the CNS, age and gender distribution, growth potential, 
extent of invasiveness, morphological features, tendency for progression, and 
clinical course. There is increasing evidence that these differences reflect the type 
and sequence of genetic alterations acquired during the process of transformation. 
Molecular genetic data have suggested that individual histologically defined types of 
astrocytomas are even more diverse at a biological level. The identification of 
genetic alterations in astrocytomas has led to the recognition that the nonrandom 
series of genetic changes reflects increasing malignancy and clinical grade. 
WHO gives details information on grading astrocytomas: 
a. WHO grade I，or pilocytic astrocytoma, the most common brain tumor in 
children and primarily a pediatric tumor, rarely undergoes neoplastic 
transformation. Even though the most benign of the astrocytomas, depending 
on location, they can interfere with vital sensory functions and often recur after 
7 
apparently complete resection. 
b. WHO grade II ’ or fibrillary astrocytomas account for 25% of all gliomas and are 
infiltrative in nature. Despite their relative lack of aggressive histologic features, 
low-grade astrocytomas in adults are fatal in the great majority of patients. 
c. WHO grade III，or anaplastic malignant astrocytomas, are highly malignant 
gliomas and have an increased tendency to progress to glioblastoma. 
d. WHO grade IV, diffuse astrocytoma or glioblastoma multiforme, is a highly 
malignant brain tumor and typically affects adults. This type of glioma has 
poor prognosis, in part, because the poorly defined tumor rapidly spreads to 
other regions of the brain. These are the most common intracranial neoplasm 
and account for more than 60% of all primary brain tumors. 
1.2.1.2 Oligodendrogliomas 
This glioma develops from oligodendrocytes, which are cells that produce the lipid 
covering of the axons of nerve cells. The type of tumor occurs normally in the 
cerebrum, particularly in the frontal or temporal lobes, and is more common in 
adults than in children and in men more than women (trend of all glioblastomas). 
Prevoiusly, the distinction between an oligodendroglial tumor and astrocytic tumor 
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had no therapeutic importance, however with the recent recognition that 
oligodendrogliomas are uniquely sensitive to chemotherapy; neuropathologists have 
made a greater effort to identify these uncommon neoplasms. Recently finding 
showed oligodendroglimas represent approximately 20% of glial neoplasms (Jeuken 
et al. 2004). 
1.2.1.3 Ependymomas 
These tumors develop from ependymal cells, which line the ventricles of the brain 
and the central canal of the spinal cord. Ependymomas account for 4-6% of all 
brain tumors and occur mainly up to the age of 20 years. However, this tumor only 
forms a minority in total number of glioma cases. 
The grading of oligodendrogliomas and ependymomas differs slightly from that of 
astrocytomas. Oligodendrogliomas are graded using a two-tiered system, where 
well-differentiated tumors are considered to be Grade I I and anaplastic variants are 
Grade III. Additionally, some acknowledge the existence of a grade IV 
oligodendroglioma marked by features similar to GBM. Ependymomas are 
essentially graded in the same fashion (well-differentiated: Grade II; anaplastic: 
Grade III) (Kelley et al. 2005). 
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1.2.2 Glioblastoma Multiforme (GBM) 
Glioblastoma multiforme (GBM) is the most common and most aggressive of the 
primary brain tumors. World Health Organization (WHO) classified GBM as a 
Grade IV astrocytoma. GBM is an anaplastic, highly cellular tumor with poorly 
differentiated cells, occasional multinucleated cells, nuclear atypia, anaplasia, 
endothelial proliferation and pseudoplaisading necrosis. The incidence of primary 
brain tumors has increased dramatically over the past several decades. More than 
half of the 18,000 patients diagnosed with malignant primary brain tumors in the 
United States of America each year are glioblastoma multiforme, which is the most 
common primary brain tumor variant in adults. Although GBM occurs in patients 
of all ages, the incidence is highest in the elderly. GBM is slightly more common 
in whites and men (Reardon and Wen 2006). Signs and symptoms of GBM depend 
on the location, size and rate of growth of the tumor and they include headaches, 
seizures, focal neurologic deficits, and may changes in mental status (Grossman and 
Batara 2004b). Despite recent advanced developments in the technology and 
technique of neurosurgery, radiotherapy and introduction of novel chemotherapeutic 
agents, the median life expectancy for patients with glioblastoma remains 
unchanged: kills patients within a year after diagnosis, only five percent of patients 
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or fewer wi l l be alive at five years. Favorable prognostic factors include young 
age, good Kamofsky performance status (KPS) score, histology, absence of 
extensive necrosis, and a small residual tumor after surgical debulking (Reardon and 
Wen 2006;Kleihues et al. 2002;Grossman and Batara 2004a). 
1.2.3 Molecular Biology of GBM 
There are two subsets of GBM derived from astrocytic lineage that have been 
recognized on the basis of the clinical and genetic makeup of the tumor (figure 
1-2-3.-1). Primary GBM develops de novo from glial cells, typically has a clinical 
history of less than six months, and is most common in older patients. Secondary 
GBM develops over months or years from preexisting low-grade astrocytomas and 
predominantly affects younger patients. GBM manifest a complex interplay of 
multiple, nonrandom genetic events that encompass activation of proto-oncogenes 
and inactivation of tumor suppressor genes, which in turn lead to aberrant 
expression of growth factor receptors and their ligands. Genetically, glioblastomas 
display losses in parts of chromosomes 6, 9，10，13, 17, 19，and 22, as well as gains 
or amplifications of chromosomes 1，5, 7，8, 11，and 12. Mutations of tumor 
suppressor genes such as CDKN2, PTEN, D M B T l , and TP53 as well as over 
11 
expression of EGFR, N-myc, PDGFR, MDM2, and gli have also been identified 
(Biemat et al. 1997;Louis and Gusella 1995;Rasheed et al. 1999;von Deimling et al. 
1995;Wooten et al. 1999). Primary, or de novo GBM occurs commonly in elderly 
patient. They exhibit overexpression (80% of cases) or amplicication (40% of 
cases) of the EGFR gene, which is located on the short arm of chromosome 7. 
Other genetic alterations include overexpression of the MDM2 (murine double 
minute 2) gene, loss of PI6，and mutation of PTEN (phosphatase and tensin 
homology deleted from chromosome 10) and retinoblastoma (Rb) genes on 
chromosomes 12, 9，10，and 13，respectively. Deletions in primary GBMs usually 
involve the CDKN2/pl6 gene (Jen et al. 1994;Schmidt et al. 1994), and three 
mutations have been described in primary GBMs with allelic loss of chromosome 9p 
(Moulton et al. 1995). The secondary type, on the other hand, occurs in younger 
population that shows histologic progression from low-grade astrocytoma. 
Numerous genetic alterations accumulate and become linked together sequentially to 
parallel malignant progression. Mutation or inactivation of TP53 gene and 
overexpression of PDGF ligands and receptors play a crucial role in the initial steps 
of the evolution (Kleihues and Ohgaki 1999). On the other hand, the subsequent 
loss of chromosomes 1，9p, 13q, and 19q is closely related to the events in tumor 
progression. The final transition from anaplastic astrocytoma to secondary GBM 
12 
requires loss of chromosome lOq, where the PTEN gene resides, although this event 
does not occur as common as in the primary GBM. 
> 
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Figure 1. 3 Formation of primary and secondary GBM 
Pathway leading to the formation of primary and secondary glioblastoma multiforme 
(GBM). Multiple genetic alternations are involved in the development of primary 
and secondary GBM. 
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1.2.4 Current Treatment for GBM 
Multi-discipline treatment for GBM is needed. Surgery, radiotherapy, and 
chemotherapy are accepted therapeutic strategy for glioblastoma multiforme. 
Resection by surgery is the initial intervention and the front line for histological 
diagnosis, relieve symptoms, provide tissue for continued studies for the disease, 
and extend patient survival by achieving maximal cytoreduction without morbidity. 
Radiotherapy (RT) has been used in the treatment of neoplasms of the brain for the 
last sixty years and the first promising data demonstrating the efficacy of 
radiotherapy after surgery for GBM in clinical trial was reported in 1976. Surgery 
is followed by involved-field radiotherapy provide significant prolongation of 
survival. There have been many efforts to intensify radiotherapy including use of 
radiosensitizers, brachytherapy, and radioactive seeds implanted in the tumor bed, 
however, none of them improved survival. Chemotherapy can be administered at 
different time points relative to other treatments or be given concurrent with other 
therapies such as radiation therapy. Chemotherapy consistently increases the 
proportion of long-term survivors form less than 5 % to approximately 15 to 20 % 
(Nieder et al. 2006). Different chemotherapeutic strategies are available, and the 
agents can be given by themselves or in combination. Chemotherapeutic agents can 
be categorized as cytotoxic or cytostatic. Cytotoxic agents result in tumor cell (and 
actively dividing cells) death by mechanisms including DNA alkylation, DNA cross 
linkage, DNA strand breaks, and mitotic spindle disruption. Temozolomide, 
BCNU are examples of cytotoxic agents. Cytostatic agents alter tumor biology by 
inhibiting tumor growth (also normal tissue cells), spread, or both, but not ki l l tumor 
cells directly. The mechanisms of action including anti-angiogenesis, 
pro-differentiation, growth factor pathway disruption, and impair invasion. 
15 
Thalidomide and Tamoxifen are cytostatic agents. Increasingly, cytotoxic agents 
are being combined with cytostatic agents or agents that inhibit drug resistance. 
In recent studies, there is a fashion that chemotherapeutic agents combined with 
non-chemotherapeutic agents (neither cytostatic nor cytotoxic) such as HMG-Co A 
reductase inhibitors that showed obvious in vitro apoptotic effects in varieties of 
cancer cell including in glioma cells. 
> 
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1.3 HMG-Co A reductase inhibitors 
Lovastatin, is a 3-hydroxy-3-methyIgutaryl Co A reductase inhibitor, commonly 
referred to as the statin. This reductase inhibitor is a white, nonhygroscopic 
crystalline powder that insoluble in water; and is isolated from a strain of 
Aspergillus terreus. HMG-Co A reductase inhibitors are widely used in 
hypercholesterolaemia and preventing cardiovascular events, in which they inhibit 
the rate-limiting step in the mevalonate pathway and thus prevent endogenous de 
novo synthesis of cholesterol (Goldstein and Brown 1990). HMG-Co A reductase 
inhibitors decrease hepatic cholesterol production, which in turn leads to increase 
LDL receptor turnover, enhances hepatic LDL-cholesterol uptake, and ultimately 
decreases the plasma LDL-cholesterol level (Ness et al. 1996). Overall, plasma 
LDL-cholesterol levels are substantially decreased by 20-60%, along with mild 
elevation in high-density 1 ipoprotein-cholesterol and reduction in triglyceride levels. 
Numerous multicentered trials have demonstrated that the efficacy of lovastatin in 
reducing mortality and morbidity in both primary and secondary prevention of 
coronary artery disease (Downs et al. 1998). The rate-limitig step of the 
mevalonate pathway is the modification of HMG-Co A to mevalonate that is 
catalyzed by HMG-Co A reductase. The mevalonate pathway leads to the 
production of various downstream products that are critical for many different 
cellular functions. These products include isoprene units incorporated into sterol 
and 'non-sterol compounds such as cholesterol, dolichol, ubiquinone, 
isopentenyladenine, GGPP, and FPR Many of cellular functions such as membrane 
integrity, cell signaling, protein synthesis and cell cycle progression are regulated by 
the downstream products. Dolichol works as a carrier molecule of 
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oligosaccharides in N-linked protein glycosylation for the production of 
glycoproteins. Cholesterol is essential in maintaining cellular membrane structure 
and integrity, it is also serves as a precursor for the synthesis of steroid hormones 
and bile acid (Edwards and Ericsson 1999). Isopentenyladenine is an essential 
substrate for the modification of certain tRNAs. Ubiquinone is involved in 
mitochondrial respiration (Goldstein and Brown 1990). Blockade of the 
mevalonate pathway by HMG-Co A reductase inhibitors results in decreased levels 
of mevalonate and its downstream products thus may produce significant influences 
on many important cellular functions. 
1.3.1 Pharmacology 
The HMG-Co A reductase inhibitor is fungal derivatives and a prodrug that 
converted into its active forms (beta-hydorxy acid) in the liver. Amount different 
kinds of HMG-Co A reductase inhibitors, only lovastatin and simvastatin are showed 
to cross the blood-brain and placental barriers (American Medical Association 1995). 
The bioavailability of the HMG-Co A reductase inhibitors is limited by extensive 
first-pass metabolism. The cytochrome P450 (CYP) system is responsible for the 
majority of the clearance of this class of drugs. Therefore, inhibitors to isozymes 




Acetyl-CoA ^ 3-hydroxy-3-methylglutaryl-CoA 
/ (HMG-CoA) 
•/ase /HMG-COA 
T / synthase if ^MG-CoA reductase 
Acetoacetyl-CoA Mevalonic acid statins 
I ^ A T P 
y Mevalonate kinase 
Mevalonate-6-phosphate 
，^ Phosphome valonate kinase 
Mevalonate-6-pyrophosphate 
Isopentenyl-PP i Me^/afonafe-5-pyrophosphate 
isomerase decarboxylase 
Dimethylallyl-PP ~ lsopentenyl-5-pyrophosphate (PP) 
/ Farnesyf-PP synthase 
\ y i . yj BISPHOSPHONATES 
^ ^ Geranyl PP 
/ \ Farnesy!-PP synthase 
/ \ yj BISPHOSPHONATES 
Geranylgeranyl-PP Farnesyl-PP 
P p I S ^ J " ^ ' " / / 4 Squalene synthase 
/ Squalene 
y / / I Squalene 
y / / y monooxygenase 
/ J 2,3 oxidosqualene 
” ^ I 『 " r « NADPH - J Squalene 
A HEME A t epoxydase 
PRENYLATED DOLICHOL Lanosterol 
P R O T E I N S U B I Q U I N O N J 19 reactions 
CHOLESTEROL 
Figure 1. 4 The Me valonate pathway 
http://en.wikipedia.org/wiki/HMG-CoA_reductase_pathway 
19 
1.3.2 Epidemiological link between HMG-Co A Reductase Inhibitors and 
Cancer 
With the exponential growth of using HMG-Co A reductase inhibitors in the past 15 
years, their long term safety has become more apparent. The major concern is that 
HMG-Co A reductase inhibitors may bear intrinsic carcinogenic properties. The 
concern originated from studies of HMG-Co A reductase inhibitors in animal models 
and from epidemiological data in humans. There was a piece of evidence showing 
the potential carcinogencity of lipid lowering drugs on rodents and concluded that 
HMG-Co A reductase inhibitors initiate or promote cancer in rodents (Newman and 
Hulley 1996). The evidence was additionally supported by human cohort studies, 
which have seemingly demonstrated that low cholesterol levels were associated with 
an increase in cancer deaths (Kritchevsky 1992). Despite the anxiety arising from 
these studies, meta-analysis of randomized controlled trials of cholesterol reduction 
did not reveal any significant increase in cancer mortality. Long term follow up 
data from major trials on secondary prevention of coronary artery disease with 
HMG-Co A reductase inhibitors provide reassurance regarding the risk of cancer 
from low serum levels of cholesterol or the use of HMG-Co A reductase inhibitors. 
Meta-analyses of major randomized controlled trials demonstrated no association 
between the use of HMG-Co A reductase inhibitors and the risk of fatal and nonfatal 
cancers (Bjerre and LeLorier 2001). Therefore, on the population level, HMG-Co 
A reductase inhibitors appear to be safe enough without an increase in cancer 
incidence. 
With contradiction to above view points, a piece of new evidence from nested 
case-control study demonstrated that users of HMG-Co A reductase inhibitors were 
28% less likely than users of bile acid-binding resins to be diagnosed with cancer 
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(Blais et al. 2000). A l l specific cancer sites under study were found to be not or 
inversely associated with the use of HMG-Co A reductase inhibitors. In addition to 
providing additional reassurance about the safety of HMG-Co A reductase inhibitors, 
this result also generated the hypothesis that these agents may have 
chemopreventive properties, which merit extra-evaluation in this area. 
Furthermore, increasing evidence suggests that statins might be useful for cancer 
prevention and treatment through their interactions with essential cellular functions, 
such as cell proliferation and differentiation. For example, both in vitro and in vivo 
studies have demonstrated that statins inhibit tumor growth and induce apoptosis in 
a variety of tumor cells, including melanoma (Shellman et al. 2005), neuroblastoma 
(Girgert et al. 1999), rhabdomyosarcoma (Werner et al. 2004), and leukemia cell 
lines (Dimitroulakos et al. 2000). Additionally, several clinical trials have also 
assessed the antitumor activity of statins (Knox et al. 2005;Minden et al. 
2001;Lamer et al. 1998) on breast, colon, and prostate cancer (Poynter et al. 
2005;Cauley et al. 2003;Shannon et al. 2005). HMG-Co A reductase inhibitors 
could become a new agent for both chemopreventive and therapeutic purposes. 
1.3.3 Current research of HMG-Co A reductase inhibitors in cancer therapy 
1.3.3.1 Inhibition of tumor cell growth 
HMG-Co A -reductase inhibitors block the production of mevalonate, which is a » 
‘ precursor of several major products regulating the cell cycle. Dolichol has a 
stimulatory effect on DNA synthesis and is linked to several tumor cell proteins 
(Wejde et al. 1998). GPP and FPP cause isoprenylation of the intracellular 
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G-proteins Ras and Rho, which in turn regulate the signal transduction of several 
membrane receptors crucial for the transcription of genes involved in cell 
proliferation, differentiation, and apoptosis. HMG-Co A reductase inhibitors have 
been showed to stabilize the cell cycle kinase inhibitors p21 and p27, and to arrest 
breast cancer cell lines in the Gi phase. HMG-Co A reductase inhibitors have also 
been demonstrated to inhibit Ras- and Rho-mediated cell proliferation. These 
observations have generated several hypothesis that HMG-Co A reductase inhibitors 
might inhibit the growth of a variety of tumor cell types, including prostate, gastric, 
and pancreatic carcinoma, neuroblastoma, glioblastoma, mesothelioma, melanoma, 
and acute myeloid leukemia cells (Sumi et al. 1992; Feleszko et al. 2002; Newman 
et al. 1997; Newman et al. 1994; Lewis et al. 2005). Latest evidence showed that 
HMG-Co A reductase inhibitors induced apoptosis linked with membrane 
famesylated Ras small G protein depletion, rather than geranylated Rho protein 
(Matzno et al. 2005). However, normal cells appear to be more resistant to the 
antiproliferative effects of HMG-Co A reductase inhibitors relative to tumor cells, 
which are much more likely to proliferate (Dimitroulakos et al. 2001; Kusama et al. 
2001). 
1.3.3.2 Inhibition of Angiogenesis 
Angiogenesis plays a critical role in primary tumor growth and metastasis (Folkman 
1995). HMG-Co A reductase inhibitors have been reported to both stimulate and > 
“ inhibit blood vessel formation depending upon the tumor cell type (Frick et al. 2003). 
There is growing evidence indicating the effects of HMG-Co A reductase inhibitors 
on angiogenesis are concentration dependent. In low concentrations (0.5 mg/kg 
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per day) of HMG-Co A reductase inhibitors enhanced endothelial cell proliferation, 
whereas high concentrations (2.5 mg/kg per day) significantly inhibited 
angiogenesis (Weis et al. 2002). 
1.3.3.3 Anti-invasive effects of HMG-Co A reductase inhibitors 
HMG-Co A reductase inhibitors have also been showed to inhibit cell signaling 
pathways associated with the invasive and metastatic properties of cancer. Both in 
vitro and in vivo studies have demonstrated that HMG-Co A reductase inhibitors 
reduce liver tumor formation and growth of established liver metastases in 
pancreatic cancer cells (Kusama et al. 2002). Similarly, the anti-invasive effect of 
HMG-Co A reductase inhibitors on an aggressive breast cancer cell line was 
observed with RhoA delocalization from the cell membrane, resulting in 
disorganization of the actin fibers and disappearance of focal adhesion sties 
(Denoyelle et al. 2001). The importance of RhoA inactivation in both of these 
inhibitory effects was supported by their reversal by GGPP. Furthermore, 
HMG-Co A reductase inhibitors were also showed to induce inactivation of nuclear 
factor K B in a RhoA inhibition-dependent manner, resulting in a decrease in 
urokinase and matrix metalloproteinase-9 expressions, which are important for cell 
migration. HMG-Co A reductase inhibitors have also been showed to suppress 
lung metastasis of renal and mammary carcinoma cells (Farina et al. 2002;Horiguchi 
et al. 2004), as well as liver metastasis of colon adenocarcinoma cells (Mehta et al. > 
‘ 1998). 
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1.3.3.4 Apoptosis induction by HMG-Co A reductase inhibitors 
Several experimental cancer models have showed that HMG-Co A reductase 
inhibitors induce apoptosis in variety of tumor cells including rhabdomyosarcoma, 
melanoma, glioma, and squamous carcinoma cells (Dimitroulakos et al. 
2001;Kikuchi et al. 1997a;Shellman et al. 2005;Wemer et al. 2004). Tumor cells 
themselves differ significantly in their sensitivity to HMG-Co A reductase 
inhibitors-induced cell death, for example, acute myeloblastic leukemia (AML) cells 
(Dimitroulakos et al. 2001;Kikuchi et al. 1997a; Shellman et al. 2005; Dimitroulakos 
et al. 1999) and neuroblastoma cells (Dimitroulakos et al. 2001;Kikuchi et al. 
1997a;Shellman et al. 2005 ；Dimitroulakos and Yeger 1996) seem to be particularly 
sensitive to HMG-Co A reductase inhibitors-induced apoptosis, whereas acute 
lymphoblastic leukemia cells are relatively insensitive. The proposed mechanisms 
of HMG-Co A reductase inhibitors-induced apoptosis include an upregulation of 
proapoptotic protein expression such as Bcl-2 family members bim, bid and bax 
(Jiang et al. 2004b), combined with decreased anti-apoptotic protein Bcl-2 
expression (Agarwal et al. 1999) due to the depletion of geranylgeranylated proteins. 
This suggested that mitochondrial-mediated apoptosis is the major event induced by 
HMG-Co A reductase inhibitors. Add-back experiments of downstream products 
of the mevalonate pathway were conducted on human A M L cells. Apoptosis 
induced by HMG-Co A reductase inhibitors were abrogated by mevalonate and 
GGPP, however, other products of the mevalonate pathway including cholersterol, » 
• squalene, dolichol, and ubiquinone did not affect HMG-Co A reductase 
inhibitors-induced apoptosis in A M L cells. This study showed that mevalonate is 
the key component for executing apoptosis of tumor cells. 
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Figure 1. 5 The intrinsic and extrinsic pathway 
HMG-Co A reductase inhibitors-induced apoptosis is most likely 
、through mitochondrial (intrinsic) pathway, while TRAIL triggers 
» 
extrinsic pathway ((MacFarlane and Williams 2004). 
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1.3.4 In vivo efficacy and synergistic effects 
HMG-Co A reductase inhibitors have been showed to have in vivo anti-tumor effects 
in different animal models. Efficacy in chemoprevention has been showed in 
radiation-induced mammary tumorigenesis (Inano et al. 1997) and chemical-induced 
colon tumorigenesis in rodent models (Narisawa et al. 1996a;Narisawa et al. 1996b). 
HMG-Co A reductase inhibitors were also demonstrated to have significant 
antiproliferative effect on human myeloid leukemia cells in severe combined 
immunodeficient mice (Clutterbuck et al. 1998), inoculation of glioma cells in nude 
mice (Kikuchi et al. 1997b), or syngeneic murine lung tumor (Hawk et al. 1996). 
In addition, HMG-Co A reductase inhibitors were showed to potentiate the antitumor 
effect of doxorubicin in three tumor models in vivo while attenuating its 
cardiotoxicity (Feleszko et al. 2000). They were also able to potentiate the 
antitumor effect of tumor necrosis factor alpha via inhibition of tumor-induced 
angiogenesis in a murine tumor model (Feleszko et al. 1999). 
New optimism regarding the use of HMG-Co A reductase inhibitors as 
anti-neoplastic agents combined with chemotherapeutic agents come from recent 
studies. HMG-Co A reductase inhibitors interact additively or synergistically with 
other chemotherapeutic agents such as 5-fluorouracil on colon cancer cells 
(Agarwal et al. 1999), N,N'bis(2choloroethyl)-N-nitrosourea on human glioma cells 
(Soma et al. 1992), cisplatin on MmB16 melanoma in mice (Feleszko et al. 1998)， 
doxorubicin on mice model and muscle tumor cells (Werner et al. 2004;Feleszko et 
al. 2000), paclitaxel in human leukemia cell lines (Holstein and Hohl 2001b), and > 
1 -p-D-arabinofuranosylcytosine in human leukemia cells (Holstein and Hohl 
2001a;Lishner et al. 2001). It is of great interest using HMG-Co A reductase 
inhibitors combined with chemotherapeutic agents as antitumor treatment since such 
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a appoiach reduces cytotoxicity to normal cells. 
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1.4 Tumor Necrosis Factor (TNF) related apoptosis-inducing 
Ligand (TRAIL) 
Tumor necrosis factor apoptosis-inducing ligand (TRAIL, Apo2L), is a type I I 
membrane bound TNF super family trimer ligand about 33-35kD that is highly 
homologous to cytotoxic FasL, shows widespread expression and is up-regulated on 
lymphocyte activation (Pitti et al. 1996;Wiley et al. 1995). The extracellular 
domain of TRAIL/Apo2L forms a bell shaped homo-trimer, much like other ligands 
of the TNF family (Pan et al. 1997;Hymowitz et al. 2000). There is a unique 
insertion loop of about 12 to 16 amino acids in soluble TRAIL/Apo2L near its 
amino-terminal end. In contrast to other members of the TNF ligand family, 
TRAIL carries a zinc ion at the trimer interface, coordinated by the single unpaired 
cysteine residue of each monomer (Liabakk et al. 2002). This zinc ion is essential 
for structural integrity of TRAIL. In humans, TRAIL can interact with any one of 
five receptors, all belonging to the TNF receptor super family. They are TRAIL 
receptor I (death receptor 4)，TRAIL I I (death receptor 5) (Pan et al. 1998;Walczak 
et al. 1997), TRAIL receptor I I I (decoy receptor I) (Pan et al. 1998), TRAIL receptor 
IV (decoy receptor II) (Marsters et al. 1997)，and osteoprotegerin (OPG/decoy 
receptor II I) (Emery et al. 1998). The cytoplasmic domain of TRAIL R1 and R2 
contain a death domain (DD), which is similar to that found in TNF receptor 1 and 
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Fas. The primary function of the two death domain containing receptors is to elicit 
an apoptotic death response upon binding of TRAIL, and these receptors are hence 
known as the "death receptors". This death receptors leading to cell death through 
apoptosis is called extrinsic pathway. While the membrane-bound decoy receptors 
TRAILR-3 and 4 (decoy receptor I and 2, DcRl, 2) are having no or a truncated 
intracellular death domain, cannot induce apoptosis (Marsters et al. 1997;LeBlanc 
and Ashkenazi 2003). Osteoprotegerin (TRAIL-R5, OPG) is a soluble receptor 
bind to TRAIL thus inhibits TRAIL-induced apoptosis. 
1.4.1 Molecular mechanisms of TRAIL-induced apoptosis 
Binding of TRAIL to its receptor 1 and 2 result in the recruitment of the death 
domain adaptor protein Fas Associated Dead Domain (FADD). FADD is crucially 
involved in triggering apoptotic signals intitiated by stimulation of death receptor 
such as Fas, TNF-Rl and DR3, comprises a carboxy-terminal death domain and an 
amino-terminal death effector domain (Schneider and Tschopp 2000). The death 
effector domain (DED) is the critical part of the molecule that recruits proteins 
downstream in the pathway that actually effect apoptosis, and overexpression of this 
domain is sufficient to induce apoptosis. FADD activates pro-caspase-8 into the 
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receptor signaling complex while pro-caspase-8 undergoes auto-proteolytic 
activation. This process forms what is known as the TRAIL Death Inducing 
Signaling Complex (DISC). The formation of DISC complex is important to next 
step for TRAIL-induced apoptosis. At this point, there are two pathways leading to 
apoptosis depends on cell specific response, they are type I and type I I cells 
response. In type I cells, TRAIL-Rl and R2 stimulate caspase-8 processing to an 
extent, which is sufficient to activate the apoptotic executioner protein, caspase-3. 
Alternatively, in type I I response, caspase-8 mediated activation of caspase-3 is 
limited, and small quantites of activated caspase-8 are sufficient to trigger the 
mitochondrial-mediated apoptosis signal (Bouralexis et al. 2005). 
1.4.2 Role for TRAIL in cancer therapy 
Despite TRAIL is the most recently identified death ligand, however, it serves 
probably the best candidate of a death ligand for systemic application in cancer 
therapy for the following reasons. Although one or both TRAIL receptors are 
expressed on most normal cells, administration of strictly trimeric, soluble TRAIL 
variants is well tolerated in mice, cynomolgus monkey and chimpanzees (Ashkenazi 
et al. 1999;Walczak et al. 1999) without observable side effects. Furthermore, 
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soluble TRAIL trimers demonstrated no cytotoxic effect on most primary human 
cells including hepatocytes and endothelial cells. However, a variety of tumor cell 
lines and primary tumor samples are TRAIL sensitive in vivo or become sensitive to 
soluble TRAIL after treatment with chemotherapeutic drugs. These data suggest 
that in non-transformed cells apoptosis induction by soluble TRAIL is prevented by 
yet only poorly understood mechanisms that for unknown reasons are absent or less 
active in tumor cells. Hence, TRAIL is potentially useful for cancer therapy 
because unlike many conventional cancer therapeutic agents, TRAIL can trigger 
tumor cell apoptosis independently of the p53 tumor suppressor gene, which is 
inactivated or mutated in more than half of human cancers. Furthermore, TRAIL 
has advantages over other family member on cancer therapy because it shows 
minimal systemic toxicity to animal model, for example, TNF and CD95L have been 
hampered by toxicity to normal tissues. Intravenous TNF administration causes 
hypotension and a systemic inflammatory syndrome that resembles septic shock by 
activation the pro-inflammatory nuclear factor-KB (NF-KB) in vascular endothelial 
cells and macrophages. Injection of agonist anti-Fas (CD95) antibodies induces 
hepatocytes apoptosis and lethal hepatic failure in mice. The ability of TRAIL to 
induce apoptosis in a wide variety of cancer cell lines, while having little toxicity 
toward many types of normal cells, suggests that this molecule may be useful for 
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cancer therapy. 
Large majority of cancer cell lines and about 50 primary human tumor specimens 
were under studied previously, including wide variety of sample from colon, lung, 
and beast cancer. Non-clinical efficacy studies in rodent xenograft models of colon 
cancer (Naka et al. 2002;Gliniak and Le 1999)，breast cancer (Chinnaiyan et al. 
2000;Walczak et al. 1999)，glioma (Fulda et al. 2002;Roth et al. 1999)，prostate 
cancer (Ray and Almasan 2003), myeloma (Mitsiades et al. 2001) demonstrate that 
TRAIL, administered as a single agent or in combination with chemotherapy or 
radiotherapy, shows substantial anti-tumor activities. These activities are 
evidenced by significant increased apoptosis in tumors, partial tumor shrinkage, and 
delayed tumor progression. The potential for TRAIL to act synergistically with 
other chemotherapeutic agents is particularly useful. Recently, TRAIL has been 
showed to act synergistically when combined with IFN-y (Mitsiades et al. 
2001;Shigeno et al. 2003), genotoxic agents such as doxorubicin (Hotta et al. 2003), 
cisplatin (Jones et al. 2003) or etoposide (Miao et al. 2003), others are irinotecan 
(Naka et al. 2002;Ray and Almasan 2003), y-radiation (Chinnaiyan et al. 2000) and 
cyclooxygenase-2 inhibitors (Cox-2 inhibitors) (Totzke et al. 2003). The 
underlying mechanisms behind this synergy vary between therapies but include 
death receptor upregulation, modulation of Bcl-2 family members, caspases pathway 
3 2 
etc. There are a lot of questions remained unknown that how chemotherapeutic 
agents sensitized tumor cells to TRAIL induced-apoptosis even though the tumor 
cells originally resistant to TRAIL. 
In summary, TRAIL targets a wide range of tumor cell types and appears to have 
distinct safety advantages over other death receptor ligands. Moreover, the 
combination of TRAIL with established chemotherapeutic agents or ionizing 
radiation has the potential to enhance the activity of either modality and may be 
overcome the resistance of some tumor cells to therapy. Furthermore, with the 
availability of numerous smart drugs, targeting relevant players along the TRAIL 
signaling pathway combinations and based on additive effects in preclinical models 




Glioblastoma Multiforme GBM is the most common primary brain tumor to arise in 
adults. Despite remarkable advances in the understanding of the molecular basis for 
their origin and development, there have been only nominal inroads made in 
improving patient survival. A new potential therapeutic strategy is needed. 
Apoptosis is an important and safe regulatory mechanism to counteract the 
uncontrolled growth of malignant cells. 
‘ The aims in this project were to investigate the effects of lovastatin-induced 
apoptosis and analyze lovastatin-modulated gene expression profile in GBM cell 
lines. Microarray analysis provided a good platform to identify differentially 
expressed genes represented a feasible approach to delineate regulatory responses 
induced by lovastatin. We also hypothesized i f both of intrinsic (mitochondrial) 
and extrinsic (receptor) apoptotic pathways are triggered simultaneously could 
amplify apoptotic cells death in GBM. Lovastatin and Tumor Necrosis Factor 
Related Apoptosis-inducing Ligand (TRAIL) were used to trigger intrinsic and 
extrinsic apoptotic pathways respectively to test our hypothesis. Thus it emerges 
potential future directions in the development of new approach on anti-GBM 
treatment. 
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Chapter 2 Methods and Materials 
2.1 Cell culture 
Glioblastoma cell lines M059J and M059K were purchased from American Type 
Culture Collection (Rockville, MD). These two cell lines were derived from a 33 
years old male human tumor specimen with untreated malignant glioblastoma. 
M059K cells express normal levels of DNA-dependent protein kinase while M059J 
cells lack of DNA-dependent protein kinase activity. Cells were cultured in 
Dulbecco's modified Eagle's medium (DMEM) / F12 medium with 10% fetal 
bovine serum, 1% penicillin and streptomycin at 37®C in a humidified incubator 
with 5% CO2. Media were routinely changed twice a week. 
Glioblastoma cell line A172 was purchased from American Type Culture Collection 
(Rockville, MD). This glioblastoma cell line was derived from a 53 years old male 
human brain tumor. Cells were cultured in Dulbecco's modified Eagle's medium 
with 10% fetal bovine serum, 1% penicillin and streptomycin at 37。C in a 
humidified incubator with 5% CO2. Media were routinely changed twice a week. 
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2.2 Cell proliferation detection (MTT) methods 
The reduction of tetrazolium salts MTT (3-(4, 5-dimethylthiazolyl-2)-2, 
5-diphenyltetrazolium bromide) is now widely accepted as a reliable way to 
examine cell proliferation. MTT is a yellow, water-soluble tetrazolium salt is 
reduced by metabolically active cells, in part by the action of dehydrogenase 
enzymes, results in intracellular purple formazan that can be quantified by optical 
density (OD) at 570nm with reference wavelength of 630nm. lO. Cells were 
seeded in 96 wells plate and treated with lovastatin with different concentrations 
(DMSO-vehicle, luM, 5uM, 20uM, and 40uM). Data were collected at 0，24, 48, 
and 72 hours. And, for synergistic effects, 500ng/ml TRAIL and OuM (DMSO 
control), luM, 5uM, 20uM and 40uM lovastatin were used and incubated for 
designated time period. Cells in 96-well plate were then incubated with 0.5 mg/ml 
MTT (sigma) for 2 to 4 hours. After plate centrifugation, medium was aspirated and 
cells solubilized in 200 ul DMSO. And the OD was measured using microplate 
reader. Lovastatin was obtained from Sigma-Aldrich (Cata. No. M4667) and 
dissolved in DMSO for designated concentrations. 
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2.3 Assay for Caspase 3, 9 activities 
A synthetic peptide substrate is labeled with 7-Amino-4-trifluoromethylcoumarin 
(AFC), a fluorescent molecule, to form a fluorogenic compound that can be used for 
measuring caspase activity. Specific caspase cleaves on a special sequence on 
peptide and release fluorescent signal that can be detected by microplate reader with 
excitation 405nm and emission 535nm. Glioblastoma cells were incubated with 
various concentrations of lovastatin (DMSO-vehicle, luM, 5uM, 20uM, and 40uM) 
for the indicated times interval (24, 48，and 72 hours). Thereafter, cells were 
washed with phosphate-buffered saline (PBS) and exposed to ice-cold caspase-lysis 
buffer (50mM PIPES (pH 7.0), 50mM KCl, 5mM EGTA, 2mM MgCb, I m M DTT), 
which was supplemented with protease inhibitors immediately before application 
(1.4|Xg ml-i aprotinin; 10|Lig ml'^ leupeptin; 100|iM pefablock (Sigma-Aldrich)). 
Membranes and microsomal fractions were separated by centrifugation at 13000rpm 
at 4°C for 20 minutes. The supernatant was collected and samples were stored at 
-80Op. The substrates for caspase 3 Ac-Asp-Glu-Val-Asp-AFC (Ac-DEVD-AFC) 
and caspase 9 Ac-Leu-Glu-His-Asp-AFC (Ac-LEHD-AFC) were obtained from 
Calbiochem (CA, USA). Aliquots of the supernatant (20|ig of total protein) were 
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incubated with reaction buffer (200mM HEPES (pH 7.5), 20% sucrose, 0.2% 
CHAPS, 0.2mg/ml bovine serum albumin and 20mM DTT) and 50|xM 
AFC-conjugated substrate at 37°C for 2 hours in dark. The change in fluorescence 
was measured at an excitation wavelength of 405nm and an emission wavelength of 
535nm by microplate reader. As a negative control, the AFC-conjugated substrates 
were diluted in lysis buffer and reaction buffer in the absence of protein. 
I 
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2.4 Detection of apoptosis by Annexin V and PI staining 
Apoptosis is a distinguished process from necrosis by characteristic morphological 
and biochemical changes. One of the characteristic of apoptosis is loss of 
membrane asymmetry. In normal viable cells, phosphatidylserine (PS) is located 
on the cytoplasmic surface of the cell membrane. However, in apoptotic cells, PS 
is translocated from the inner to the outer leaflet of the plasma membrane, thus 
exposing PS to the external cellular environment. The human anticoagulant, 
annexin V，is a 35-36kD Ca+ dependent phospholipids-binding protein that has high 
affinity for PS. While Propidium Iodine (PI), a fluorochrome, is used to label 
nucleic acid. PI is impermeable to live cells and apoptotic cells, but stains necrotic 
cells with red fluorescence, binding tightly to the nucleic acids in the cell. After 
staining a cell population with annexin V and PI in the provided binding buffer， 
apoptotic cells show green fluorescence, dead cells or necrotic cells show red and 
green fluorescence, and live cells show no fluorescence at all. This population can 
be distinguished using a flow cytometer with the 488 nm line of an argon-ion laser 
for excitation. 10^ cells were seeded in 6 wells plate in 24 hours advance to 
experiments. Cells were then treated with lovastatin at OuM (control), luM, 5uM, 
20uM, 40uM, which combined with/or 500 ng/ml TRAIL, Mevalonic acid and 
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Bongkrekic acid for 24 to 72 hours depended on the set of experiments. 
> 
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2.5Cell cycle analysis protocols 
Propidium Iodide, which binds to DNA that provides a rapid and accurate means for 
quantitating both total nuclear DNA content and the fraction of cells in each phase of 
the cell cycle. The fluorescence signal intensity of the PI is directly proportional to 
the amount of DNA in each cell, which equivalent to the different phase in cell cycle. 
10^ Cells were treated with normal medium, serum free medium and 20uM 
lovastatin for 24 hours. Cells were rinsed with PBS and librated by using trypsin 
solution, followed by centrifiigation at 3000 rpm for 5 minutes. 10^ cells were 
collected and resuspended in 5ml PBS in a centrifuge tube and centrifuge 5 minutes 
at 3000 rpm. Cells were resuspended in 0.5 ml PBS and then added into a 
centrifuge tube, which pre-filled with 4.5 ml 70% ethanol. Samples were stored at 
-20®C and fixed overnight. Cells fixed overnight were centrifuged at 3000 rpm for 
5 minutes, afterward, supernatant was decanted. Cell pellets were resuspended in 5 
ml PBS and sat for 1 minute, and centrifuged at 3000 rpm for 5 minutes. 
Supernatant was removed, then finally, cell pellets were resuspended in 1 ml 
Pi/Triton X-100 staining solution (4ng/ml, 0.1% Triton X-100 (Sigma)) for 15 
minutes in dark at room temperature. Then flow cytometry analysis was 
preformed. 
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2.6 DNA fragmentation ELISA detection kit protocols 
DNA fragmentation is one of the specific characteristics of apoptotic cell. The 
cellular DNA fragmentation ELISA is a photometric enzyme-linked 
immmunosorbent assay (ELISA) for the detection of BrdU-labeled DNA fragments 
in culture supematants and cell lysates. Preparation procedures: cells were 
seeded in each well in micro-titer plate with BrdU labeling solution (10|LIM, solution 
7) overnight in 37°C humidified incubator with 5% CO2. Then cells labeled with 
BrdU were treated with Designated methods and periods of time. Sample 
preparation procedures: Micro-titer plate was centrifuged for 10 minutes at 250g 
and supernatant was removed carefully. Cells in wells were lysed by adding 200|il 
IX incubation solution (solution 5) per well and incubated for 30 minutes in room 
temperature. 100 | i l sample from each well was used to analyze in ELISA 
procedure. Procedures for coating of the micro-titer plate: 100 )il anti-DNA 
coating solution (solution 3) was transferred into each well of micro-titer plate for 
one hour at 37®C. Coating buffer was removed then 200 |i l of IX incubation 
solution (solution 5) was added in each well with incubation time 30 minutes at 
room temperature. Incubation solution was removed by inverting the micro-titer 
plate. Each well was washed for three times by using washing solution (solution 4) 
4 2 
for 3 minutes each wash. Washing solution was removed completely by inverting. 
Micro-titer plate was already for analysis procedures. Procedures for ELISA and 
photometric measurement: 100 |xl of sample was added into the pre-coated 
micro-titer plate and incubated in dark for 90 minutes at room temperature. 
Samples were removed by inverting and washed each well for 3 time by 300 |i l 
washing solution for 5 minute each. The fragmented DNA in sample was fixed and 
denatured in microwave (500W) for irradiating 5 minutes, then immediately, the 
whole plate was cooled down in -20®C for 10 minutes. At room temperature, 100 
|i l of anti-BrdU-POD conjugated solution (solution6) was added to wells for 90 
minutes in dark. Sample wells were washed for three times with washing solution 
for 5 minutes each. For detecting fragmented DNA in sample, 100 |i l substrate 
solution was added to each sampled well. Samples were incubated in dark on a 
shaker until color development is sufficient. Samples were read using micro-titer 
plate reader at 450 nm with reference wavelength 690nm. OD of the samples is 
directly proportional to the fragmented DNA amount. 
> 
4 3 
2.7 Reverse Transcription (RT) Polymerase Chain Reaction (PGR) 
Reverse Transcription Polymerase Chain Reaction (RT-PCR) is a modification of 
Polymerase Chain Reaction (PCR) for amplifying RNA expression by converting it 
into cDNA, then amplifying it. In our experiments, Promega Reverse Transcription 
System was employed. Reverse Transcription reaction procedures: RNA was 
extracted by RNeasy extraction kits (see bio-molecule extraction protocols), then 1 
|ig of total RNA were denatured by incubating at 70®C for 10 minutes. Sample 
RNA were spun down and dipped on ice, then, the following components were 
added for reverse transcripting to cDNA: 
MgCl2,25mM 4|il 
Reverse transcription lOX buffer 2\il 
dNTPs Mixture, lOmM 2^1 
Recombinant RNasin Ribonuclease Inhibitor 0.5|xl 
A M Y Reverse Transcriptase (15unit/ul) l | i l 
Qligo T primer 0.5fig 
Nuclease-Free Water to final volume 20^.1 
Then the reaction mix was incubated at 42®C for 15 minutes, and 95°C for 5 minutes. 
» 
• Sample was dipped on ice and proceeded to PCR amplification or stored in -80°C. 
PCR Amplification procedures: the following components were added for 20 j i l 
PCR reaction: 
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First-strand cDNA reaction 2 |j.l 
dNTPs Mixture, lOmM 0.4|il 
MgClz, 25mM 1.5|il 
Reverse Transcription lOX buffer 2|il 
Up stream primer 2|ll1 (50pmol) 
Down stream primer 2|il (SOpmol) 
Tag DNA Polymerase 2.5units (0.1 |il) 
Nuclease-free water to a final volume 20)11 




2.8 Polymerase Chain Reaction (PGR) 
PCR technique is today a powerful standard tool for molecular biology. The idea 
of making unlimited DNA copies from a single copy of DNA which was later called 
"Polymerase Chain Reaction" was bom in 1983 by Kary B. Mullis. Ten years later, 
he was awarded the nobel Prize in Stockholm for his brilliant idea. 
Taq-polymerase was used for PCR reaction in our experiments (Promega, Madison, 
Catalog# Ml668). Following components were added for PCR reaction with final 
volume 25 |ll: 
Sterile deionized water 8 [i\ 
lOXTaq buffer 2.5 \i\ 
2mM dNTP Mix 0.5 ^ll(0.2mM of each) 
Up-stream Primer 5 |il(50pmol) 
Down-stream Primer 5 |il(50pmol) 
Taq DNA polymerase 1 |il(15 unit) 
25mM MgCb 2 |i l(2mM) 
Template DNA (from RT) m i 
Total Volume 25|il 
The PCR reaction was performed using the following primers: TRAIL-R l , 
5，-CTGAGCAACGCAGACTCGCTGTCC AC-3 ’ and 
5'-TCCAAGGACACGGCAGAGCCTGTGCCAT-3，； TRAIL-R2, 
» 
• 5 '-GCCTCATGGACAATGAGATAAAGGTGGCT-3 ’ and 
5 ' -CCAAATCTCAAAGTACGCACAAACGG-3 ’ ； TRAIL-R3， 
5'-GAAGAATTTGGTGCCAATGCCACTG-3 ’ and 
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5'-CTCTTGGACTTGGCTGGGAGATGTG-3 ’ ； TRAIL-R4, 
5'-CTTTTCCGGCGGCGTTCATGTCCTTC-3' and 
5 '-GTTTCTTCCAGGCTGCTTCCCTTTGTAG-3 ‘. The thermal programme was 
one cycle at 94°C for 5 minutes, 30 cycles of 94°C 1 minute, 55®C for 1 minute, 
72°C for 2 minutes, and 5 minutes at 72°C. PCR-amplified products were resolved 
and electrophoresed on 2 % agarose gel and visualized with ethidium bromide. 
» 
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2.9 Bio-molecules extraction/purification protocols 
Protein extraction protocols: For caspase 3 and 9 protein extraction protocol, 
please refer to caspase 3 and 9 activities protocols. Proteins concentration 
measurement (Bio-Rad DC Protein Assay): 5 |xl sample was added into each well 
(micro-titer plate) with triplicates, 25 |i l reagent AS (20 |i l reagent S per ml was 
added into reagent A) was added in each well. Samples were shaken on micro-titer 
shaker to mix well, 200 |i.l reagent B was added into each well and samples were 
incubated in dark for 15 minutes. To determine protein concentration, samples 
were read at 750nm in micro-titer plate reader (with BSA standard curve, 0.2-1.5 
mg/ml). 
DNA purification protocols: DNA was recovered and purified from samples 
solution by GFX PCR DNA and Gel Band Purification (Amersham Biosciences 
#27-9602-01) kit. 500 |i l of capture buffer was added into the GFX column. Up 
to 100 j i l of DNA sample solution was transferred in to the GFX column with 
mixing by pipetting up and down 4-6 times. Column was centrifiiged at full speed 
for 30 seconds. Flow-through was removed; 500 |i l wash buffer was filled into the 
column and centrifiiged for 30 seconds in full speed. Again, flow-through was 
discarded and the column was transferred to a new 1.5 ml microcentrifuge tube (not 
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collection tube). Either 530 )il elution buffer or RNase/DNAse free water was 
added directly to the top of the glass fiber matrix in the GFX column. The sample 
was sat in room temperature for at least one minute. Purified DNA sample was 
eluted by centrifuged the column for 1 minute in full speed. The last procedure 
was repeated to collect 60 |i l purified DNA sample. 
RNA extraction protocols (Using Qiagen RNeasy extraction kit): Cells were 
treated with designated methods and librated using trypsin solution. Cells were 
then spun down for 5 minutes at 1000 rpm. Supernatant was removed, then 350 }il 
of RLT buffer (10 )il beta-mercaptoethanol was pre-added for every 1 ml of RLT) 
was applied on cell pellet, sample was mixed thoroughly by pipetting up and down 
the sample solution. 350 j i l 70% RNase free ethanol was filled in the sample 
solution, mixed well. Up to 700 | i l sample solution was transferred to RNeasy 
mini column (with collection tube), then column was centrifuged for 15 seconds at 
full speed (>10,000 rpm). Flow through was discarded. 700 | i l RWl buffer was 
added into the column and centrifuged for 15 seconds at full speed. Flow through 
was discarded again. The column was then placed into a new collection tube; 500 
of RPE buffer was transferred into the column then centrifuged for 15 seconds at 
full speed, afterward, flow through was removed from the collection tube. The 
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previous procedure was repeated once. 30 |i l of RNAse free water was added onto 
the column membrane and incubated in room temperature for at least one minute. 
Sample was then centrifuged for 1 minute in full speed, elutant containing purified 
RNA. This step was repeated to obtain 60 |i l purified RNA solution. Sample 
purity was examined using spectrophotometer at 260/280nm. 
> 
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2.10 Microarray analysis on lovastatin treated glioblastoma cells 
A172，M059J and M059K 
2.10.1 Cells treatment and RNA extraction 
Glioblastoma cells A172，M059J and M059K were subjected with 20uM lovastatin 
treatment for 0，12 and 36 hours. Cells were harvested and total RNA was 
extracted using RNeasy kit (see bio-molecule extraction procedures). Total RNA 
samples were measured and quantified by UV spectrophotometry (NanoDrop, 
ND-1000 spectrophotometry). A l l of the RNA samples must reach good quality to 
proceed to microarray procedures. 
Bacterial control mRNA dilution methods for target preparation 
Bacterial mRNA was used for an accurate assessment at a specific concentration at 
the start of cDNA synthesis. Dilution methods were as follow: 
A clean 1.5 ml appendoff tube and bacterial controls were dipped on ice. 16.7 
ng/|Lll was prepared by combining spike stock solution (bacterial control) as follow: 
» 
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0.1 |ig/|il Bacterial control mRNA araB 5 [i\ 
0.1 |Lig/|il Bacterial control mRNA entF 5 | i l 
0.1 Bacterial control mRNA fixB 5 |i l 
0.1 |lg/p.l Bacterial control mRNA gnd 5 |il 
0.1 Bacterial control mRNA hisB 5 |i l 
0.1 jug/ul Bacterial control mRNA leuB 5 
Final volume 30 |i l 
Bacterial control mix was mixed well by tapping the side of the tube, then the tube 
was centrifuged in brief. Nine of clean 0.5 ml appendoff tubes were prepared, 3 |xl 
bacterial control mix was aliquot into each tube and stored in -70°C. 
50.2 pg/|il of bacterial control mRNA combined spike stock solution was prepared 
as follow: 
16.7 ng/|il combined spike stock 3 |i l 
Nuclease-free water 997 fil 
Final volume/concentration 1000 |il/ 50.2 pg/|il 
0.1 pg/|il bacterial control mRNA working stock solution was prepared as follow: 
50.2 pg/|Lil combined spike control 2 |i l 
Nuclease-free water 998 \i\ 
Final volume/concentration 1000 |LI1/ 0.1 pg/|i.l 
1 | i l of working bacterial control rtiRNAs was added for every 1 |ig of sample RNA 
in first strand cDNA synthesis. 
> 
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2.10.2 Synthesis of first strand cDNA 
Each total RNA sample was prepared for manual target preparation: 
Total RNA sample (from cell treatment) 0.2-2 |xg 
Working bacterial control solution 1 |Lil per l | ig sample RNA added 
T7 oligo (dT) primer 1 |i l 
Nuclease-free water Top up to final volume 12 
Samples were incubated at 70°C for 10 minutes in thermocycler (ABI 2700 
thermocycler) for denaturing RNA and were immediately dipped in ice for three 
minutes. The tubes were then centrifuged in brief to collect the samples at the 
bottom of the tubes. The following components were added for first strand cDNA 
synthesis: 
lOX first strand buffer 2 [l\ 
5mM dNTP mix 4 |i l 
RNase inhibitor 1 |xl 
Reverse transcriptase 1 |J-1 
Final volume 20 |i l 
Sample tubes were incubated at 42 ®C in thermocycler for 2 hours, after the 
incubation, all samples were spun down and placed on ice for next step. 
> 
5 3 
2.10.3 Synthesis of second strand cDNA 
The below reaction mix for each sample was prepared: 
First strand cDNA reaction from previous step 20 \i\ 
Nuclease free water 63 
lOX second strand buffer 10 |i l 
5 mM dNTP mix 4 ^il 
DNA polymerase mix 2 |i l 
RNase H U l 
Final volume 100 |i l 
The sample tubes were gently tapped to mix and spun down in full speed to combine 
the reactants, afterward, samples were incubated at 16 for 2 hours in thermocycler. 
Tubes were then spun down in brief and placed on ice for further use. 
2.10.4 Purification of double stranded cDNA 
500 )il capture buffer was added to each cDNA sample from previous step and 
mixed gently pipetting up and down. QIAquick spin columns were placed into 2 
ml collection tubes. cDNA samples were transferred into the columns and then 
> 
• columns were centrifuged at full speed for not less than one minute. Flow through 
was discarded. Columns were washed by adding 700 |i l washing buffer and 
centrifuged at full speed not less than one minute. New collection tubes were 
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prepared and columns were transferred to those tubes. Columns were subjected to 
centrifugation at full speed for one minute, flow through was removed. QIAquick 
columns were place into a clean 1.5 ml microcentrifuge tubes and 30 |i l of nuclease 
free water was added into column membranes to elute recovered cDNA. Tubes 
were spun at fiill speed for one minute. The previous step was repeated to generate 
60 )ll eluate. cDNA solution samples were then placed in a SpeedVac concentrator 
under medium heat to concentrate to 9.5 \i\ final volume (do not dry cDNA to 
completion). 
2.10.5 Synthesis of cRNA by in vitro transcription (IVT) 
IVT reaction components were added for each sample: 
1 OX T7 Reaction buffer 4 |i l 
T7 ATP solution 4 )il 
T7 GTP solution 4 ^il 
T7 CTP solution 4 ^il 
T7 UTP solution 3 
lOmM biotin-l l-UTP 7.5^1 
IPX T7 enzyme mix 4 |LI1 
Total volume 30.5 [i\ plus 9.5 | i l cDNA = 40 
» 
Sample tubes were mixed by vortexing and centriftiged briefly, then samples were 
transferred to thermocycle tubes. The samples were incubated at 37 for 14 
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hours in thermocycler. 
2.10.6 Recovery of biotin-labelled cDNA 
350 |i l of RLT buffer (with beta-mercaptoethanol, 10 |i l per ml RLT) were added to 
each IVT reaction tube and mixed thoroughly by pipetting up and down. Then 250 
|Lil of 100% ethanol were filled to the reaction sample and mixed thoroughly by 
pipetting up and down. 700 |LI1 reaction samples in each tube were transferred to 
RNeasy spin columns with collection tube; were then spun in ftill speed for 15 
seconds. Flow through was discarded. 500 \i\ RPE buffer was added to each 
column to wash and centrifuged in full speed for 15 seconds; flow through was 
discarded. This step was repeated to clean the columns. 30 \i\ nuclease free water 
was filled directly onto the column membrane with incubation time not less than 
five minutes. Columns were pun in full speed for one minute, eluent contained 
cRNA. The previous step was repeated to generate 60 |i l concentrated cRNA 
solution for each sample. The concentrations of cRNA in samples were measured. 
2.10.7 Fragmentation of cRNA 
20 |ig of cRNA in each sample was input and nuclease free water was used to top up 
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to 40 |Lil in thin wall microcentrifuge tube. 10 )il 5X fragmentation buffer for each 
bioarray reaction. Samples mixed were then incubated at 94 °C for 20 minutes and 
immediately cooled down to 0°C for at least five minutes in thermocycler (MJ 
research inc. thermocycler). 
2.10.8 Preparation of hybridization reaction mixtures 
Fragmented cRNA samples from thin wall tubes were transferred to 1.5 
microcentrifuge tubes. Hybridization solution was prepared as follows: 
Hybridization buffer component A 86 |i l 
Hybridization buffer component B 143 [l\ 
Nuclease free water 5 |LI1 
Fragmented cRNA 50 \i\ 
Total volume 284 i l l 
The sample solutions were then vortexed for 5 seconds and centrifuged briefly. 
Reaction samples were incubated at 90 for 5 minutes to denature cRNA, 




2.10.9 Loading of reaction mixtures into bioarray chambers 
Bioarrays were placed on a stable surface with input ports facing up. Hybridization 
reaction mixtures were vortexed and centrifiiged to gather the liquid at the bottom of 
the tubes. A l l of the solution for each sample was then drawn into a 1 ml 
wide-bore pipette tip. The pipette tip containing the hybridization solution was 
placed over the array input port closest to the right edge of the slide label and 
pressed until the tip forms seal with the chamber. Hybridization solution was then 
injected into the Flex chamber entirely without using blowout feature. When the 
Flex chamber is filled, pipette tip was removed from the input port slowly. Flex 
chambers were sealed using sealing strips and port sealing tool. 
2.10.10 Hybridization 
Al l of the bioarrays were put into a shaker tray and placed into a shaker incubator. 
Bioarrays were allowed to incubate with shaking (300 rpm) at 37 for at least 18 
but not more than 24 hours. It is critical that arrays used in any form of 
comparison are hybridized for the same amount of time within the given range. 
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2.10.11 Post-hybridization wash 
Each slot in the medium reagent reservoir was filled with 13 ml of filtered 0.75 TNT 
buffer; bioarray holding rack was placed into the reservoir. Overnight hybridized 
bioarrays were taken out from shaker incubator. By using Flex chamber removal 
tool, cover tabs were removed under supplier's construction. To avoid potential 
cross-contamination, all bioarrays were rinsed with approximately 5 ml of ambient 
temperature 0.75X TNT buffer dispensed from a squirt bottle. Bioarrays were then 
dipped into the holding rack in the medium reagent reservoir. Striped bioarrays 
were then submerged into pre-warmed (46 ®C) 0.75 TNT buffer and incubated for 
exactly 1 hour at 46 water bath. 
2.10.12 2.11.12Detection with streptavidin-dye conjugate 
Bioarrays were removed from 46 incubator; the holding rack was removed from 
the reservoir and placed into a small reagent reservoir pre-filled with 
Cy5-Streptavidin working solution at ambient temperature in dark for 30 minutes. 
After Cy-5-streptavidin staining, bioarray rack was removed form the reservoir and 
placed into large reagent reservoir containing IX TNT buffer with gentle up and 
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down agitation for 5 minutes in dark. The bioarrays were washed for four times 
with IX TNT buffer. Bioarray rack was transferred into a large reservoir pre-filled 
with O.IX SSC/0.05% Tween 20 solution as a final wash for 30 second with 
continuously agitating mildly up and down. Bioarrays were then removed from the 
rack and placed into 50 ml centrifuge tubes which were centrifuged at 2000 rpm for 




2.10.13 Bioarray scanning and analysis 
The bioarray scanner was turned on 30 minutes prior to use. Cover on the scanner 
was opened to expose the slide holder. The slide holder's upper latch was lifted 
and bioarray was loaded into the tray with the label side down and closest to the 
front of the scanner. The clip on the left of the slide out was pulled; the bioarray 
could fall into place to fit. The scanner's cover was closed. GenePix software 
was opened and the 635nm wavelength was chosen. The PMT voltage was then 
adjusted to 600V with pixel size at 10 |im. Finally the focus position was turned to 
0 \im and expand file name was sat as lOum.gps. 
In the report tab, the scanning script was opened by clicking Scan CodeLink Slide. 
Bioarray serial number was typed in and Next button was clicked to let experiment 
and scan information interface was being displayed. Scan Slide button was clicked 
on the display and scanner ran automatically. Once the scanning processing 
stopped, the scanned image then was saved. The image from each bioarray was 
analyzed by using CodeLink Expression Analysis software. 
» 
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Chapter 3: Results 
3.1 Morphological effects of Lovastatin on human glioblastoma cells 
Human glioblastoma cells undergo dramatic morphological changes after exposure 
to lovastatin for 24 hours (Figure 3.1a-f). The pictures were captured when cells 
were treated with 2OuM lovastatin after 24 hours incubation. The cells were 
shrunken and the ratio of the nuclear to cytoplasmic volume decreased. The 
overall shape of the cells turns into spherical and finally cells detach from 96-wells 
plate surface. Mevalonic acid was capable of rescuing the cells from 
lovastatin-induced morphological alterations and cells death. The morphological 
changes were more or less the same in treatment with l | iM, 5|iM and 40^M 





Figure 3. 1 Glioblastoma morphologies 
Cell morphologies altered by Lovastatin. A172 control and treatment (a and b 
respectively), M059J control and treatment (c and d), and M059K control and 
treatment (e and f). 
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3.2 Anti-proliferation effects on glioblastoma cell lines 
The anti-proliferation effect of lovastatin was determined by MTT assay with 
different concentrations (vehicle-DMSO, luM, 5uM, 20uM and 40uM). The 
effects of lovastatin on glioblastoma cell lines were showed in figure 3-2 to 3-4. 
The viable cells were detected at different time points at 24, 48 and 72 hours. In 
general, Lovastatin showed anti-proliferation effect on these glioblastoma cells from 
1 to 40uM in dose dependent manner. A l l of the three glioblastoma cell lines were 
sensitive to lovastatin treatment. High proportion of cells was induced to cell death 
at 72 hours. In A172 glioblastoma cells, there were 33%, 61.8%, 74.7%, and 77% of 
cell death induced by luM, 5uM, 20uM and 40uM lovastatin at 72 hours incubation, 
respectively. In M059J glioblastoma cells, there were 29%, 70 %, 69%, and 85% 
of cell death induced by lovastatin. And in M059K glioblastoma cells, the cell 
death rates were 24.3% ( luM), 40% (5uM), 84% (20uM), and 90% (40uM). 
M059J glioblastoma cells were more resistant to lovastatin-induced cell death. The 
groups (added back treatment) with lovastatin and mevalonic acid were 
demonstrated with little cell death which suggested lovastatin blocked mevalonic 
acid pathway was the major event to trigger cell death. However, mevalonic acid 
failed to rescue M059K cells with 40uM lovastatin treatment while with 20uM or 
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lower dosage showed only low percentage of cell death. Bongkrekic acid also 
failed to prevent cell death that at high concentration suggested lovastatin can induce 
cell death other than mitochondrial stress because bongkrekic acid is a potent 
inhbitor of the adenine nucleotide transporter, which is an essential part of the 
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Figure 3. 2 Anti-proliferation effects on A172 
The anti-proliferation effect on glioblastoma cell lines at different time points. 
Glioblasoma cells A172，M059J and M059K were exposed to different 
concentrations of Lovastatin (Vehicle-DMSO, luM, 5uM, 20uM and 40uM) 
with/without M A or bongkrekic acid. Cell death was measured by MTT assay at 
different time intervals (24, 48 and 72). Lovastatin had significant effects on cell 
death (by student-t test). Experiment set were repeated at least three times with 
triplicate wells for each condition (mean士SD). * = p<0.05, • * 二 p<0.005 
representing significant effects. Groups with 5uM, 20uM, and 40uM were showed 
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3.3 Lovastatin-induced caspase3 and 9 activation in human 
glioblastoma cell lines 
In order to confirm cell death was undergone apoptosis, caspase activities assay 
were used. The effector caspase 3 plays a critical role in apoptosis as an 
executioner protein to trigger apoptosis. Figure 3-5 to 3-7 showed caspase 3 
activities in these glioblastoma cell lines. Lovastatin significantly increased 
caspase 3 activities at time 72 hours with different concentrations (Control 
vehicle-DMSO, luM, 5uM, 20uM and 40uM (in A172 cells only)). In A172 
glioblastoma cells, caspase 3 activities were increased 2.5X, 4.3X, 7.2X and 5.5X 
with respect to the lovastatin concentrations at 72 hours incublation. In M059J 
glioblastoma cells, 1.8X, 2.7X, and 3.IX increase of caspase 3 activities were 
observed. And in M059K glioblastoma cells, 1.4X, 2.0X, and 3.0X caspase 3 
activities enhancement were observed. Noted there was no 40uM lovastatin 
treatment on M059J and M059K glioblastoma cells because of no sufficient protein 
was recovered for the assays. Points of significant were showed with * = p<0.05 or 
* * = p<0.005. A U is representing arbitrary unit in the figures. 
Caspase 9 activities were also measured due to caspase 3 can be activated either or 
both by death receptor mediated and mitochondrial stress induced cascade, 
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measurement of caspase 9 demonstrated that lovastatin-induced apoptosis through 
mitochondrial stress cascade. Figure 3-8 to 3-10 showed caspase 9 activities in 
glioblastoma cells. Caspase 9 activity was significantly elevated in human 
glioblastoma cell lines after 72 hours of exposure to different concentrations of 
lovastatin ( luM, 5uM, 20uM, and 40uM (A 172 cells only)). In A172 glioblastoma 
cells, there were 2.3X, 4.4X, 6.7X, and 4.6X increased of caspase 9 activities with 
respect to lovastatin concentrations. M059J showed 1.8X, 2.IX, and 2.6X caspase 
9 activities enhancement at luM, 5uM, and 20uM lovastatin concentrations with 72 
hours incubation. However, M059K glioblastoma cells only showed 1.6X, 1.8X, and 
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Figure 3. 5 Caspase 3 activity in A172 
Caspase 3 activity in human glioblastoma cell lines induced by lovastatin. Each 
experiment was repeated at least three times (meaniSD) and analyzed by student-t 
test for significant levels. Significant was showed with * = p<0.05 and * * = p<0.005 
(compare with control, D M SO). A U is representing arbitrary unit in the figures. 
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Figure 3. 8 Caspase 9 activity in A172 
Caspase 9 activities in human glioblastoma cell lines induced by lovastatin. Each 
experiment was repeated at least three times (meardiSD) and analyzed by student-t 
test for significant levels. Significant was showed with * 二 p<0.05 and ** = 







200 - ^ ^ 
100 - • • • 
50 -
Control 
0 ‘ ‘ ‘ ‘ ^ ‘ • " • " l / z M 
20 30 40 50 60 70 80 5 flU Hours 1 + 20/zM 





250 - * 
如 G -
100 - • • 
50 - 1 
+ Control 
0 ‘ ‘ ‘ ‘ ^ ‘ " • " l / z M 
20 30 40 50 60 70 80 5 / / M Hours 1 + 20/zM 
Figure 3. 10 Caspase 9 activity in M059K 
> 
7 6 
3.4 Cell cycle determination by PI staining 
Cells were treated with normal serum medium, serum free medium and 20uM 
lovastatin with normal serum medium for 48 hours incubation time. Preparation 
work was follow as Materials and Methods. PI stained cells were analysis using 
flow cytometry to quantify cells in certain cell cycle stages. A l l glioblastoma cells 
increase the number of cells arrested in GO/Gl phase in both serum free or/and 
lovastatin groups. Lovastatin significantly arrested cells in G Q - G I phase while 
serum free condition failed to induct glioblastoma cells arrest (figure 3-11). After 
48 hours incubation with 20uM lovastatin, cell arrest in GQ-GI phase were risen 
15.2%, 9.4%, and 11.3% in A172, M059J and M059K glioblastoma cells 
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Figure 3. 11 Lovastatin-arrested glioblastoma cells 
Lovastatin-induced G Q - G I arrest in human glioblastoma cell lines. Lovastatin 
significantly arrested glioblastoma cells at concentration 20uM. SF=semm free, 
MJ=M059J cell line and MK=M059K cell line. ANOVA were used for statistics 
analysis and significant was showed with * = p<0.05 and ** = p<0.005 (compare 
with control, DMSO). Experimental set were repeated for at least three times for 
each condition (meaniSD). 
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Figure 3. 12 Cell cycle analysis 
Lovastatin induced G Q / G ] arrest in cells after 48 hours incubation time, followed by 
PI staining of the nuclei and analysis by flow cytometry. Data are showed as 
percentages of total number of cells. A172 control and with 20uM lovastatin (a, b); 
M059J (c, d); M059K (e, fg). Interestingly, a small number of M059J cells 
undergone apoptosis even in normal serum condition (sub G l peak fig. a and f). 7 9 
3.5 Quantification of apoptotic cell death by annexin V and 
propidium iodide staining 
In order to confirm the major cell death event is apoptosis other than necrosis, 
annexin V and propidium iodide staining was employed for analysis. Apoptosis 
was induced significantly in glioblastoma cells by different concentrations of 
lovastatin ( luM, 5uM, 20uM and 40uM) after 72 hours incubation. The 
percentages of apoptotic cells were more or less directly proportional to the 
concentration of lovastatin, especially in M059J and M059K cells, which showed 
similar apoptotic cell death pattern. The percentages of apoptotic cells in A172 
glioblastoma were 12.4%, 34.7%, 40.7%, and 33.8% at luM, 5uM, 20uM and 40uM 
lovastatin concentrations respectively. In M059J glioblastoma cells, 11.1%, 27%, 
27.6%, and 62.1% apoptotic cells were detected with respect to the lovastatin 
concentrations. There were 3.2%, 12.4%, 38.8%, and 55.7% apoptotic cells 
detected in M059K cells with respect to the lovastatin concentrations. Mevalonic 
acid and bangkrekic acid were significantly rescuing glioblastoma cells from 
apoptosis. Figure 3-13 showed apoptotic cell death at 72 hours incubation time 
with vary concentration of lovastatin. 
8 0 
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Figure 3. 13 Apoptotic cell death induced by lovastatin 
Each experiment was repeated at least three times and analyzed by student-t test for 
significant levels. ANOVA were used for statistics analysis and * = p<0.05, * * = 
p<0.005 (compared with control, DMSO). Experimenatl set were repeated for at 
least three times for each condition (meaniSD). 
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3.6 Microarray analysis of lovastatin-modulated gene expression 
profiles 
In this study, three glioblastoma cell lines were treated with solvent control and 
2OuM lovastatin for 12 and 36 hours. These conditions are prior to the onset of 
overt apoptosis that is triggered by lovastatin in these cell line models (see annexin 
V staining, apoptosis reached the peak at 72 hours). Expression signal was 
generated by Codelink Expression Analysis software under manufacturer's protocols. 
Normalized intensity was compared between control and treatment group, 
expression ratio was generated. I f ratio is directly indicated the fold change; i.e. 2 
= 2 folds up regulation while 0.5 = 2 folds down regulation. Total RNA was 
extracted from treated cells and relative expression data of 20K genes were 
generated using Amersham Codelink bioarray system. There were 57 and 171 genes 
showed more than 3 folds up- and down regulation in A172 glioblastoma cells 
respectively. Surprisingly, in M059J glioblastoma cells, 745 genes were 
up-regulated and 629 genes were down-regulated with 3 folds changes. However, in 
M059K cells, there were only 59 and 91 genes were up-regulated and } 
down-regulated respectively (more than 3 folds change). As there is no different 
between M059K and M059J cells except the lack of protein kinase A activity in 
8 2 
M059J cells. This suggested M059J cells were vulnerable to lovastatin-induced 
regulation. The modulated genes involved in wide variety of biological functions 
like cytoskeleton regulations, cell cycle control, tumor suppressor and 
transcriptional factor etc. Appendix tables showed modulated genes in these 
glioblastoma cells. Figure 3-14a to f showed hierarchical tree of the modulated 
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3.7 Synergistic effects induced by lovastatin and Tumor Necrosis Factor 
related apoptosis-inducing Ligand (TRAIL) 
3.7.1 M059J and M059K glioblastoma cells was resistant to TRAIL attack 
We first examined the proliferation effects of TRAIL against three glioblastoma cell lines. 
M059K and M059J glioblastoma cells are resistant to TRAIL-induced cell death and 
remained 100% cell viable following treatment. Only A172 showed minor cell death 
(~20 %) after TRAIL treatment. Figure 3-15 showed the effects in these glioblastoma 
cells. 
3.7.2 Synergistic cell death was induced by lovastatin and TRAIL 
Cell death was measured by MTT assay. The synergistic effects of lovastatin and 
TRAIL were seen in glioblastoma cells A172, M059J and M059K. Cell death was 
induced by lovastatin in a dose dependent manner when with a fixed amount of 
TRAIL (500ng/ml). Significant synergy was observed after 48 hours incubation 
time. The patterns of the synergy in these glioblastoma cells were more or less the 
same, but M059J and M059K were more vulnerable to lovastatin-sensitized 
87 
TRAIL-induced cell deaths than A172 cells. The cell viability (MTT activity) of 
the treated cells is expressed as a percentage of the viability of the untreated cells for 
the same time interval. A172 glioblastoma cells, there was dramatic drop of viable 
cell from 50.8% and 39.7% viable cell (lovastatin alone) to 22.1% and 6.4% 
incubated 500ng/ml TRAIL with 5uM and 20uM lovastatin respectively. The 
synergistic effects were more obvious in M059J and M059K cells. Cells viability 
in lovastatin treated cells were 59% ( luM), 45% (5uM), 40.9% (40uM), compared 
with co-treatment with TRAIL, the viability were 17.1%, 6.0%, and 5.1%, which 
dropped 42%, 39%, and 45% respectively in M059J glioblastoma cells. While in 
M059K cells, viable cells number decreased from 74.2%, 48.8%, 41.9%, and 29% to 
2.7%, 2.0%, 2.0%, and 3.1% after co-treatment, respectively, which dropped 72.6%, 
46.8%, 39.9%, and 26%. Data are presented as the mean 土 SD (n=4). 
88 
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Figure 3. 15 TRAIL resistant glioblastoma 
TRAIL failed to induce cell death in M059J and M059K glioblastoma cells. While 
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Figure 3.16 Synergistic effects on A172 
Synergistic effects in A172，M059J, and M059K glioblastoma cells were showed in 
figure 3-16 to 3-18. Each experiment was repeated at least three times (meantSD) 
and analyzed by student-t test for significant levels. Significant was showed with • 
=p<0.05 and * * = p<0.005 (compare with lovaststin groups respectively). 
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Figure 3. 17 Synergistic effects on M059J 
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Figure 3. 18 Synergistic effects on M059K 
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3.7.3 A combination of TRAIL and lovastatin induces synergistic apoptosis 
in glioblastoma cells 
The percentage of cell death of glioblastoma cells treated with both lovastatin and 
TRAIL were significantly higher than when treated with either agent alone (Figure 
3-19, to 3-21). Glioblastoma cells were treated with A172 glioblastoma cells were 
vulnerable to TRAIL induce apoptosis (Figure 3-19) and mutual amplification of 
apoptosis was observed following treatment with both TRAIL and lovastatin 
(p<0.005). Significant synergistic effects were seen in M059K and M059J cells 
(p<0.005) (Fig. 3-20 and 3-21), with up to 10-fold increases in apoptotic cells. 
Interestingly, M059J cells, which lack of DNA-dependent protein kinase expression, 
were less vulnerable to the two agents, implying that DNA-dependent protein kinase 
plays an important role in TRAIL and lovastatin induced apoptosis. Figure 3-22a 
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Figure 3.19 Synergistic apoptosis on A172 
Synergistic apoptosis in these glioblastoma cells: A172 (Figure 3.19), M059J 
(Figure 3.20) and M059K (Figure 3.21). The percentages of apoptotic cells were 
showed in the figures. Each experiment was repeated at least three times (meant 
SD). * * = p<0.005, * 二 p<0.05 compared with control and lovastatin control 
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11 M Figure 3. 22 Flow cytometry analysis on glioblastoma 
Annexin V staining revealed the synergistic effects exerted by 500ng TRAIL and 
20uM lovastatin. A172 cells - control, 20iiM lovastatin alone, 500ng TRAIL alone 
and 20uM plus 500ng TRAIL with respect to figure 3-22a, b, c, and d. M059J cells 
(e, f, g, and h) and M059K (i, j , k，and 1). 
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3.7.4 DNA fragmentation on glioblastoma cells 
DNA fragmentation is one of the hall marks of cells under apoptosis. We 
performed ELISA assay to confirm apoptosis was induced by the action of 
synergistic effects of lovastatin and TRAIL. Synergistic effects on DNA 
fragmentation were showed to occur in all of the three cell lines (Fig. 3-23 to 3-25). 
DNA fragmentations were observed significantly in these glioblastoma cells 
combined with lovastatin and TRAIL. A172 glioblastoma cell was just reached 
significant level at concentration 20uM with 500ng/ml TRAIL, and the level of 
DNA fragmentation was less than in M059J and M059K glioblastoma cells. 
M059J and M059K glioblastoma cells were subjected to substantial DNA 
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Figure 3. 23 DNA fragmentation in A172 
Increased DNA fragmentation following treatment confirmed the induction of 
apoptotic cell death by this drug combination. Each experiment was repeated at 
least three times (meaniSD). Significant was showed as * = p<0.05, * * = p<0.005 
compared to Control and lovastatin control groups while + = p<0.05, ++ = p<0.005 
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Figure 3. 24 DNA fragmentation in M059J 
Increased DNA fragmentation following treatment confirmed the induction of 
apoptotic cell death by this drug combination. Each experiment was repeated at 
least three times (meaniSD). Significant was showed as * = p<0.05, * * = p<0.005 
compared to Control and lovastatin control groups while + = p<0.05, ++ = p<0.005 
compared with TRAIL control. 
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Figure 3. 25 DNA fragmentation in M059K 
Increased DNA fragmentation following treatment confirmed the induction of 
apoptotic cell death by this drug combination. Each experiment was repeated at 
least three times (meanlSD). Significant was showed as * = p<0.05, * * = p<0.005 
compared to Control and lovastatin control groups while + 二 p<0.05, ++ = p<0.005 
compared with TRAIL control. 
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3.7.5 Four TRAIL receptors mRNA expression profiles on glioblastoma 
cells 
Receptors expression does not correlate with sensitivity with TRAIL induced-cell 
death. Resistant of TRAIL induced cell death may adapt by low expression rate of 
TRAIL receptors. To investigate the expression profiles on these glioblastoma 
cells, RT-PCR was performed for screening. Cells were treated with normal serum 
medium, serum free medium, serum medium with 5uM or 20uM lovastatin for 48 
hours. TRAIL receptor 4 (Decoy receptor 1) and 5 (Decoy receptor 2) were not 
detected in all conditions and cell types. TRAIL receptor 1 (Death receptor 4) was 
only detected on M059J cell with serum free or lovastatin induced groups (Figure 
3.26A). While TRAIL receptor 2 (Death receptor 5) was expressed on all cell 
types and groups. Interestingly, the expression of TRAIL receptor 2 was both 
up-regulated in serum free and lovastatin groups (Figure 3-26B). The expression 
level of TRAIL receptor 2 had a tendency to correlate with the sensitivity of 
TRAIL-induced cell death, however, up-regulation of TRAIL R2 was observed in 
both M059k and M059J that were treated with serum free or lovastatin whereas cells 
in serum free condition still resistant to TRAIL but not in lovastatin treated groups. 
This suggested that lovastatin sensitized M059J and M059K through other unknown 
mechanism thus revealed TRAIL receptors expression does not correlate with 
1 0 2 
sensitivity with TRAIL induced-cell death (Figure 3-26B). 
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Chapter 4 Discussion 
Programmed cell death (apoptosis) plays critical roles in a wide variety of 
physiological processes during fetal development and in adult tissues. The 
evolutionary conserved process allows for the elimination of large numbers of cells 
no longer needed during embryogenesis without harm to the developing organism, 
moreover, apoptotic cells can be cleared from the organism in the absence of 
inflammatory responses. Apoptotic cell death characterized by nuclear condensation 
and fragmentation, membrane blebbing and the formation of apoptotic bodies 
(Steinbach and Weller 2004). A l l of these features distinguish apoptosis from 
necrosis that are commonly caused by external trauma, whereas apoptosis fall into a 
safe strategy for diseases related treatment. Induction of apoptosis in cancer cells 
become an important strategy for cancer therapy. 
In this study, we demonstrated that lovastatin-induced apoptosis in glioblastoma cell 
lines A172，M059J and M059K. We also showed our successful work on induction 
of apoptosis in GBM cell lines by using two non-chemotherapeutic agents. The 
two agents triggered different apoptotic pathways results in synergistic apoptotic 
effects in GBM cell lines. These results give a light leading to new treatment 
insight to GBM with low cytotoxicity and tolerable dosage. 
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It is worth while to mention about why these glioblastoma were choosen in our 
experiments. A172 classificied as anaplastic astrocytoma (malignant glioblastoma, 
grade III) while M059J and M059K are glioblastoma multiforme derived from 
single patient. Malignant glioblastoma may exhibit very differently in responing to 
different therapeutic treatments. There is limited information on how these 
glioblastoma cells responses to both lovastatin and TRAIL in current research. Our 
study may boarden current knowledges on glioblastoma's acceptability and 
sensitability during these in vitro treatments. Concentrations of lovastatin were 
tested (by MTT) prior to our systemic experiments. Glioblastoma cell lines were 
responsed to dosage higher than 0.5|iM but lower than 50|xM lof lovastatin (killed 
all of the cells within 72 hours). 
> 
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4.1 Lovastatin exhibited anti-proliferation effects in human 
glioblastoma cells 
MTT assay results showed that lovastatin caused anti-proliferation effects on 
glioblastoma cells in dose dependent manner. A l l of the three glioblastoma cell 
lines were sensitive to various lovastatin concentrations. Concentrations of 
lovastatin were choosen in our experiments at IJIM, 5|LIM, 20|XM and 40|XM. 
Interestingly, M059J cells that lack of DNA-dependent protein kinase K activity 
were more resistant to lovastatin-induced cell death or apoptotic injury. These 
results were strongly correlated to our previous works, although lack of 
DNA-dependent protein kinase K expression was reported to associate with 
disturbed cell cycle and unstable DNA integrity, M059J cells showed resistant to cell 
death (Chen et a l 2005a;Chen et al. 2005b). 
> 
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4.2 Lovastatin activated caspase 3 and caspase 9 in human 
glioblastoma cells 
Lovastatin activated caspase 3 and 9 activities in these glioblastoma cells suggested 
that lovastatin-induced apoptosis through mitochondrial stress and caspase 
dependent pathway. Release of cytochrome C from mitochondria is a hall mark of 
mitochondria stress to activate caspase pathway. Ctyochrome C releases from 
mitochondria, which then interacts with Apaf-1 (apoptosis protease-activating factor 
1) and forming an apoptosome, which leads to self-cleavage of pro-caspase-9 to 
activate caspase 9, and then activate downstream effector caspase (Birch-Machin 
2006). The results suggested that lovastatin inhibits downstream products 
synthesis along the mevalonate pathway finally run out all of available substrates 
thus leaded to cell apoptosis at 72 hours, in which rose the activities of caspase 3 
and 9. Although all of the glioblastoma cell lines were sensitive to 
lovastatin-induced caspase activation, A172 was more vulnerable compared with 
M059J and M059K. The level (Arbitrary unit) of both caspase 3 and 9 in A172 
cells were much higher then in M059J and K, even all of the glioblastoma cells 
subjected to nearly same amount of cell death. In higher dosage of lovastatin 
» 
(40uM), bongkrekic acid failed to prevent cell death while it could rescue cell death 
at 20uM. This suggest in higher concentration of lovastatin that triggered more 
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4.3 Gene expression profile modulated by Lovastatin in human 
glioblastoma cells 
Microarray analysis gave a wider angle to answer how lovastatin modulates gene 
expression profiles. Surprisingly, lovastatin had not given a huge regulation 
profiles in glioblastoma cells, only several hundreds genes were modulated in 20K 
bioarray chip. There were 57 and 171 genes with three folds up- and 
down-regulation in A172 cells respectively. It is impossible to go through all of the 
regulated genes in this chapter but we would focus on several interesting finding and 
what genes involved. The number of genes up- and down-regulated by lovastatin 
in these glioblastoma cells was showed in appendix table. Up-regulated genes 
involved in wide variety of biological functions including transcriptional factor 
GATAl (GATA binding protein 1) and DSIPI (Delta sleeping inducer protein 
immunoreactor), and a very famous statin-regulated protein, ARHB (RHOB) and 
MRAS (muscle Ras viral oncogene homology). Among down-regulated genes in 
A172 glioblastoma cells, which including several cell cycle regulation protein 
CDC2 (cell division cycle 2), CDC20 (cell division cycle 20), CCNAl (cyclin Al) 
and 2, cell cytoskeleton gene CNN2 (calponin 2, remember the cells shape change 
tramatically in results, part 1), oncogenesis related genes FGF 1，FGF 5 (fibroblast 
growth factor), EPHB 2 (ephrin receptor ephB 2). Spindle assembly checkpoint 
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protein BubRl is thought to act by forming an inhibitory complex with Cdc20 that 
essential for chromosomes achieve bipolar attachment (Davenport et al. 2006). It 
was reported in breast cancer that FGF 1 and 5 might closely related to 
tumorigenesis (Penault-Llorca et al. 1995). 
M059J and M059K were derived from human glioblastoma multiforme that M059J 
lack of DNA protein kinase expression. Interestingly, in microarray analysis, there 
were 745 and 629 genes up- and down-regulated respectively in M059J cells, 
however, in M059K cells, there were only 59 and 91 genes were up- and 
down-regulated respectively. These intriguing results inferred that DNA protein 
kinase may play an important role in regulation of wide variety of genes expression 
in glioblastoma cells. Unexpectedly, There were only few genes found that 
up-regulated simultaneously in these glioblastoma, which included NDRG 1 (heavy 
metal response), KLF 2 (unknown function), ARHB (RhoB), DSIPI (transcription 
regulation) and TIMP3 (metalloprotease inhibitor). Whereas CTGF (insulin-like 
factor receptor binding protein), CYR 61 (unknown biological function), BDNF 
(growth factor-brain derived neurotrophic factor), and SNK (unknown biological 
function) were down-regulated simultaneously after lovastatin treatment. 
Proteins of the RAS superfamily, including Ras, Rho and RaplA, are highly 
dependent upon famesylation and geranylgeranylation for membrane localization. 
I l l 
That the lovastatin-induced impairment of proliferation is reversed by mevalonic 
acid, but not cholesterol, strongly suggests that the effects is attributable to 
alterations in protein isoprenlyation (Wennerberg et al. 2005). Ras homologous 
(Rho) proteins also serve as key regulators of extracellular-stimulus-mediated 
signaling networks that regulate actin organization, cell cycle progression and gene 
expression. In cancer cell, Rho B can limit cell proliferation, survival, invasion, 
and metastasis, and during malignant progression its levels are attenuated commonly. 
Thus up-regulation of Rho B acts to suppress different aspects of cancer 
pathophysiology, however, the mechanism underlay remaining unknown (Huang and 
Prendergast 2006). Although Rho A and Ras contributed to malignant 
transformation, there are growing of evidence showed that Rho B acts as tumor 
suppressive protein in lung, cervical and pancreatic cells (Jiang et al. 2004a;Adnane 
et al. 2002). The majority of GBMs have aberrant EGFR (epithelial growth factor 
receptor) activity through EGFR overexpression, amplification or mutation, Ras 
family pathway plays an important role in activation of EGFRF, which suggested 
that lovastatin could be used to suppress the growth of glioblastoma cells by 
disturbing Rho A and/or Ras (as Rho B suppress those protein). There is only 
limited information about Rho B expression in glioblastoma cell although Rho B 
expression has been reported as a brain tumor marker (Forget et al. 2002), and this is 
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the first report that Rho B was up-regulated by lovastatin in these glioblastoma cell 
lines. Furthermore, from fore-mentioned up-regulated genes, a vague relationship 
can be seen that the linkage of lovastatin mediated the change of glioblastoma genes 
profiles, from RHO to cycle proteins (CDC2 and 20). DSIPI (Delta sleeping 
inducing protein immunoreacter) is generally recognized as glucocorticoid-induced 
leucine zipper (GILZ), with limited attention, recently has been reported to associate 
to apoptosis-related molecule that might be useful for cancer treatment. In this 
study, we have not answered a question that why and how lovastatin sensitized 
glioblastoma (at least in our cell lines) to TRAIL attack. This question may be 
partial answered by the up-regulated gene, GILZ. The gene was first described to 
be up-regulated by glucocorticoid in 1999 in T-cell (Riccardi et al. 1999). Later, 
GILZ has been report to associate with T-cell apoptosis reduction and inhibition, 
binary functions of this gene, which also stimulated production of FasL and Fas to 
mediate self-triggered apoptosis in T-cell (Riccardi et al. 2000). According to this 
limited information, lovastatin sensitized TRAIL-induced apoptosis in glioblastoma 
may be triggered by up-regulation of GILZ as an amplification loop to apoptosis, 
end point at an executioner protein, caspase 3. As Fas and TRAIL reserved the 
same death domain (Fas associated-death domain) to activate downstream product 
caspase 8 (may be caspase 10 also), this hypothetical amplification loop of apoptosis 
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that can be achieved without increase any expression of TRAIL receptor (TRAIL 
receptor has not been up-regulated by lovastatin). In 2001, Mittelstadt P.R. et al 
reported that transient expression of GILZ in Jurkat T cells blocked induction of a 
reporter construct driven by the FasL promoter, which might addressed to 
GILZ-mediated inhibition of Egr-2 and Egr-3, NFAT/AP-1 -inducible transcription 
factors that bind a regulatory element in the FasL promoter and up-regulate FasL 
expression (Mittelstadt and Ashwell 2001). The differential expression of GILZ in 
human has been investigated (Cannarile et al. 2001), hGILZ RNA is clearly 
detectable in brain, lung, spleen and skeletal muscle. Up-regulation of GILZ by 
lovastatin in glioblastoma cells is a valuable finding and need to be further 
elucidated. There were also few pieces of work which showed GILZ associated 
with Ras family protein (Ayroldi et al. 2002), and NF kappa B (Riccardi et al. 
2001;Ayroldi et al. 2001), which are closely related to tumorigenesis and malignant 
transformation. Especially Rho B were up-regulated in these glioblastoma cell 
suggested their strong relation. 
There were only four genes down-regulated in these glioblastoma cells 
simultaneously, which included CTGF (connective tissue growth factor), CYR 61 
(insulin-like growth factor-binding protein 10), BDNF (brain derived neurotrophic 
factor), and SNK (serum-induced kinase). It was not surprising that CTGF and 
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CYR 61 were down-regulated in pair because these two proteins come from same 
family. CTGF and CYR 61 are members of the CCN gene family, which encodes 
six secreted proteins involved in cell cycle control, cell differentiation and cell 
survival (Brigstock 2003) and is named form the initials of the first three family 
members: CYR 61 (CNN 1)， CTGF (CNN 2), and NOV 
(neuroblastoma-overexpressed, CNN 3). The proteins have conserved domains 
homologous to insulin-like growth factor binding proteins, von Willebrand factor 
type C repeat, thrombospondin type I repeat and cysteine-rich motifs (Planque and 
Perbal 2003). The CCN proteins are involved in the control of skeletogenesis and 
expressed by bone cells (Planque and Perbal 2003). Recent studies have showed 
that CCN genes are involved in tumorigenesis. Consistent with its profibrotic 
properties, CTGF is overexpressed in pancreatic cancers (Wenger et al. 1999) and 
melanomas (Kubo et al. 1998) while many of the human tumor cell lines express 
CYR 61，suggesting that CYR 61 expression may also promote tumorigenesis 
(Babic et al. 1999). Furthermore, CYR 61-nonexpressing tumor cell lines tend to 
be less tumorigenic compared with those that do express the protein (Xie et al. 
2001;Tsai et al. 2000). Latest study revealed that gender, tumor stage, and 
pathology were significant associated with overexpression of CTGF in primary 
tumors (Xie et al. 2004). Furthermore, CYR 61 acts as an oncogeen through the 
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integrin-1 inked kinase (ILK) to stimulate p-catenin-TCF/Lef and Akt signaling 
pathways (Frederick et al. 2000). Forced expression of CYR 61 in U343 glioma 
cells accelerated their growth in liquid culture and significantly increased their 
ability to form tumors in nude mice (Xie et al. 2004). There were several reports 
showed that HMG-CoA reductase inhibitors reduced the expression level in human 
renal fibroblast cells(Eberlein et al. 2001) and lung fibroblast (Watts et al. 2005). 
This is the first report that lovastatin showed down-regulatory effects of CYR 61 and 
CTGF in these glioblastoma cells. Down regulatory of these two genes by 
lovastatin may defer the progressive malignancy, and suppress the rate of growth of 
glioblastoma cells. 
In brief, there were only 5 and 4 genes up- and down- regulated (3 folds) 
simultaneously in glioblastoma cells by lovastatin. There is a closely relationship 
between these genes, especially between Rho B, DSIPI (up-regulated) and CTGF, 
CYR 61 (CNN family, down-regulated) in glioblastoma growth regulation and 
induction of apoptosis. 
I 
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4.4 Lovastatin-sensitized TRAIL-induced apoptosis in human 
glioblastoma cells 
Our results demonstrated interaction between lovastatin and TRAIL in several 
cellular events. In glioblastoma cell lines, lovastatin was found to enhance 
TRAIL-induced cytotoxicity in a synergistic manner. The major mode of cell death 
is apoptosis that showed in Annexin V and PI staining results. Cell cycle analysis 
showed that lovastatin induced Go/Gi arrest in glioblastoma cells; however, there 
was no synergistic effect on increasing GO/Gl phase arrest when treated with both 
serum free and lovastatin (data not showed). We further demonstrated that two of 
glioblastoma cell lines were resistant to TRAIL induced apoptosis even though 
TRAIL receptor 2 was up-regulated or G1 arrested, but synergism persisted. We 
inferred that lovastatin sensitized these glioblastoma cells not merely via effects on 
the TRAIL receptor pathway but triggered an unknown mechanism (could probably 
affect by the CNN family down-regulation). This suggests that TRAIL and 
lovastatin together may form a new treatment for glioblastoma multiform, acting 
extrinsic (receptor) and intrinsic (mitochondrial) pathways. In addition, the 
concentration of lovastatin in our experiments (From luM to 40uM, luM to 20uM 
combined with TRAIL) were relatively low when compared with other related 
studies, where concentrations as high as 30-100uM were used (Jones et al. 
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1994;Marcelli et al. 1998). Preclinical data of lovastatin on animals, including 
mouse, rat, rabbit, and dog, revealed linear pharmacokinetics. Doses close to 200 
mg/kg/day would produce serum concentrations in the range of 2-20uM (Gerson et 
al. 1989). Circulating concentrations of 2-4uM were well tolerated for months in 
all models, whereas levels of 20-25uM were associated with progressive anorexia 
and death in rabbits (Kombrust et al. 1989). 
The mechanism how lovastatin sensitized glioblastoma cells to TRAIL 
induced-apoptosis remains unknown. Mevalonate is a critical component of a 
complex biochemical pathway and their products are vital for a variety of important 
cellular functions including cell signaling, protein synthesis, and cell cycle 
regulation (Goldstein and Brown 1990). Little is known about the molecular 
events leading to apoptosis of cancer cells due to lovastatin exposure, probably 
apoptosis was abrogated by mevalonate and GGPP and was partially reversed by 
FPP (Chan et al. 2003). The main apoptotic event induced by lovastatin is 
mitochondrial-dependent pathway which BCL-2 family protein plays an important 
role. Globe gene expression analysis by microarray served an excellent method to 
elucidate molecular basis on how lovastatin regulates and induces apoptosis on 
glioblastoma cells. 
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There is growing evidence that cross-talk between the extrinsic and intrinsic 
pathways acts as an amplification loop. This cross-talk involves BCL-2 family 
members like bid, which is cleaved by caspase 8 and translocates to the 
mitochondria, where it and mediates cytochrome c effects in response to extrinsic 
death pathway activation (Knight et al. 2004;Green 2000). Furthermore, in some 
tumor cells, TRAIL is capable to induce either mitochondrial-independent or 
dependent apoptotic pathway, characteristic of cells termed type I or type II， 
respectively (Bouralexis et al. 2005;Reed 2000). Unfortunately, the synergy by 
TRAIL and lovastatin may not involve in this amplification loop due to unchanged 
level of bid expression (data not showed). It is not completely understood why 
some tumor cells are resistant to TRAIL-induced apoptosis although some 
mechanisms of action have been proposed. Our RT-PCR showed that there were 
no decoy receptors up-regulated implied that resistant of TRAIL was not through 
this mechanism. 
Our results also reinforced our previous study that DNA-dependent protein kinase 
play an important role in cell apoptosis. M059J lacked of DNA-PK activity and 
are resistant not only to total cell death but also apoptosis (Chen et al. 2005b;Chen et 
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al. 2005a). There is much controversy with respect to the functions of DNA-PK in 
cell regulation. DNA-PK had been reported to promote cell death by interacting 
with telomeres, whereas other reports suggest that DNA-PK protects cells from cell 
death via caspase-independent or p53 independent pathways. The reason for this 
paradoxical finding remains unknown. 
Finally, our studies demonstrated a synergistic interaction between lovastatin and 
TRAIL. Our results are in accord with the concept of combined action via both 
intrinsic and extrinsic apoptotic cell death pathways. This combination of 
non-chemotherapeutic drugs offers potential form of glioblastoma treatment. 
I 
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Chapter Five: Conclusion and Future perspective 
In a brief review of our study, our findings demonstrated that lovastatin caused 
anti-proliferation, apoptotic effects in human glioblastoma cell lines A172, M059J, 
and M059K. Synergistic effects were found by combining lovastatin and TRAIL to 
induced glioblastoma cells death and apoptosis, thus support our hypothesis that 
triggers both of the intrinsic and extrinsic pathway might act as a new approach of 
treatment on human glioblastoma cells. Moreover, form the simultaneously 
expressed genes in these glioblastoma cells, there is a close relationship that 
lovastatin involved in Rho family proteins regulation and CNN family proteins. 
Induction of apoptosis in glioblastoma cells is a promising method for low 
cytotoxicity without trigger systematic inflammation. Lovastatin and TRAIL are 
ideal candidates for new treatment development for GBM. 
Future perspective 
Although we showed that lovastatin strongly related to Rho Family proteins and 
CNN family proteins regulation that may contribute to sensitized TRAIL-induced 
apoptosis, there was an im-answered question: how does lovastatin do that? A 
detail investigation on the regulation of DSIPI gene is an excellent direction to relate 
the apoptotic amplification loop. Moreover, overexpression or knockout 
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approaches for fore-mentioned genes could be used for understanding the 
mechanism behind. M059J and M059K glioblastoma cells are capable to form 
turmor lump when injected in nude mice, which served an excellent follow up work 
in vivo. Combining lovastatin and TRAIL to in vivo study is a critical step to develop 
reliable and plausible scheme. Defining the maximum tolerate dosage for both 
lovastatin and TRAIL would be essential for clinical trial (although pharmacokinetic 
of lovastatin is well known, TRAIL has not been fully investigated). 
» 
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Appendix 
Gene expression induced by lovastatin in A172 glioblastoma cells 
NCBI_ACC Gene Initials DESCRIPTION Fold 
Changes 
U1708 丨 #N/A #N/A 48.38 
AK026253 NULL Homo sapiens cDNA: FLJ22600 fis, clone HS104447, 21.00 
highly similar to AF105036 Homo sapiens zinc finger 
transcription factor GKLF mRNA 
NM_004089 DSIPI Homo sapiens delta sleep inducing peptide, 12.87 
immunoreactor (DSIPI), mRNA. 
NM一003603 ARGBP2 Homo sapiens Arg/Abl-interacting protein ArgBP2 11.53 
(ARGBP2), transcript variant 1, mRNA 
NM_004102 FABP3 Homo sapiens fatty acid binding protein 3，muscle and 11.45 
heart (mammary-derived growth inhibitor) (FABP3), 
mRNA 
NM_002274 KRT13 Homo sapiens keratin 13 (KRT13), mRNA 11.30 
AK026253 NULL Homo sapiens cDNA: FLJ22600 fis, clone HSI04447, 11.18 
highly similar to AF 105036 Homo sapiens zinc finger 
transcription factor GKLF mRNA 
NM_001674 ATF3 Homo sapiens activating transcription factor 3 (ATF3), 10.50 
mRNA 
NM_013230 CD24 Homo sapiens CD24 antigen (small cell lung carcinoma 9.32 
cluster 4 antigen) (CD24), mRNA 
NM一004040 ARHB Homo sapiens ras homolog gene family, member B 9.30 
(ARHB), mRNA 
NM_000760 CSF3R Homo sapiens colony stimulating factor 3 receptor 9.30 
(granulocyte) (CSF3R), mRNA. 
NM—004433 ELF3 Homo sapiens E74-like factor 3 (ets domain transcription 8.36 
factor, epithelial-specific ) (ELF3), mRNA 
NM_000362 TIMP3 Homo sapiens tissue inhibitor of metalloproteinase 3 7.54 
(Sorsby fundus dystrophy, pseudoinflammatory) (TIMP3), 
mRNA 
ABOS1470 KIAA1683 Homo sapiens mRNA for KIAA1683 protein, partial cds 6.67 
• J00287 NULL Human pepsinogen gene, exon 9 6.55 
NM_020672 LOC57402 Homo sapiens SlOO-type calcium binding protein A M 6.23 
(LOC57402), mRNA. “ 
NM_002421 MMPl Homo sapiens matrix metalloproteinase 1 (interstitial 6.02 
collagenase) (MMPl) , mRNA 
1 5 0 
NM_006720 ABLIM Homo sapiens actin binding LIM protein (ABLIM), 5.79 
transcript variant ABLIM-s, mRNA. 
NM_003122 SPINK 1 Homo sapiens serine protease inhibitor, Kazal type 1 5.76 
(SPINKl), mRNA 
X06389 SYP Human mRNA for synaptophysin (p38) 5.65 
Y00705 NULL Serine protease inhibitor Kazal type 1, inhibitor of 5.61 
pancreatic secreted trypsin, protects integrity of 
gastrointestinal mucosa and shows decreased levels in 
ulcerative colitis; mutations in the corresponding gene are 
associated with chronic pancreatitis 
NM_020987 ANK3 Homo sapiens ankyrin 3, node of Ranvier (ankyrin G) 5.21 
(ANK3), transcript variant 1，mRNA. 
NM_000574 DAF Homo sapiens decay accelerating factor for complement 5.17 
(CD55, Cromer blood group system) (DAF), mRNA. 
NM_006096 NDRGl Homo sapiens N-myc downstream regulated gene 1 4.80 
(NDRGl) , mRNA. 
BQ430788 NULL AGENCOURT_7776027 Homo sapiens cDNA 5' end 4.71 
AF288741 0SBP2 Homo sapiens oxysterol binding protein 2 (0SBP2) 4.61 
mRNA, complete cds 
NM_016270 KLF2 Homo sapiens Kruppel-like factor (LOC51713), mRNA. 4.41 
NM_024111 MGC4504 Homo sapiens hypothetical protein MGC4504 4.41 
(MGC4504), mRNA 
M62324 MRF-1 Human modulator recognition factor I (MRF-1) mRNA, 3' 4.40 
end 
NM_033016 PDGFB Homo sapiens platelet-derived growth factor beta 4.37 
polypeptide (simian sarcoma viral (v-sis) oncogene 
homolog) (PDGFB), transcript variant 2，mRNA. 
AK024270 NULL Homo sapiens cDNA FLJ14208 fis, clone NT2RP3003264 4.30 
NM_019058 RTP801 Homo sapiens HlF-1 responsive RTP801 (RTP801), 4.17 
mRNA 
NM_001505 GPR30 Homo sapiens G protein-coupled receptor 30 (GPR30), 4.00 
mRNA 
AK055334 NULL Homo sapiens cDNA FLJ30772 fis, clone 3.82 
> FEBRA2000757, moderately similar to Homo sapiens 
“ BM-009 mRNA 
NM_014731 KIAA0552 Homo sapiens KIAA0552 gene product (ICIAA0552), 3.81 
mRNA. 
BC004158 ELAC2 Homo sapiens, putative prostate cancer susceptibility 3.79 
1 5 1 
protein, clone MGC:2441 丨MAGE:2820640，mRNA, 
complete cds 
NM_002049 GATAl Homo sapiens GATA binding protein 1 (globin 3.77 
transcription factor 1) (GATA 1), mRNA. 
AB033043 D1CFZP761L0424 Homo sapiens mRNA for KlAAl217 protein, partial cds 3.75 
NM一004083 DDIT3 Homo sapiens DNA-damage-inducible transcript 3 3.74 
(DDIT3), mRNA 
AB058688 F E M I A Homo sapiens mRNA for KIAA1785 protein, partial cds 3.70 
NM_012219 MRAS Homo sapiens muscle RAS oncogene homolog (MRAS), 3.54 
mRNA. 
S71824 N C A M l N-CAM=145 kda neural cell adhesion molecule [human, 3.51 
small cell lung cancer cell line 0S2-R, mRNA, 2960 nt] 
NM_003036 SKI Homo sapiens v-ski sarcoma viral oncogene homolog 3.39 
(avian) (SKI), mRNA 
BE263911 NULL 601191247F1 NIH_MGC_7 Homo sapiens cDNA clone 3.39 
IMAGE:3535307 5’，mRNA sequence 
AW888226 NULL MXRAl Homo sapiens cDNA 3.38 
NM_004836 EIF2AK3 Homo sapiens eukaryotic translation initiation factor 3.35 
2-alpha kinase 3 (EIF2AK3), mRNA. 
NM_001305 CLDN4 Homo sapiens claudin 4 (CLDN4), mRNA. 3.31 
AF131821 NULL Homo sapiens clone 24877 mRNA sequence 3.30 
NM_006813 P R 0 L 2 Homo sapiens proline rich 2 (PR0L2) , mRNA 3.22 
AB020677 KIAA0870 Homo sapiens mRNA for KIAA0870 protein, partial cds 3.21 
NM_003706 PLA2G4C Homo sapiens phospholipase A2, group IVC (cytosolic, 3.21 
calcium-independent) (PLA2G4C), mRNA. 
NM_004417 DUSPl Homo sapiens dual specificity phosphatase 1 (DUSPl) , 3.19 
mRNA. 
AKOOOlll FLJ20093 Homo sapiens cDNA FLJ20104 fis, clone COL04806 3.13 
NM_000432 MYL2 Homo sapiens myosin, light polypeptide 2, regulatory, 3.06 
cardiac, slow (MYL2), mRNA. 
NM一004209 SYNGR3 Homo sapiens synaptogyrin 3 (SYNGR3), mRNA. 3.03 
Gene expression reduced by lovastatin in A172 glioblastoma cells 
NCBJ_ACC Gene Initials DESCRIPTION Fold 
. Changes 
NM_001901 CTGF Homo sapiens connective tissue growth factor 37.27 
(CTGF), mRNA. 
NM_004657 SDPR Homo sapiens serum deprivation response 19.16 
(phosphatidylserine binding protein) (SDPR), 
1 5 2 
mRNA. 
NM一031958 KRTAP3-1 Homo sapiens keratin associated protein 3.1 15.80 
(KRTAP3.1), mRNA 
NM_016192 TMEFF2 Homo sapiens transmembrane protein with 14.65 
EGF-like and two follistatin-like domains 2 
(TMEFF2), mRNA. 
NM_001554 CYR61 Homo sapiens cysteine-rich, angiogenic inducer, 12.56 
61 (CYR61), mRNA 
NM_002924 RGS7 Homo sapiens regulator of G-protein signalling 7 11.86 
(RGS7), mRNA. 
NM_006622 SNK Homo sapiens serum-inducible kinase (SNK), 10.84 
mRNA. 
NM一004018 DMD Homo sapiens dystrophin (muscular dystrophy, 10.51 
Duchenne and Becker types), includes DXS142, 
DXS164, DXS206, DXS230, DXS239, DXS268, 
DXS269, DXS270, DXS272 (DMD), transcript 
variant Dp71ab, mRNA. 
NM_016448 RAMP Homo sapiens RA-regulated nuclear 9.00 
matrix-associated protein (RAMP), mRNA. 
NM_003542 H4FG Homo sapiens H4 histone family, member G 8.73 
(H4FG), mRNA. 
NM_014736 KIAAOlOl Homo sapiens KIAAOlOl gene product 7.66 
(KIAAOlOl), mRNA. 
NM_016201 A M 0 T L 2 Homo sapiens Leman coiled-coil protein (LCCP), 7.56 
mRNA. 
NM_001071 TYMS Homo sapiens thymidylate synthetase (TYMS), 7.54 
mRNA. 
NM_020675 AD024 Homo sapiens AD024 protein (AD024), mRNA 7.52 
NM_018518 MCMIO Homo sapiens homolog of yeast MCM10; 7.39 
hypothetical protein PR02249 (PR02249), 
mRNA. 
NM_001450 FHL2 Homo sapiens four and a half LIM domains 2 7.20 
I (FHL2), mRNA. 
• L19183 MAC30 Human MAC30 mRNA, 3' end 7.06 
NM_018154 FLJ10604 Homo sapiens hypothetical protein FLJ10604 6.98 
(FU10604), mRNA. 
NM_002692 P0LE2 Homo sapiens polymerase (DNA directed), 6.77 
epsilon 2 (p59 subunit) (P0LE2), mRNA 
1 5 3 
NM_005824 P37NB Homo sapiens 37 kDa leucine-rich repeat (LRR) 6.76 
protein (P37NB), mRNA. 
NM_018410 DKFZp762E1312 Homo sapiens hypothetical protein 6.53 
DKFZp762E 1312 (DKFZp762E 1312)，mRNA. 
NM_001175 ARHGDIB Homo sapiens Rho GDP dissociation inhibitor 6.33 
(GDI) beta (ARHGDIB), mRNA. 
AB075863 FLJ30681 Homo sapiens mRNA for KIAA1983 protein 6.14 
NM_032117 GAJ Homo sapiens GAJ protein (GAJ), mRNA 5.57 
AB051510 DLCl Homo sapiens mRNA for KIAA1723 protein, 5.48 
partial cds 
NM—022346 HCAP-G Homo sapiens chromosome condensation protein 5.44 
G (HCAP-G), mRNA. 
NM一007036 ESMl Homo sapiens endothelial cell-specific molecule 1 5.44 
(ESMl) , mRNA. 
NM_005627 SGK Homo sapiens serum/glucocorticoid regulated 5.27 
kinase (SGK), mRNA. 
NM_012294 KIAA0277 Homo sapiens guanine nucleotide exchange factor 5.25 
for Rap l ; M-Ras-regulated GEF (KIAA0277), 
mRNA. 
AB037820 KIAA1399 Homo sapiens mRNA for KIAA1399 protein, 5.22 
partial cds 
NM_007305 BRCA1 Homo sapiens breast cancer 1，early onset 5.15 
(BRCAl) , transcript variant 
BRCA 1 -delta9- 10- l lb , mRNA. 
NM_032772 MGC2555 Homo sapiens hypothetical protein MGC2555 5.10 
(MGC2555), mRNA 
NM_007057 ZWINT Homo sapiens ZWIO interactor (ZWINT), 5.07 
transcript variant 1，mRNA 
NM_024053 MGC861 Homo sapiens hypothetical protein MGC861 5.05 
(MGC861), mRNA 
NM_012474 UMPK Homo sapiens uridine monophosphate kinase 5.00 
(UMPK), mRNA. 
NM—000057 BLM Homo sapiens Bloom syndrome (BLM), mRNA. 5.00 
• NM_018153 TEM8 Homo sapiens tumor endothelial marker 8 4.91 
(TEM8), transcript variant 3’ mRNA. 
NM_002592 PCNA Homo sapiens proliferating cell nuclear antigen 4.89 
(PCNA), mRNA. 
NM_002889 RARRES2 Homo sapiens retinoic acid receptor responder 4.84 
1 5 4 
(tazarotene induced) 2 (RARRES2), mRNA 
NM_001424 EMP2 Homo sapiens epithelial membrane protein 2 4.79 
(EMP2), mRNA. 
NM_004464 FGF5 Homo sapiens fibroblast growth factor 5 (FGF5), 4.78 
transcript variant 1，mRNA 
NM_018454 ANKT Homo sapiens nucleolar protein ANKT (ANKT), 4.69 
mRNA. 
AF095719 CPA4 Homo sapiens carboxypeptidase A3 mRNA, 4.67 
complete cds 
NM_001709 BDNF Homo sapiens brain-derived neurotrophic factor 4.64 
(BDNF), mRNA 
NM_002105 H2AFX Homo sapiens H2A histone family, member X 4.63 
(H2AFX), mRNA. 
NM_000465 BARDl Homo sapiens BRCAl associated RING domain 1 4.62 
(BARDl) , mRNA. 
NM_004675 ARHI Homo sapiens ras homolog gene family, member I 4.55 
(ARHI), mRNA. 
NM_000800 FGFl Homo sapiens fibroblast growth factor 1 (acidic) 4.54 
(FGFl), transcript variant 1, mRNA 
NM_018492 TOPK Homo sapiens T-LAK cell-originated protein 4.40 
kinase (TOPK), mRNA 
AK024303 NULL Homo sapiens cDNA FU14241 fis, clone 4.34 
OVARC1000533 
NM_005651 T D 0 2 Homo sapiens tryptophan 2,3-dioxygenase 4.32 
(TD02), mRNA. 
NM_024094 MGC5528 Homo sapiens hypothetical protein MGC5528 4.32 
(MGC5528), mRNA. 
NM_001254 CDC6 Homo sapiens CDC6 cell division cycle 6 4.32 
homolog (S. cerevisiae) (CDC6), mRNA. 
NM_000248 MITF Homo sapiens microphthalmia-associated 4.32 
transcription factor (MITF), mRNA. 
NM_016095 LOC51659 Homo sapiens HSPC037 protein (LOC51659), 4.29 
� mRNA. 
• BF675037 NULL 602136629F1 Homo sapiens cDNA 5' end 4.27 
NM_024629 FLJ23468 Homo sapiens hypothetical protein FLJ23468 4.27 
(FU23468), mRNA 
AL833007 NULL Homo sapiens mRNA; cDNA DKFZp666H224 4.24 
(from clone DKFZp666H224) 
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NM_004217 STK12 Homo sapiens serine/threonine kinase 12 4.20 
(STK12), mRNA. 
NM_012112 C20orfl Homo sapiens chromosome 20 open reading 4.19 
frame 1 (C20orfl), mRNA. 
AF113511 NULL Homo sapiens integrin subunit alpha-2 (ITGA2) 4.17 
gene, ITGA2-2 allele, 3'UTR 
AK024835 NULL Homo sapiens cDNA: FLJ21182 fis, clone 4.16 
CAS 11560, highly similar to D83735 Homo 
sapiens mRNA for neutral calponin 
NM_003384 VRKl Homo sapiens vaccinia related kinase 1 (VRKl) , 4.15 
mRNA. 
NM_032297 DKFZp761D112 Homo sapiens hypothetical protein 4.15 
DKFZp761D112 (DKFZp761D112), mRNA 
NM_004523 KNSLl Homo sapiens kinesin-like 1 (KNSLl) , mRNA. 4.14 
NM_031299 MGC2577 Homo sapiens hypothetical protein MGC2577 4.14 
(MGC2577), mRNA. 
NM_003579 RAD54L Homo sapiens RAD54-like (S. cerevisiae) 4.14 
(RAD54L), mRNA. 
NM_013300 HSU79274 Homo sapiens protein predicted by clone 23733 4.14 
(HSU79274), mRNA 
S53374 NULL SCImputative trans-acting factor involved in cell 4.12 
cycle control [human, mRNA, 2481 nt] 
NM O 14096 EEGl Homo sapiens hypothetical protein 4.11 
DKFZp762A227 (DKFZp762A227), mRNA 
BCO19075 FLJ11252 Homo sapiens, hypothetical protein F U l 1252, 4.08 
clone MGC:29639 IMAGE:5091386, mRNA, 
complete cds 
NM_006681 NMU Homo sapiens neuromedin U (NMU), mRNA. 4.08 
NM_014397 NEK6 Homo sapiens NIMA (never in mitosis gene 4.07 
a)-related kinase 6 (NEK6), mRNA. 
NM_014176 HSPC150 Homo sapiens HSPC150 protein similar to 4.03 
ubiquitin-conjugating enzyme (HSPC150), 
� mRNA. 
• X74794 MCM4 H.sapiens Pl-Cdc21 mRNA 4.02 
NM_000055 BCHE Homo sapiens butyrylcholinesterase (BCHE), 4.00 
mRNA. 
AK024998 NULL Homo sapiens cDNA: FLJ21345 fis, clone 4.00 
COL02694 
1 5 6 
NM—024680 FLJ23311 Homo sapiens hypothetical protein FLJ23311 3.98 
(FU23311), mRNA 
BCO15050 NULL Homo sapiens, clone MGC:9610 3.96 
IMAGE:3908972, mRNA, complete cds 
NM_000791 DHFR Homo sapiens dihydrofolate reductase (DHFR), 3.95 
mRNA 
AK002195 MacGAP Homo sapiens cDNA FU11333 fis, clone 3.93 
PLACE1010616 
NM—031300 MXD3 Homo sapiens likely ortholog of mouse Max 3.88 
dimerization protein 3 (MAD3), mRNA 
NM_013962 NRGl Homo sapiens neuregulin 1 (NRG 1)，transcript 3.88 
variant GGF2, mRNA. 
U79415 CTSC Homo sapiens prepro dipeptidyl peptidase I 3.87 
(DPP-I) gene, complete cds 
AF402776 BIC Homo sapiens BIC noncoding mRNA, complete 3.87 
sequence 
A L U 7 6 5 3 NULL Homo sapiens mRNA; cDNA DKFZp586C0224 3.86 
(from clone DKFZp586C0224) 
NM—004237 TRIP 13 Homo sapiens thyroid hormone receptor 3.86 
interactor 13 (TRIP 13)，mRNA. 
NM_005438 FOSLl Homo sapiens FOS-like antigen 1 (FOSLl) , 3.86 
mRNA 
NM_004431 EPHA2 Homo sapiens EphA2 (EPHA2), mRNA. 3.84 
NM_032737 LMNB2 Homo sapiens hypothetical protein MGC2721 3.84 
(MGC2721), mRNA 
NM_145697 CDCAl Homo sapiens cell division cycle associated 1 3.82 
(CDCAl) , transcript variant 1，mRNA 
NM_014109 PR02000 Homo sapiens PR02000 protein (PR02000) , 3.82 
mRNA. 
NM_000331 SAAl Homo sapiens serum amyloid Al (SAAl) , 3.79 
mRNA. 
NM_006596 POLQ Homo sapiens polymerase (DNA directed), theta 3.76 
� (POLQ), mRNA. 
’ NM_004789 LHX2 Homo sapiens LIM homeobox protein 2 (LHX2), 3.74 
mRNA. 
NM_001905 CTPS Homo sapiens CTP synthase (CTPS), mRNA. 3.71 
NM_001237 CCNA2 Homo sapiens cyclin A2 (CCNA2), mRNA. 3.70 
AB067482 FLJ22794 Homo sapiens mRNA for KIAA1895 protein, 3.70 
1 5 7 
partial cds 
NM_024314 MGC4294 Homo sapiens hypothetical protein MGC4294 3.69 
(MGC4294), mRNA 
NM一022909 CENPH Homo sapiens centromere protein H (CENPH), 3.68 
mRNA 
NM_002388 MCM3 Homo sapiens MCM3 minichromosome 3.68 
maintenance deficient 3 (S. cerevisiae) (MCM3), 
mRNA 
NM一005855 RAMPl Homo sapiens receptor (calcitonin) activity 3.66 
modifying protein 1 (RAMPl) , mRNA. 
NM_025108 FU13909 Homo sapiens hypothetical protein FU13909 3.64 
(FU13909), mRNA 
NM_000745 CHRNA5 Homo sapiens cholinergic receptor, nicotinic, 3.62 
alpha polypeptide 5 (CHRNA5), mRNA. 
AK025833 NULL Homo sapiens cDNA: FU22180 fis, clone 3.60 
HRC00936 
NM一004368 CNN2 Homo sapiens calponin 2 (CNN2), mRNA. 3.59 
NM_030583 MATN2 Homo sapiens matrilin 2 (MATN2) precursor, 3.55 
transcript variant 2，mRNA. 
NM_031908 C1QTNF2 Homo sapiens CIq and tumor necrosis factor 3.55 
related protein 2 (C1QTNF2), mRNA 
NM—031966 CCNBl Homo sapiens cyclin B1 (CCNBl) , mRNA. 3.53 
NM_018092 FLJ10430 Homo sapiens hypothetical protein F U 10430 3.53 
( F U 10430), mRNA. 
NM_006845 KNSL6 Homo sapiens kinesin-like 6 (mitotic 3.52 
centromere-associated kinesin) (KNSL6), mRNA. 
AL833733 NULL Homo sapiens mRNA; cDNA DKFZp666J045 3.51 
(from clone DKFZp666J045) 
NM_004442 EPHB2 Homo sapiens EphB2 (EPHB2), transcript variant 3.51 
UniRNA. 
AK057236 NULL Homo sapiens cDNA FLJ32674 fis, clone 3.46 
TESTI1000142, highly similar to 
‘ TRANSDUCIN-LIKE ENHANCER PROTEIN 4 
» NM_005225 E2F1 Homo sapiens E2F transcription factor 1 (E2F1), 3.45 
mRNA. 
NM_003057 SLC22A1 Homo sapiens solute carrier family 22 (organic 3.44 
cation transporter), member 1 (SLC22A1), 
mRNA. 
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NM_001255 CDC20 Homo sapiens CDC20 cell division cycle 20 3.41 
homolog (S. cerevisiae) (CDC20), mRNA. 
NM_025080 FLJ22316 Homo sapiens hypothetical protein FLJ22316 3.41 
(FU22316), mRNA. 
NM_030952 DKFZP434J037 Homo sapiens hypothetical protein 3.40 
DKFZp434J037 (DKFZP434J037), mRNA 
NM_001786 CDC2 Homo sapiens cell division cycle 2, G1 to S and 3.39 
G2 to M (CDC2), transcript variant 1，mRNA. 
NM—015895 GMNN Homo sapiens geminin (LOC51053), mRNA 3.38 
NM_005102 FEZ2 Homo sapiens fasciculation and elongation 3.38 
protein zeta 2 (zygin II) (FEZ2), mRNA. 
NM_020394 LOC57116 Homo sapiens zinc finger protein SBZF3 3.37 
(LOC57116), mRNA 
NM_020165 RAD18 Homo sapiens postreplication repair protein 3.37 
hRAD18p (RAD 18), mRNA 
AK022705 FLJ12643 Homo sapiens cDNA FLJ12643 fis, clone 3.37 
NT2RM4001969, moderately similar to 
R.norvegicus mRNA for 1P63 protein 
AJ420504 NULL Homo sapiens mRNA full length insert cDNA 3.35 
clone EUROIMAGE 2069692 
NM_020038 ABCC3 Homo sapiens ATP-binding cassette, sub-family C 3.34 
(CFTR/MRP), member 3 (ABCC3), transcript 
variant MRP3B, mRNA. 
AB046790 NULL Homo sapiens mRNA for KIAAl 570 protein, 3.33 
partial cds 
NM_006444 SMC2L1 Homo sapiens SMC2 structural maintenance of 3.33 
chromosomes 2-like 1 (yeast) (SMC2L1), mRNA. 
NM_002291 LAMBl Homo sapiens laminin, beta 1 (LAMBl) , mRNA 3.32 
NM_005887 DLEUl Homo sapiens deleted in lymphocytic leukemia，1 3.32 
(DLEUl), mRNA. 
NM_006195 PBX3 Homo sapiens pre-B-cell leukemia transcription 3.32 
factor 3 (PBX3), mRNA. 
BI823044 NULL 603039652F1 Homo sapiens cDNA 5’ end 3.31 
. D 3 8 5 5 3 KIAA0074 Homo sapiens HCAP-H mRNA, partial cds 3.31 
NM_003503 CDC7L1 Homo sapiens CDC7 cell division cycle 7-like 1 3.31 
(S. cerevisiae) (CDC7L1), mRNA 
NM_003897 IER3 Homo sapiens immediate early response 3 (IER3), 3.29 
transcript variant short, mRNA. 
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NM J 52524 TRIPIN Homo sapiens tripin (TRIPIN), mRNA 3.28 
NM_024745 SHCBPl Homo sapiens hypothetical protein FLJ22009 3.26 
(FU22009) , mRNA 
AL049437 NULL Homo sapiens mRNA; cDNA DKFZp586El 120 3.26 
(from clone DKFZp586E1120) 
AK026748 NULL Homo sapiens cDNA: FU23095 fis, clone 3.26 
LNG07413 
NM_013290 HUMGT198A Homo sapiens GT198, complete ORF 3.25 
(HUMGT198A), mRNA 
NM_032472 NULL Homo sapiens peptidylprolyl isomerase 3.24 
(cyclophilin)-like 3 (PPIL3), mRNA. 
NM_030941 LOC81691 Homo sapiens exonuclease NEF-sp (LOC81691), 3.23 
mRNA. 
NM_006350 FST Homo sapiens follistatin (FST), transcript variant 3.20 
FST317, mRNA. 
NM_000224 K.RT18 Homo sapiens keratin 18 (KRT18), mRNA 3.20 
AF288571 LEFl Homo sapiens lymphoid enhancer factor-1 (LEFl ) 3.19 
mRNA, complete cds 
NM_002358 MAD2L1 Homo sapiens MAD2 mitotic arrest deficient-like 3.19 
1 (yeast) (MAD2L1)，mRNA. 
NM_014708 KNTCl Homo sapiens kinetochore associated 1 (KNTCl) , 3.18 
mRNA. 
NM_003016 SFRS2 Homo sapiens splicing factor, arginine/serine-rich 3.18 
2 (SFRS2), mRNA. 
AA196960 NULL zq59g01.rl Stratagene neuroepithelium (#937231) 3.18 
Homo sapiens cDNA clone IMAGE:645936 5’， 
mRNA sequence 
NM_032642 WNT5B Homo sapiens wingless-type MMTV integration 3.17 
site family, member 5B (WNT5B), transcript 
variant 1，mRNA. 
NM_003567 BCAR3 Homo sapiens breast cancer anti-estrogen 3.17 
resistance 3 (BCAR3), mRNA. 
NM_016553 NUP62 Homo sapiens nucleoporin 62kD (NUP62), 3.15 
‘ mRNA. 
NM_022748 TEM6 Homo sapiens tumor endothelial marker 6 3.15 
(TEM6), mRNA 
BM928826 NULL AGENCOURT_6683145 Homo sapiens cDNA 5' 3.14 
end 
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NM_014783 A R H G A P l l A Homo sapiens KIAAOO13 gene product 3.14 
(ARHGAPl lA) , mRNA 
NM一004526 MCM2 Homo sapiens MCM2 minichromosome 3.13 
maintenance deficient 2，mitotin (S. cerevisiae) 
(MCM2), mRNA. 
NM_032024 CDA017 Homo sapiens CD AO 17 protein (CDAO17)， 3.13 
mRNA. 
AL832194 EDG3 Homo sapiens mRNA; cDNA DKFZp686C042 3.11 
(from clone DKFZp686C042) 
NM_003914 CCNAl Homo sapiens cyclin A1 (CCNAl) , mRNA 3.10 
AL080111 NULL Homo sapiens mRNA; cDNA DKFZp586G2222 3.09 
(from clone DKFZp586G2222) 
ALl 33055 DKFZp434J1015 Homo sapiens mRNA; cDNA DKFZp434J1015 3.09 
(from clone DKFZp434J1015) 
NM_005483 CHAFl A Homo sapiens chromatin assembly factor 1, 3.08 
subunit A (pi50) (CHAFl A), mRNA 
J04621 SDC2 Human heparan sulfate proteoglycan (HSPG) core 3.07 
protein, 3’ end 
NM_000022 ADA Homo sapiens adenosine deaminase (ADA), 3.05 
mRNA. 
NM_006528 TFPI2 Homo sapiens tissue factor pathway inhibitor 2 3.05 
(TFPI2), mRNA. 
AL136883 NULL Homo sapiens mRNA; cDNA DKFZp434D166 3.05 
(from clone DKFZp434D166); complete cds 
NM_031209 TGT Homo sapiens tRNA-guanine transglycosylase 3.05 
(TGT), mRNA. 
NM_005737 ARL7 Homo sapiens ADP-ribosylation factor-like 7 3.04 
(ARL7), mRNA. 
Gene expression induced by lovastatin in M059J glioblastoma cells 
NCBI_ACC Gene Initials DESCRIPTION Fold 
Changes 
NM_003564 TAGLN2 Homo sapiens transgelin 2 (TAGLN2), mRNA. 43.28 
AB028944 A T P l l A Homo sapiens mRNA for KIAA1021 protein, 42.50 
‘ partial cds 
NM-014945 KIAA0843 Homo sapiens KIAA0843 protein (KIAA0843), 29.67 
mRNA. 
NM_000967 RPL3 Homo sapiens ribosomal protein L3 (RPL3), 24.40 
mRNA. 
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NM_004317 ASNA1 Homo sapiens arsA arsenite transporter, 21.16 
ATP-binding, homolog 1 (bacterial) (ASNAl) , 
mRNA. 
NM_001513 GSTZl Homo sapiens glutathione transferase zeta 1 21.02 
(maleylacetoacetate isomerase) (GSTZl) , mRNA. 
NM_015368 PANXl Homo sapiens pannexin 1 (PANXl)，mRNA. 20.95 
NM_002109 HARS Homo sapiens histidyl-tRNA synthetase (HARS), 19.50 
mRNA 
NM_003481 USPS Homo sapiens ubiquitin specific protease 5 17.84 
(isopeptidase T) (USPS), mRNA. 
NM_015680 CGI-57 Homo sapiens hypothetical protein (CGI-57), 17.05 
mRNA. 
NM_003079 SMARCEl Homo sapiens SWI/SNF related, matrix 16.57 
associated, actin dependent regulator of 
chromatin, subfamily e, member 1 (SMARCEl) , 
mRNA 
NM_000182 HADHA Homo sapiens hydroxyacyl-Coenzyme A 15.86 
dehydrogenase/3-ketoacyl-Coenzyme A 
thiolase/enoyl-Coenzyme A hydratase 
(trifunctional protein), alpha subunit (HADHA), 
mRNA 
NM_002764 PRPSl Homo sapiens phosphoribosyl pyrophosphate 15.04 
synthetase 1 (PRPSl) , mRNA. 
NM_016026 ARSDRl Homo sapiens CGI-82 protein (LOC51109), 14.69 
mRNA. 
NM一018113 LIMR Homo sapiens lipocalin-interacting membrane 14.66 
receptor (LIMR), mRNA. 
NM_014610 G2AN Homo sapiens alpha glucosidase II alpha subunit 14.34 
(G2AN), mRNA 
NM_145298 A P 0 B E C 3 F Homo sapiens similar to Phorbolin 3 13.40 
(APOBECl-l ike) (LOC200316), mRNA 
NM_015966 SDBCAG84 Homo sapiens serologically defined breast cancer 13.34 
- antigen 84 (SDBCAG84), mRNA 
，N M _ 0 0 4 9 2 2 SEC24C Homo sapiens SEC24 related gene family, 13.18 
member C (S. cerevisiae) (SEC24C), mRNA. 
NM—004436 ENSA Homo sapiens endosulfme alpha (ENSA), mRNA 12.76 
NM_005167 ARHC Homo sapiens ras homolog gene family, member 12.48 
C (ARHC), mRNA. 
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NM—004925 AQP3 Homo sapiens aquaporin 3 (AQP3), mRNA. 12.35 
NM_001640 APEH Homo sapiens N-acylaminoacyl-peptide 12.24 
hydrolase (APEH), mRNA. 
NM_152374 FLJ38984 Homo sapiens hypothetical protein FLJ38984 12.11 
(FU38984), mRNA 
NM_003299 TRAl Homo sapiens tumor rejection antigen (gp96) 1 12.07 
(TRAl) , mRNA 
NM_016816 OASl Homo sapiens 2',5'-oligoadenylate synthetase 1 11.97 
(40-46 kD) (OASl) , transcript variant E l8 , 
mRNA. 
NM_001490 GCNTl Homo sapiens glucosaminyl (N-acetyl) 11.93 
transferase 1，core 2 
(beta-1,6-N-acetylglucosaminyltransferase) 
(GCNTl) , mRNA 
NM_007271 STK38 Homo sapiens serine/threonine kinase 38 11.72 
(STK38), mRNA. 
NM一005104 BRD2 Homo sapiens bromodomain-containing 2 11.58 
(BRD2), mRNA. 
NM_014046 MRPS18B Homo sapiens mitochondrial ribosomal protein 11.38 
S18B (MRPS18B), nuclear gene encoding 
mitochondrial protein, mRNA. 
NM_018845 LOC55974 Homo sapiens stromal cell protein (LOC55974), 11.38 
mRNA. 
NM_003739 AKR1C3 Homo sapiens aldo-keto reductase family 1, 10.95 
member C3 (3-alpha hydroxysteroid 
dehydrogenase, type II) (AKR1C3), mRNA 
NM_006470 TRIM 16 Homo sapiens tripartite motif-containing 16 10.22 
(TRIM 16)，mRNA. 
NM一001353 A K R I C I Homo sapiens aldo-keto reductase family 1, 10.15 
member CI (dihydrodiol dehydrogenase 1; 
20-alpha (3-alpha)-hydroxysteroid 
dehydrogenase) ( A K R l C l ) , mRNA 
NM二053047 MGC16063 Homo sapiens hypothetical protein MGC16063 10.12 
, (MGC16063), mRNA. 
NM_001402 E E F l A l Homo sapiens eukaryotic translation elongation 9.98 
factor 1 alpha 1 (EEFlAl ) , mRNA 
NM_003198 TCEB3 Homo sapiens transcription elongation factor B 9.97 
(SIII), polypeptide 3 ( l lOkD, elongin A) 
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(TCEB3), mRNA. 
NM—002373 MAPI A Homo sapiens microtubule-associated protein 1A 9.92 
(MAPIA), mRNA. 
NM_016481 HSPC219 Homo sapiens hypothetical protein (HSPC219), 9.69 
mRNA. 
NM_004868 GPSN2 Homo sapiens glycoprotein, synaptic 2 (GPSN2), 9.64 
mRNA 
NM_014077 DKFZP58600120 Homo sapiens DKFZP58600120 protein 9.40 
(DKFZP58600120), mRNA. 
NM一001417 EIF4B Homo sapiens eukaryotic translation initiation 9.33 
factor 4B (EIF4B), mRNA 
NM—022481 ARAP3 Homo sapiens ARF-GAP, RHO-GAP, ankyrin 9.19 
repeat and plekstrin homology 
domains-containing protein 3 (ARAP3), mRNA 
NM_004184 WARS Homo sapiens tryptophanyl-tRNA synthetase 9.10 
(WARS), mRNA 
NM_015373 C22orf2 Homo sapiens chromosome 22 open reading 9.03 
frame 2 (C22orf2), mRNA. 
NM_006796 AFG3L2 Homo sapiens AFG3 ATPase family gene 3-like 2 9.00 
(yeast) (AFG3L2), nuclear gene encoding 
mitochondrial protein, mRNA. 
AF400226 BPAGl Homo sapiens bullous pemphigoid antigen 1 eA 9.00 
(BPAGl) mRNA, complete cds 
NM_020187 DC12 Homo sapiens DC 12 protein (DC 12), mRNA 8.94 
NM_006337 MCRSl Homo sapiens microspherule protein 1 (MCRSl) , 8.93 
mRNA 
NM_018053 FLJ10307 Homo sapiens hypothetical protein F U 10307 8.92 
( F U 10307), mRNA. 
NM_004870 MPDUl Homo sapiens mannose-P-dolichol utilization 8.91 
defect 1 (MPDUl) , mRNA. 
NM—007370 RFC5 Homo sapiens replication factor C (activator 1) 5 8.88 
(36.5kD) (RFC5), mRNA. 
NM二015046 KIAA0625 Homo sapiens KIAA0625 protein (K1AA0625), 8.73 
. mRNA 
NM_025182 FLJ 11560 Homo sapiens hypothetical protein FLJ 11560 8.71 
( F U 11560), mRNA 
NM_000175 GPI Homo sapiens glucose phosphate isomerase 8.69 
(GPI), mRNA. 
1 6 4 
NM_004120 GBP2 Homo sapiens guanylate binding protein 2, 8.63 
interferon-inducible (GBP2), mRNA. 
NM_016162 ING4 Homo sapiens candidate tumor suppressor p33 8.61 
INGl homolog(LOC51147), mRNA. 
AL365404 GPR108 Homo sapiens mRNA full length insert cDNA 8.60 
clone EUROIMAGE 1703145 
NM_022110 FKBPL Homo sapiens FK506 binding protein like 8.47 
(FKBPL), mRNA. 
NM_001724 BPGM Homo sapiens 2,3-bisphosphoglycerate mutase 8.35 
(BPGM)’ mRNA. 
NM_006819 STIPl Homo sapiens stress-induced-phosphoprotein 1 8.26 
(Hsp70/Hsp90-organizing protein) (STIPl), 
mRNA. 
NM_001205 BNIPl Homo sapiens BCL2/adenovirus E l B 19kD 8.14 
interacting protein 1 (BNIPl), transcript variant 
BNIPl , mRNA 
BC007008 CRYAB Homo sapiens, crystallin, alpha B, clone 8.07 
MGC: 12326 IMAGE:3933748, mRNA, complete 
cds 
NM_025047 FLJ22595 Homo sapiens hypothetical protein FU22595 8.06 
(FLJ22595), mRNA 
NM_022664 ECMl Homo sapiens extracellular matrix protein 1 8.05 
(ECMl) , transcript variant 2, mRNA. 
NM一002817 PSMD13 Homo sapiens proteasome (prosome, macropain) 7.96 
26S subunit, non-ATPase, 13 (PSMD13), mRNA 
NM一018208 FLJ10761 Homo sapiens hypothetical protein FLJ10761 7.91 
(FUl0761) , mRNA. 
AB046844 GPR107 Homo sapiens mRNA for KIAA1624 protein, 7.84 
. partial cds 
NM_018678 LSR68 Homo sapiens lipopolysaccharide specific 7.80 
response-68 protein (LSR68), mRNA 
NM_002224 ITPR3 Homo sapiens inositol 1,4,5-triphosphate receptor, 7.78 
‘ type 3 (ITPR3), mRNA. 
‘ NM_033551 MGC19556 Homo sapiens hypothetical protein MGC19556 7.78 
(MGC19556), mRNA 
NM_000434 NEUl Homo sapiens sialidase 1 (lysosomal sialidase) 7.78 
(NEUl) , mRNA. 
M80899 AHNAK Human novel protein AHNAK mRNA, partial 7.76 
1 6 5 
sequence 
NM_013388 PREB Homo sapiens prolactin regulatory element 7.70 
binding (PREB), mRNA 
NM_002525 NRDl Homo sapiens nardilysin (N-arginine dibasic 7.66 
convertase) (NRDl) , mRNA 
NM_001975 E N 0 2 Homo sapiens enolase 2, (gamma, neuronal) 7.63 
(EN02), mRNA. 
NM_000295 SERPINAl Homo sapiens serine (or cysteine) proteinase 7.51 
inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 1 (SERPINAl), mRNA. 
NM_005418 ST5 Homo sapiens suppression of tumorigenicity 5 7.49 
(ST5), transcript variant 1，mRNA 
NM_006291 TNFAIP2 Homo sapiens tumor necrosis factor, 7.48 
alpha-induced protein 2 (TNFAIP2), mRNA. 
NM_000304 PMP22 Homo sapiens peripheral myelin protein 22 7.42 
(PMP22), mRNA. 
NM—003363 LJSP4 Homo sapiens ubiquitin specific protease 4 7.40 
(proto-oncogene) (USP4), mRNA. 
NM_014287 PM5 Homo sapiens pM5 protein (PM5), mRNA 7.37 
AK000838 FLJ20831 Homo sapiens cDNA FU20831 fis, clone 7.31 
ADKA03080 
NM_015367 MILl Homo sapiens MILl protein (MILl) , nuclear gene 7.30 
encoding mitochondrial protein, mRNA. 
NM_024863 FLJ21174 Homo sapiens hypothetical protein FU21174 7.26 
(FU21174), mRNA 
NM一002444 MSN Homo sapiens moesin (MSN), mRNA 7.24 
NM_004089 DSIPI Homo sapiens delta sleep inducing peptide, 7.23 
immunoreactor (DSIPI), mRNA. 
NM_000137 FAH Homo sapiens flimarylacetoacetate hydrolase 7.21 
(fumarylacetoacetase) (FAH), mRNA. 
NM_002961 S100A4 Homo sapiens SI00 calcium binding protein A4 7.18 
(calcium protein, calvasculin, metastasin, murine 
- placental homolog) (S100A4), transcript variant 
, l , m R N A 
AJ306399 SEPNl Homo sapiens partial mRNA for selenoprotein N 7.17 
(SEPNl gene) 
NM_021871 FGA Homo sapiens fibrinogen, A alpha polypeptide 7.08 
(FGA), transcript variant alpha, mRNA 
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NM_078471 TIAFl Homo sapiens TGFB1-induced anti-apoptotic 7.03 
factor 1 (TIAFl), transcript variant 1，mRNA. 
NM_012429 SEC14L2 Homo sapiens SEC 14-like 2 (S. cerevisiae) 6.97 
(SEC14L2), mRNA. 
NM_016406 HSPC155 Homo sapiens hypothetical protein (HSPC155), 6.95 
mRNA. 
NM_004475 FL0T2 Homo sapiens flotillin 2 (FL0T2), mRNA. 6.95 
NM_001469 G22P1 Homo sapiens thyroid autoantigen 70kD (Ku 6.88 
antigen) (G22P1), mRNA 
NM_001258 CDK3 Homo sapiens cyclin-dependent kinase 3 (CDK3), 6.85 
mRNA. 
NM_002815 PSMDl l Homo sapiens proteasome (prosome, macropain) 6.85 
26S subunit, non-ATPase, 11 (PSMDl l ) , mRNA. 
NM_006112 PPIE Homo sapiens peptidylprolyl isomerase E 6.84 
(cyclophilin E) (PPIE), mRNA. 
NM_002676 PMMl Homo sapiens phosphomannomutase 1 (PMMl) , 6.78 
mRNA. 
NM_005745 BCAP31 Homo sapiens accessory protein BAP31 6.75 
(DXS1357E), mRNA 
NM_013975 LIG3 Homo sapiens ligase III, DNA, ATP-dependent 6.73 
(LIG3), transcript variant alpha, mRNA 
NM_006437 ADPRTLl Homo sapiens ADP-ribosyltransferase (NAEH; 6.61 
poly (ADP-ribose) polymerase)-like 1 
(ADPRTLl), mRNA. 
NM_001188 BAK1 Homo sapiens BCL2-antagonist/killer 1 (BAKl) , 6.59 
mRNA. 
D83778 K1AA0194 Human mRNA for KIAA0194 gene, partial cds 6.56 
NM_014847 KIAA0144 Homo sapiens KIA AO 144 gene product 6.55 
(KIAA0144), mRNA. 
NM一003001 SDHC Homo sapiens succinate dehydrogenase complex, 6.53 
subunit C, integral membrane protein, 15kD 
(SDHC), nuclear gene encoding mitochondrial 
- protein, mRNA. 
• NM_021198 NLI-IF Homo sapiens nuclear LIM interactor-interacting 6.53 
factor (NLI-IF), mRNA 
NM_006608 PHTFl Homo sapiens putative homeodomain 6.47 
transcription factor (PHTFl) , mRNA. 
ABO 18337 KIAA0794 Homo sapiens mRNA for KIAA0794 protein, 6.45 
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partial cds 
NM—014964 KIAA1065 Homo sapiens KIAA1065 protein (KIAA1065), 6.44 
mRNA. 
NM_004295 TRAF4 Homo sapiens TNF receptor-associated factor 4 6.44 
(TRAF4), transcript variant 1，mRNA 
NM_024662 FLJ 10774 Homo sapiens hypothetical protein FLJ 10774 6.37 
(FLU 0774)，mRNA. 
NM_022750 FLJ22693 Homo sapiens hypothetical protein FLJ22693 6.36 
(FU22693) , mRNA. 
NM_012486 PSEN2 Homo sapiens presenilin 2 (Alzheimer disease 4) 6.35 
(PSEN2), transcript variant 2, mRNA. 
U17077 BENE Human BENE mRNA, partial cds 6.31 
NM_152272 MGC29816 Homo sapiens hypothetical protein MGC29816 6.28 
(MGC29816), mRNA 
NM_012470 TRN-SR Homo sapiens transportin-SR (TRN-SR), mRNA. 6.13 
NM_000623 BDKRB2 Homo sapiens bradykinin receptor B2 6.12 
(BDKRB2), mRNA. 
NM_003100 SNX2 Homo sapiens sorting nexin 2 (SNX2), mRNA 6.06 
NM_001251 CD68 Homo sapiens CD68 antigen (CD68), mRNA 6.04 
NM_014186 HSPC166 Homo sapiens HSPC166 protein (HSPC166), 6.03 
mRNA. 
NM_012103 AUPl Homo sapiens ancient ubiquitous protein 1 5.96 
(AUPl) , mRNA 
NM_006523 XPNPEPL Homo sapiens X-prolyl aminopeptidase 5.96 
(aminopeptidase P)-like (XPNPEPL), mRNA. 
NM_022152 PP1201 Homo sapiens PP1201 protein (PP1201), mRNA. 5.92 
NM_003929 RAB7L1 Homo sapiens RAB7, member RAS oncogene 5.91 
family-like 1 (RAB7L1), mRNA 
NM_024506 MGC10771 Homo sapiens hypothetical protein MGC10771 5.90 
(MGC10771), mRNA 
NM一024956 FLJ23375 Homo sapiens hypothetical protein FLJ23375 5.90 
(FU23375) , mRNA 
NM_023079 FLJ 13855 Homo sapiens hypothetical protein F U 1 3 8 5 5 5.89 
‘ ( F U 13855), mRNA 
NM_002265 KPNBl Homo sapiens karyopherin (importin) beta 1 5.82 
(KPNBl) , mRNA 
NM_005908 MANBA Homo sapiens mannosidase, beta A, lysosomal 5.80 
(MANBA), mRNA. 
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NM_022758 FLJ22195 Homo sapiens hypothetical protein FU22195 5.79 
(FLJ22195), mRNA 
NM_018706 KIAAl630 Homo sapiens hypothetical protein 5.79 
DKFZp762M115 (KIAAl630), mRNA. 
NM_024293 MGC3035 Homo sapiens hypothetical protein MGC3035 5.78 
(MGC3035), mRNA. 
AL 162074 CEP4 Homo sapiens mRNA; cDNA DKFZp762L106 5.76 
(from clone DKFZp762L106); partial cds 
NM_015670 SENP3 Homo sapiens sentrin/SUMO-specific protease 3 5.76 
(SENP3), mRNA. 
NM一003292 TPR Homo sapiens translocated promoter region (to 5.76 
activated MET oncogene) (TPR), mRNA. 
NM_001038 SCNNIA Homo sapiens sodium channel, nonvoltage-gated 5.75 
1 alpha (SCNNIA), mRNA. 
NM_006456 STHM Homo sapiens sialyltransferase (STHM), mRNA 5.73 
NM_000701 ATPlAl Homo sapiens ATPase, Na+/K+ transporting, 5.71 
alpha 1 polypeptide (ATPlAl) , mRNA. 
AJ007798 STAG3 Homo sapiens mRNA for stromal antigen 3 5.69 
(STAG3 gene) 
NM_025222 PR02730 Homo sapiens hypothetical protein PR02730 5.68 
(PR02730), mRNA 
NM_002487 NDN Homo sapiens necdin homolog (mouse) (NDN), 5.64 
mRNA. 
NM一002205 ITGA5 Homo sapiens integrin, alpha 5 (fibronectin 5.63 
receptor, alpha polypeptide) (ITGA5), mRNA. 
NM一021922 FANCE Homo sapiens Fanconi anemia, complementation 5.63 
group E (FANCE), mRNA 
NM_013393 FTSJ2 Homo sapiens FtsJ homolog 2 (E. coli) (FTSJ2), 5.54 
mRNA. 
NM_022362 MMS19L Homo sapiens MMS19-like (MET 18 homolog, S. 5.50 
cerevisiae) (MMS19L), mRNA. 
NM_003033 SIAT4A Homo sapiens sialyltransferase 4A 5.50 
- (beta-galactosidase alpha-2,3-sialytransferase) 
’ （SIAT4A)，mRNA. 
NM_025230 PR02389 Homo sapiens hypthetical protein PR02389 5.47 
(PR02389), mRNA. 
NM—006829 APM2 Homo sapiens adipose specific 2 (APM2), 5.45 
“ mRNA. 
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NM_006743 RBM3 Homo sapiens RNA binding motif protein 3 5.42 
(RBM3), mRNA 
U86453 PIK3CD Human phosphatidyl inositol 3-kinase catalytic 5.41 
subunit p 11 Odelta mRNA, complete cds 
NM_016135 TEL2 Homo sapiens transcription factor ets (TEL2), 5.40 
mRNA. 
NM_003077 SMARCD2 Homo sapiens SWI/SNF related, matrix 5.38 
associated, actin dependent regulator of 
chromatin, subfamily d, member 2 (SMARCD2), 
mRNA 
NM_144641 FLJ32332 Homo sapiens hypothetical protein FLJ32332 5.38 
(FU32332) , mRNA 
NM—017706 FLJ20195 Homo sapiens hypothetical protein F U 2 0 1 9 5 5.37 
(FU20195) , mRNA. 
NM_002136 HNRPAl Homo sapiens heterogeneous nuclear 5.37 
ribonucleoprotein A l (HNRPAl) , transcript 
variant 1，mRNA 
NM_005900 MADHl Homo sapiens MAD，mothers against 5.35 
decapentaplegic homolog 1 (Drosophila) 
(MADHl) , mRNA. 
AL713789 DKFZp761H079 Homo sapiens mRNA; cDNA DKFZp761H079 5.34 
(from clone DKFZp761H079) 
NM_000520 HEXA Homo sapiens hexosaminidase A (alpha 5.32 
polypeptide) (HEXA), mRNA 
NM_006044 HDAC6 Homo sapiens histone deacetylase 6 (HDAC6), 5.28 
mRNA. 
NM_025267 MGC2744 Homo sapiens hypothetical protein MGC2744 5.28 
(MGC2744), mRNA. 
AB040886 KIAA1453 Homo sapiens mRNA for KIAA1453 protein, 5.26 
partial cds 
AB051535 DKFZP586K0524 Homo sapiens mRNA for KIAA1748 protein, 5.26 
partial cds 
NMi018142 FLJ10569 Homo sapiens hypothetical protein FLJ10569 5.26 
， (FU10569) , mRNA 
NM一001664 ARHA Homo sapiens ras homolog gene family, member 5.25 
A(ARHA) , mRNA 
NM_014856 KIAA0476 Homo sapiens KIAA0476 gene product 5.21 
(KIAA0476), mRNA. 
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NM_016249 MAGEEl Homo sapiens melanoma antigen, family E, 1, 5.21 
cancer/testis specific (MAGEEl) , mRNA. 
NM_004433 ELF3 Homo sapiens E74-like factor 3 (ets domain 5.20 
transcription factor, epithelial-specific ) (ELF3), 
mRNA 
NM_018187 FLJ10707 Homo sapiens hypothetical protein FLJ10707 5.20 
( F U 10707), mRNA. 
NM_001908 CTSB Homo sapiens cathepsin B (CTSB), mRNA 5.20 
NM_014640 KIAA0173 Homo sapiens KIAA0173 gene product 5.19 
(KIAA0173), mRNA 
NM_002771 PRSS3 Homo sapiens protease, serine, 3 (mesotrypsin) 5.18 
(PRSS3), mRNA 
NM_014508 A P 0 B E C 3 C Homo sapiens apolipoprotein B mRNA editing 5.18 
enzyme, catalytic polypeptide-like 3C 
(AP0BEC3C), mRNA 
NM_021807 SEC8 Homo sapiens secretory protein SEC8 (SEC8), 5.17 
mRNA. 
NM_017750 FLJ20296 Homo sapiens hypothetical protein F U 2 0 2 9 6 5.14 
(FU20296) , mRNA. 
NM一002388 MCM3 Homo sapiens MCM3 minichromosome 5.14 
maintenance deficient 3 (S. cerevisiae) (MCM3), 
mRNA 
NM_001416 EIF4A1 Homo sapiens eukaryotic translation initiation 5.13 
factor 4A, isoform 1 (EIF4A1), mRNA 
NM-005736 A C T R I A Homo sapiens ARPl actin-related protein 1 5.13 
homolog A, centractin alpha (yeast) (ACTRIA), 
mRNA. 
NM_000181 GUSB Homo sapiens glucuronidase, beta (GUSB), 5.08 
mRNA. 
NM_004530 MMP2 Homo sapiens matrix metalloproteinase 2 5.05 
(gelatinase A, 72kD gelatinase, 72kD type IV 
collagenase) (MMP2), mRNA 
NM二005290 GPR15 Homo sapiens G protein-coupled receptor 15 5.05 
• (GPR15), mRNA 
NM_014458 AB026190 Homo sapiens Kelch motif containing protein 5.02 
(AB026190), mRNA. 
AB023156 KIAA0939 Homo sapiens mRNA for KIAA0939 protein, 5.02 
partial cds 
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D79998 KIAA0176 Human mRNA for KIAA0176 gene, partial cds 5.02 
NM一006958 ZNF16 Homo sapiens zinc finger protein 16 (KOX 9) 4.99 
(ZNF16), mRNA 
NM_015922 H105E3 Homo sapiens NAD(P) dependent steroid 4.99 
dehydrogenase-like; H105e3 (H105E3), mRNA 
NM_005719 ARPC3 Homo sapiens actin related protein 2/3 complex, 4.96 
subunit 3 (21 kD) (ARPC3), mRNA. 
NM_004881 PIG3 Homo sapiens quinone oxidoreductase homolog 4.94 
(PIG3), mRNA. 
NM_016061 CGI-127 Homo sapiens yippee protein (CGI-127), mRNA 4.93 
NM_032887 MGC16037 Homo sapiens hypothetical protein MGC16037 4.92 
(MGC16037), mRNA 
NM一030877 C20orf33 Homo sapiens chromosome 20 open reading 4.89 
frame 33 (C20orf33), mRNA. 
NM_018244 C20orf44 Homo sapiens chromosome 20 open reading 4.88 
frame 44 (C20orf44), mRNA. 
NM一014147 HSPC047 Homo sapiens HSPC047 protein (HSPC047), 4.87 
mRNA 
NM_023011 UPF3A Homo sapiens similar to yeast UpO, variant A 4.84 
(UPF3A), transcript variant 1，mRNA 
NM一003810 TNFSF10 Homo sapiens tumor necrosis factor (ligand) 4.84 
superfamily, member 10 (TNFSF 10), mRNA. 
NM_002821 PTK7 Homo sapiens PTK7 protein tyrosine kinase 7 4.83 
(PTK7), mRNA 
NM_004632 DAP3 Homo sapiens death associated protein 3 (DAP3), 4.83 
transcript variant 2, nuclear gene encoding 
mitochondrial protein, mRNA. 
NM_025138 FLJ 12661 Homo sapiens hypothetical protein FLJ 12661 4.83 
( F U 12661), mRNA 
NM_005793 NM23-H6 Homo sapiens nucleoside diphosphate kinase type 4.83 
6 (inhibitor of p53-induced apoptosis-alpha) 
(NM23-H6), mRNA 
NM_016270 KLF2 Homo sapiens Kruppel-like factor (LOC51713), 4.80 
， mRNA. 
NM_016332 SEPXl Homo sapiens selenoprotein X, 1 (SEPXl) , 4.80 
mRNA 
NM_002636 PHFl Homo sapiens PHD finger protein 1 (PHFl) , 4.78 
transcript variant 1，mRNA 
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NM_012311 KIN Homo sapiens KIN, antigenic determinant of recA 4.77 
protein homolog (mouse) (KIN), mRNA 
NM_003709 KLF7 Homo sapiens Kruppel-like factor 7 (ubiquitous) 4.76 
(KLF7), mRNA 
NM_005216 DDOST Homo sapiens 4.76 
dolichyl-diphosphooligosaccharide-protein 
glycosyltransferase (DDOST), mRNA 
NM_005452 C6orfl 1 Homo sapiens chromosome 6 open reading frame 4.75 
11 (C6or f l l ) , mRNA 
NM_014753 KIAA0187 Homo sapiens KIAAO187 gene product 4.75 
(KIAA0187), mRNA. 
U79241 PP591 Human clone 23759 mRNA, partial cds 4.75 
NM_005225 E2F1 Homo sapiens E2F transcription factor 1 (E2F1), 4.75 
mRNA. 
NM—019018 FLJ11127 Homo sapiens hypothetical protein ( F U l 1127), 4.74 
mRNA. 
AF051941 NM23-H6 Homo sapiens type 6 nucleoside diphosphate 4.72 
kinase NM23-H6 (NM23-H6) mRNA, complete 
cds 
NM_032924 ZNF38 Homo sapiens hypothetical protein MGC16040 4.72 
(MGC16040)，mRNA. 
NM_014225 PPP2R1A Homo sapiens protein phosphatase 2 (formerly 4.66 
2A), regulatory subunit A (PR 65)，alpha isoform 
(PPP2R1A), mRNA 
BC003637 DDIT3 Homo sapiens, Similar to DNA-damage-inducible 4.63 
transcript 3, clone MGC:4154 丨MAGE:3530545， 
mRNA, complete cds 
NM_032324 MGC13186 Homo sapiens hypothetical protein MGC13186 4.63 
(MGC13186), mRNA 
NM一024803 F U 2 1 6 6 5 Homo sapiens hypothetical protein FLJ21665 4.63 
(FU21665) , mRNA. 
NM一021052 H2AFA Homo sapiens H2A histone family, member A 4.62 
- (H2AFA), mRNA 
‘ NM一021160 BATS Homo sapiens HLA-B associated transcript 5 4.62 
(BATS), mRNA 
NM_007047 BTN3A2 Homo sapiens butyrophilin, subfamily 3, member 4.61 
A2 (BTN3A2), mRNA 
NM_004040 ARHB Homo sapiens ras homolog gene family, member 4.61 
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B (ARHB), mRNA 
NM_017803 FLJ20399 Homo sapiens hypothetical protein FLJ20399 4.59 
(FU20399) , mRNA. 
NM_003915 CPNEl Homo sapiens copine I (CPNEl) , mRNA. 4.58 
D89060 DDOST Homo sapiens DNA for oligosaccharyltransferase, 4.58 
complete cds 
NM_020153 FLJ21827 Homo sapiens hypothetical protein LOC56912 4.58 
(LOC56912), mRNA 
NM_002488 NDUFA2 Homo sapiens NADH dehydrogenase 4.57 
(ubiquinone) 1 alpha subcomplex, 2 (8kD, B8) 
(NDUFA2), mRNA. 
NM_001182 ALDH7A1 Homo sapiens aldehyde dehydrogenase 7 family, 4.55 
member A1 (ALDH7A1), mRNA. 
NM_018091 ELP3 Homo sapiens hypothetical protein F U l 0 4 2 2 4.54 
(FUl0422)，mRNA 
NM_005710 PQBPl Homo sapiens polyglutamine binding protein 1 4.54 
(PQBPl) , mRNA. 
NM—032998 DEDD Homo sapiens death effector domain-containing 4.53 
(DEDD), transcript variant 1, mRNA. 
NM_007317 KNSL4 Homo sapiens kinesin-like 4 (KNSL4), mRNA. 4.52 
NM_003691 STK16 Homo sapiens serine/threonine kinase 16 4.50 
(STK16), mRNA. 
AF375884 POFUTl Homo sapiens protein o-fticosyltransferase 4.49 
(POFUTl) mRNA, complete cds 
NM_000308 PPGB Homo sapiens protective protein for 4.49 
beta-galactosidase (galactosialidosis) (PPGB), 
mRNA. 
AL050173 C21orf25 Homo sapiens mRNA; cDNA DICFZp586F0422 4.48 
(from clone DKFZp586F0422); partial cds 
NM_017842 F U 2 0 4 8 9 Homo sapiens hypothetical protein F U 2 0 4 8 9 4.48 
(FU20489) , mRNA 
NM一018380 DDX28 Homo sapiens DEAD/H (Asp-Glu-Ala-Asp/His) 4.48 
- box polypeptide 28 (DDX28), mRNA. 
• NM_020672 LOC57402 Homo sapiens SlOO-type calcium binding protein 4.47 
A14(LOC57402) , mRNA. 
AB037864 KIAA1443 Homo sapiens mRNA for KIAA1443 protein, 4.47 
partial cds 
NM_003995 NPR2 Homo sapiens natriuretic peptide receptor 4.46 
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B/guanylate cyclase B (atrionatriuretic peptide 
receptor B) (NPR2), mRNA. 
NM_003869 CES2 Homo sapiens carboxylesterase 2 (intestine, liver) 4.46 
(CES2), mRNA. 
NM_033035 TSLP Homo sapiens thymic stromal lymphopoietin 4.46 
(TSLP), transcript variant 1’ mRNA 
NM_016086 MK-STYX Homo sapiens map kinase phosphatase-like 4.45 
protein MK-STYX (LOC51657), mRNA 
NM_000362 TIMP3 Homo sapiens tissue inhibitor of 4.45 
metalloproteinase 3 (Sorsby fundus dystrophy, 
pseudoinflammatory) (TIMP3), mRNA 
NM_002080 G 0 T 2 Homo sapiens glutamic-oxaloacetic transaminase 4.45 
2, mitochondrial (aspartate aminotransferase 2) 
(G0T2), nuclear gene encoding mitochondrial 
protein, mRNA. 
NM一001325 CSTF2 Homo sapiens cleavage stimulation factor, 3' 4.44 
pre-RNA, subunit 2，64kD (CSTF2), mRNA. 
NM_022823 FLJ22362 Homo sapiens hypothetical protein FU22362 4.43 
(FU22362), mRNA. 
AK021799 RNPSl Homo sapiens cDNA FLJ 11737 fis, clone 4.42 
HEMBA1005469 
NM_004564 PET112L Homo sapiens PETl 12-like (yeast) (PETl 12L), 4.42 
mRNA 
NM_003743 NCOAl Homo sapiens nuclear receptor coactivator 1 4.42 
(NCOAl) , mRNA. 
NM_003477 PDXl Homo sapiens Pyruvate dehydrogenase complex, 4.40 
lipoyl-containing component X; E3-binding 
protein (PDXl) , mRNA 
NM_007158 D1S155E Homo sapiens NRAS-related gene (D1S155E), 4.38 
mRNA 
NM_001561 TNFRSF9 Homo sapiens tumor necrosis factor receptor 4.38 
superfamily, member 9 (TNFRSF9), mRNA 
NM_004848 ICB-1 Homo sapiens basement membrane-induced gene 4.37 
‘ (ICB-1), mRNA. 
NM_030796 DKFZP564K0822 Homo sapiens hypothetical protein 4.37 
DKFZp564K0822 (DKFZP564K0822), mRNA. 
NM_005826 HNRPR Homo sapiens heterogeneous nuclear 4.37 
, ribonucleoprotein R (HNRPR), mRNA. 
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NM—030580 MGC10520 Homo sapiens hypothetical protein MGC10520 4.36 
(MGC10520), mRNA. 
NM_012104 BACE Homo sapiens beta-site APP-cleaving enzyme 4.36 
(BACE), mRNA. 
NM_022774 FLJ21144 Homo sapiens hypothetical protein FU21144 4.35 
(FU21144) , mRNA 
NM_000183 HADHB Homo sapiens hydroxyacyl-Coenzyme A 4.35 
dehydrogenase/3-ketoacyl-Coenzyme A 
thiolase/enoyl-Coenzyme A hydratase 
(trifunctional protein), beta subunit (HADHB), 
mRNA 
NM_000688 ALASl Homo sapiens aminolevulinate, delta-, synthase 1 4.34 
(ALASl) , nuclear gene encoding mitochondrial 
protein, mRNA. 
NM_004428 EFNAl Homo sapiens ephrin-Al (EFNAl) , mRNA. 4.33 
AB029012 K1AA1089 Homo sapiens mRNA for KIAA1089 protein, 4.31 
partial cds 
NM_001674 ATF3 Homo sapiens activating transcription factor 3 4.31 
(ATF3), mRNA 
NM Ol 3272 SLC21A11 Homo sapiens solute carrier family 21 (organic 4.29 
anion transporter), member 11 (SLC21 A l 1)， 
mRNA. 
NM_016407 C20orf43 Homo sapiens chromosome 20 open reading 4.28 
frame 43 (C20orf43), mRNA 
NM_013374 PDCD6IP Homo sapiens programmed cell death 6 4.28 
interacting protein (PDCD6IP), mRNA 
NM_019619 PARD3 Homo sapiens par-3 partitioning defective 3 4.28 
homolog (C. elegans) (PARD3), mRNA 
NM_020137 GRASPl Homo sapiens GRIP-associated protein 1 4.26 
(GRASP 1), mRNA. 
NM_031295 WBSCR21 Homo sapiens Williams Beuren syndrome 4.26 
chromosome region 21 (WBSCR21), mRNA 
NM二030587 B4GALT2 Homo sapiens UDP-Gal:betaGlcNAc beta 1,4- 4.26 
， galactosyltransferase, polypeptide 2 (B4GALT2), 
transcript variant 1，mRNA. 
NM_004429 EFNBl Homo sapiens ephrin-Bl (EFNBl) , mRNA. 4.25 
BC034235 LOC90550 Homo sapiens, Similar to hypothetical protein 4.25 
BCO10682, clone MGC:39792 IMAGE:5296557， 
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mRNA, complete cds 
NM_001935 DPP4 Homo sapiens dipeptidylpeptidase IV (CD26, 4.24 
adenosine deaminase complexing protein 2) 
(DPP4), mRNA. 
NM—005362 MAGEA3 Homo sapiens melanoma antigen, family A, 3 4.24 
(MAGEA3), mRNA 
X74794 MCM4 H.sapiens PI-Cdc21 mRNA 4.23 
NM_032667 MGC4694 Homo sapiens hypothetical protein MGC4694 4.22 
(MGC4694), mRNA. 
NM_001985 ETFB Homo sapiens electron-transfer-flavoprotein, beta 4.22 
polypeptide (ETFB), mRNA 
NM_002802 PSMCl Homo sapiens proteasome (prosome, macropain) 4.21 
26S subunit, ATPase, 1 (PSMCl) , mRNA. 
NM_001549 IF1T4 Homo sapiens interferon-induced protein with 4.21 
tetratricopeptide repeats 4 (IFIT4), mRNA. 
NM_000387 SLC25A20 Homo sapiens solute carrier family 25 4.20 
(camitine/acylcamitine translocase), member 20 
(SLC25A20), mitochondrial protein encoded by 
nuclear gene, mRNA 
NM_005628 SLC1A5 Homo sapiens solute carrier family 1 (neutral 4.19 
amino acid transporter), member 5 (SLC1A5), 
mRNA. 
NM_017787 FLJ20154 Homo sapiens hypothetical protein FLJ20154 4.18 
(FU20154) , mRNA. 
NM_000784 CYP27A1 Homo sapiens cytochrome P450, subfamily 4.18 
XXVIIA (steroid 27-hydroxylase, 
cerebrotendinous xanthomatosis), polypeptide 1 
(CYP27A1), nuclear gene encoding mitochondrial 
protein, mRNA. 
X73459 SRP14 H.sapiens mRNA for signal recognition particle 4.17 
subunit 14 
NM_016328 GTF2IRD1 Homo sapiens GTF2I repeat domain-containing 1 4.17 
- (GTF2IRD1 )，transcript variant 1，mRNA. 
’ Y12790 SUPT5H H.sapiens mRNA for suptSh protein 4.17 
NM_002694 P 0 L R 2 C Homo sapiens polymerase (RNA) II (DNA 4.16 
directed) polypeptide C (33kD) (P0LR2C) , 
transcript variant alpha, mRNA 
NM—024844 FLJ 12549 Homo sapiens hypothetical protein FLJ 12549 4.15 
1 7 7 
(FLJ 12549), mRNA. 
AK074553 LOC91875 Homo sapiens cDNA FLJ90072 fis，done 4.14 
HEMBA1004085 
NM_013384 LASS2 Homo sapiens LAGl longevity assurance 4.14 
homolog 2 (S. cerevisiae) (LASS2), mRNA. 
NM_014481 APEX2 Homo sapiens APEX nuclease 4.13 
(apurinic/apyrimidinic endonuclease) 2 (APEX2), 
nuclear gene encoding mitochondrial protein, 
mRNA 
NM_003104 SORD Homo sapiens sorbitol dehydrogenase (SORD), 4.13 
mRNA 
NM_014369 PTPN18 Homo sapiens protein tyrosine phosphatase, 4.11 
non-receptor type 18 (brain-derived) (PTPN18), 
mRNA 
M80899 AHNAK Human novel protein AHNAK mRNA, partial 4.11 
sequence 
NM_002622 PFDNl Homo sapiens prefoldin 1 (PFDNl) , mRNA. 4.11 
NM_024952 FLJ20950 Homo sapiens hypothetical protein F U 2 0 9 5 0 4.10 
(FU20950) , mRNA 
NM_018108 FLJ 10483 Homo sapiens hypothetical protein F U 10483 4.10 
( F U 10483), mRNA. 
NM_003275 TMOD Homo sapiens tropomodulin (TMOD), mRNA. 4.10 
NM_001022 RPS19 Homo sapiens ribosomal protein S19 (RPS19), 4.10 
mRNA 
NM_014042 DKFZP564M082 Homo sapiens DKFZP564M082 protein 4.07 
(DKFZP564M082), mRNA. 
AB038651 KLPl Homo sapiens mRNA for K562 cells-derived 4.06 
leucine-zipper-like protein 1，complete cds 
NM_016482 LOC51759 Homo sapiens hepatocellular 4.06 
carcinoma-associated antigen 59 (L0C51759) , 
mRNA 
NM_025126 RNF34 Homo sapiens ring finger protein 34 (RNF34), 4.06 
- mRNA 
‘ NM 022455 NSDl Homo sapiens nuclear receptor binding SET 4.05 
domain protein 1 (NSDl) , mRNA 
NM_005412 SHMT2 Homo sapiens serine hydroxymethyltransferase 2 4.05 
(mitochondrial) (SHMT2), mRNA. 
NM_013285 HUMAUANTIG Homo sapiens nucleolar GTPase 4.05 
1 7 8 
(HUMAUANTIG), mRNA. 
AB029021 TRIM35 Homo sapiens mRNA for K1AA1098 protein, 4.05 
partial cds 
NM_024908 FLJ 12973 Homo sapiens hypothetical protein F U 12973 4.05 
( F U 12973), mRNA 
NM_005895 G 0 L G A 3 Homo sapiens golgi autoantigen, golgin subfamily 4.04 
a, 3 (G0LGA3), mRNA. 
NM_031899 G0LPH5 Homo sapiens golgi phosphoprotein 5 (G0LPH5), 4.04 
mRNA. 
NM_017567 NAGK Homo sapiens N-acetylglucosamine kinase 4.03 
(NAGK), mRNA 
NM_005093 CBFA2T2 Homo sapiens core-binding factor, runt domain, 4.01 
alpha subunit 2; translopated to, 2 (CBFA2T2), 
mRNA. 
NM_005087 FXRl Homo sapiens fragile X mental retardation, 4.01 
autosomal homolog 1 (FXRl) , mRNA. 
Gene expression reduced by lovastatin in M059J glioblastoma cells 
NCB1_ACC Gene Initials DESCRIPTION Fold 
Changes 
NM_001901 CTGF Homo sapiens connective tissue growth factor 29.94 
(CTGF), mRNA. 
NM_031957 KRTAP1 -5 Homo sapiens keratin associated protein 1.5 22.21 
(KRTAP1.5), mRNA 
NM_002924 RGS7 Homo sapiens regulator of G-protein signalling 7 11.16 
(RGS7), mRNA. 
NM_014226 RAGE Homo sapiens renal tumor antigen (RAGE), 10.73 
mRNA. 
NM_006622 SNK Homo sapiens serum-inducible kinase (SNK), 10.36 
mRNA. 
NM_007005 BCE-1 Homo sapiens BCE-1 protein (BCE-1), mRNA 10.28 
NM_005139 ANXA3 Homo sapiens annexin A3 (ANXA3), mRNA. 10.22 
NM_001114 ADCY7 Homo sapiens adenylate cyclase 7 (ADCY7), 8.23 
I mRNA. 
‘ NM_003633 ENCl Homo sapiens ectodermal-neural cortex (with 7.89 
BTB-like domain) (ENCl) , mRNA 
NM OOSlOO AKAP12 Homo sapiens A kinase (PRKA) anchor protein 7.71 
(gravin) 12 (AKAP12), mRNA. 
NM_001794 CDH4 Homo sapiens cadherin 4, type 1, R-cadherin 7.58 
1 7 9 
(retinal) (CDH4), mRNA. 
NM_003483 HMGA2 Homo sapiens high mobility group AT-hook 2 7.45 
(HMGA2), mRNA 
NM_003798 CTNNALl Homo sapiens catenin (cadherin-associated 7.20 
protein), alpha-like 1 (CTNNALl) , mRNA. 
NM_00I485 GBX2 Homo sapiens gastrulation brain homeo box 2 7.19 
(GBX2), mRNA 
BC004880 NME4 Homo sapiens, non-metastatic cells 4, protein 6.75 
expressed in, clone MGC: 11088 
IMAGE:3830205, mRNA, complete cds 
NM_005603 ATP8B1 Homo sapiens ATPase, Class I, type 8B, member 6.60 
1 (ATP8B1), mRNA. 
NM_024629 FLJ23468 Homo sapiens hypothetical protein FLJ23468 6.58 
(FU23468) , mRNA 
NM_006601 TEBP Homo sapiens unactive progesterone receptor, 23 6.38 
kD (P23), mRNA 
NM_145697 CDCAl Homo sapiens cell division cycle associated 1 6.18 
(CDCAl) , transcript variant 1，mRNA 
NM_001159 AOXl Homo sapiens aldehyde oxidase 1 (AOXl) , 6.16 
mRNA. 
NM_001839 CNN3 Homo sapiens calponin 3, acidic (CNN3), mRNA 6.13 
D43639 ADM Human gene for preproadrenomedullin, complete 6.13 
cds (exon 1-4) 
NM一001709 BDNF Homo sapiens brain-derived neurotrophic factor 6.06 
(BDNF), mRNA 
ALl36924 RIN2 Homo sapiens mRNA; cDNA DKFZp586G2120 5.98 
(from clone DKFZp586G2120); complete cds 
NM_016651 L0C51339 Homo sapiens heptacellular carcinoma novel 5.88 
. gene-3 protein (L0C51339) , mRNA. 
NM_005824 P37NB Homo sapiens 37 kDa leucine-rich repeat (LRR) 5.71 
protein (P37NB), mRNA. 
NM_032297 DKFZp761D112 Homo sapiens hypothetical protein 5.69 
^ DKFZp761D112 (DKFZp761D112)，mRNA 
‘ NM_000135 FANCA Homo sapiens Fanconi anemia, complementation 5.69 
group A (FANCA), mRNA. 
NM_058172 CMG2 Homo sapiens capillary morphogenesis protein 2 5.61 
(CMG2), mRNA. 
X69086 UTRN H.sapiens mRNA for utrophin 5.53 
1 8 0 
NM_019114 EHM2 Homo sapiens EHM2 gene (EHM2), mRNA 5.52 
NM_001442 FABP4 Homo sapiens fatty acid binding protein 4, 5.48 
adipocyte (FABP4), mRNA 
NM_032547 HRIHFB2072 Homo sapiens short coiled-coil protein 5.44 
(HRIHFB2072), mRNA. 
NM_004236 TRIP 15 Homo sapiens thyroid receptor interacting protein 5.39 
15 (TRIP 15)，mRNA. 
NM_000916 OXTR Homo sapiens oxytocin receptor (OXTR), 5.32 
mRNA. 
AF061324 ABCC9 Homo sapiens sulfonylurea receptor 2B (SUR2) 5.31 
gene, alternatively spliced product, exon 38b and 
complete cds 
NM_001237 CCNA2 Homo sapiens cyclin A2 (CCNA2), mRNA. 5.27 
NM_002485 NBSl Homo sapiens Nijmegen breakage syndrome 1 5.27 
(nibrin) (NBSl) , mRNA. 
NM O 16042 RRP40 Homo sapiens exosome component Rrp40 5.23 
(RRP40), mRNA 
NM_018042 FLJ 10260 Homo sapiens hypothetical protein FLJ 10260 5.22 
( F U l 0 2 6 0 ) , mRNA. 
NM_015714 G0S2 Homo sapiens putative lymphocyte GO/Gl switch 5.20 
gene (G0S2), mRNA 
AK026065 NMNAT Homo sapiens cDNA: FLJ22412 fis, clone 5.20 
HRC08458 
NM_002153 HSD17B2 Homo sapiens hydroxysteroid (17-beta) 5.16 
dehydrogenase 2 (HSD17B2), mRNA. 
NM_018171 FLJ 10659 Homo sapiens hypothetical protein FLJ 10659 5.14 
(FUl0659)，mRNA. 
NM_003384 VRKl Homo sapiens vaccinia related kinase 1 (VRKl) , 5.12 
mRNA. 
NM_022977 FACL4 Homo sapiens fatty-acid-Coenzyme A ligase, 5.12 
long-chain 4 (FACL4), transcript variant 2’ 
mRNA. 
NM_020182 TMEPAI Homo sapiens transmembrane, prostate androgen 5.10 
• induced RNA (TMEPAI), mRNA 
NM_022346 HCAP-G Homo sapiens chromosome condensation protein 5.09 
G (HCAP-G), mRNA. 
NM_017652 FLJ20070 Homo sapiens hypothetical protein FLJ20070 5.06 
(FU20070) , mRNA 
1 8 1 
M64497 NR2F2 Human apolipoprotein Al regulatory protein 5.06 
(ARP-1) mRNA, complete cds 
NM_002053 GBPl Homo sapiens guanylate binding protein 1, 5.03 
interferon-inducible, 67kD (GBPl), mRNA 
NM—016396 HSPC129 Homo sapiens hypothetical protein (HSPC129), 5.03 
mRNA. 
NM_003358 UGCG Homo sapiens UDP-glucose ceramide 5.03 
glucosyltransferase (UGCG), mRNA. 
AB050468 LIGl Homo sapiens mRNA for membrane glycoprotein 4.97 
LIG-1, complete cds 
NM_005102 FEZ2 Homo sapiens fasciculation and elongation 4.93 
protein zeta 2 (zygin II) (FEZ2), mRNA. 
NM_000640 IL13RA2 Homo sapiens interleukin 13 receptor, alpha 2 4.92 
(IL13RA2), mRNA. 
AK021539 NCAGl Homo sapiens cDNA F U l 1477 fis, clone 4.91 
HEMBA1001746, weakly similar to Homo 
sapiens squamous cell carcinoma antigen 
recognized by T cell (SART-2) mRNA 
NM一006713 PC4 Homo sapiens activated RNA polymerase II 4.91 
transcription cofactor 4 (PC4), mRNA 
NM_152478 FLJ31030 Homo sapiens hypothetical protein FLJ31030 4.89 
(FU31030), mRNA 
AF039291 LOX Homo sapiens lysyl oxidase mRNA, complete cds 4.83 
NM_001323 CST6 Homo sapiens cystatin E/M (CST6), mRNA. 4.83 
NM_003794 SNX4 Homo sapiens sorting nexin 4 (SNX4), mRNA 4.80 
NM_001554 CYR61 Homo sapiens cysteine-rich, angiogenic inducer, 4.77 
61 (CYR61), mRNA 
NM_003588 CUL4B Homo sapiens cullin 4B (CUL4B), mRNA. 4.77 
NM_004301 BAF53A Homo sapiens BAF53 (BAF53A), mRNA 4.76 
NM_003336 UBE2A Homo sapiens ubiquitin-conjugating enzyme E2A 4.75 
(RAD6 homolog) (UBE2A), mRNA. 
NM_000110 DPYD Homo sapiens dihydropyrimidine dehydrogenase 4.73 
� (DPYD), mRNA. 
» AF151039 NCUBEl Homo sapiens HSPC205 mRNA, complete cds 4.72 
NM_152388 FLJ33282 Homo sapiens hypothetical protein FLJ33282 4.71 
(FU33282) , mRNA 
NM_024683 FLJ22729 Homo sapiens hypothetical protein FLJ22729 4.71 
(FU22729) , mRNA 
1 8 2 
NM—015480 PVRL3 Homo sapiens nectin 3 (DKFZP566B0846), 4.62 
mRNA 
NM_001822 CHN1 Homo sapiens chimerin (chimaerin) 1 (CHN1)’ 4.60 
mRNA 
NM_017542 KIAA1513 Homo sapiens KIAA1513 protein (KIAA1513), 4.58 
mRNA. 
NM_002710 PPPICC Homo sapiens protein phosphatase 1, catalytic 4.56 
subunit, gamma isoform (PPPICC), mRNA. 
NM_006934 SLC6A9 Homo sapiens solute carrier family 6 4.54 
(neurotransmitter transporter, glycine), member 9 
(SLC6A9), mRNA. 
NM_005746 PBEF Homo sapiens pre-B-cell colony-enhancing factor 4.50 
(PBEF), mRNA 
NM—014783 A R H G A P l l A Homo sapiens 1CIAA0013 gene product 4.48 
(ARHGAPl lA) , mRNA 
AF042838 MAP3K1 Homo sapiens MEK kinase 1 (MEKKl) mRNA, 4.46 
partial cds 
AF081567 PRKRIR Homo sapiens death associated protein 4 (DAP4) 4.45 
mRNA, complete cds 
NM一024900 Jade-1 Homo sapiens PHD protein Jade-1 (Jade-1 )， 4.45 
mRNA 
NM_030751 TCF8 Homo sapiens transcription factor 8 (represses 4.45 
interleukin 2 expression) (TCF8), mRNA. 
AB033038 FLJ 10392 Homo sapiens mRNA for KIAA1212 protein, 4.44 
partial cds 
NM_002006 FGF2 Homo sapiens fibroblast growth factor 2 (basic) 4.42 
(FGF2), mRNA. 
U03851 CAPZA2 Human capping protein alpha mRNA, partial cds 4.41 
AF220656 PHLDAl Homo sapiens apoptosis-associated nuclear 4.40 
protein PHLDAl (PHLDAl) mRNA, partial cds 
NM_001550 IFRDl Homo sapiens interferon-related developmental 4.40 
regulator 1 (IFRDl), mRNA 
NM—004442 EPHB2 Homo sapiens EphB2 (EPHB2), transcript variant 4.39 
. l , m R N A . 
NM_014345 HRIHFB2436 Homo sapiens endocrine regulator 4.33 
(HRIHFB2436), mRNA. 
NM_001379 DNMTl Homo sapiens DNA 4.33 
(cytosine-5-)-methyltransferase 1 (DNMTl) , 
1 8 3 
mRNA. 
NM_002618 PEX13 Homo sapiens peroxisome biogenesis factor 13 4.32 
(PEX13), mRNA. 
NM_031217 DKFZP434G2226 Homo sapiens hypothetical protein 4.31 
DKFZp434G2226 (D1CFZP434G2226), mRNA 
NM_000820 GAS6 Homo sapiens growth arrest-specific 6 (GAS6), 4.29 
mRNA. 
NM_002345 LUM Homo sapiens lumican (LUM), mRNA 4.29 
NM—005032 PLS3 Homo sapiens plastin 3 (T isoform) (PLS3), 4.28 
mRNA. 
NM_017782 FLJ20360 Homo sapiens hypothetical protein FLJ20360 4.27 
(FU20360) , mRNA. 
M34715 PSGl Human pregnancy-specific beta-1-glycoprotein 4.26 
mRNA PSG95, complete cds 
NM一006746 SCMLl Homo sapiens sex comb on midleg-like 1 4.26 
(Drosophila) (SCMLl) , mRNA. 
NM_058166 TRIM6 Homo sapiens tripartite motif-containing 6 4.26 
(TRIM6), mRNA 
NM_024604 FLJ21908 Homo sapiens hypothetical protein FLJ21908 4.26 
(FLJ21908), mRNA 
NM—016472 HSPC210 Homo sapiens hypothetical protein (HSPC210), 4.26 
mRNA. 
AB040916 KIAA1483 Homo sapiens mRNA for KIAAl483 protein, 4.25 
partial cds 
NM_000788 DCK Homo sapiens deoxycytidine kinase (DCK), 4.20 
mRNA. 
NM_001634 AMDl Homo sapiens S-adenosylmethionine 4.20 
decarboxylase 1 (AMDl) , mRNA. 
NM_014415 ZNF-U69274 Homo sapiens zinc finger protein (ZNF-U69274), 4.19 
mRNA. 
NM一016626 LOC51320 Homo sapiens hypothetical protein (L0C51320)， 4.18 
mRNA. 
AF131740 PCMF Homo sapiens clone 25030 mRNA sequence 4.15 
‘ AK024476 CHL12 Homo sapiens mRNA for F U 0 0 0 6 9 protein, 4.12 
partial cds 
U21128 LUM Human lumican mRNA, complete cds 4.12 
NM_003011 SET Homo sapiens SET translocation (myeloid 4.12 
leukemia-associated) (SET), mRNA 
1 8 4 
AL049943 DKFZP564F0522 Homo sapiens mRNA; cDNA DKFZp564F0522 4.12 
(from clone DKFZp564F0522) 
NM_003797 EED Homo sapiens embryonic ectoderm development 4.11 
(EED), mRNA 
NM_003318 TTK Homo sapiens TTK protein kinase (TTK), 4.09 
mRNA. 
AB023163 HYPH Homo sapiens mRNA for KIAA0946 protein, 4.09 
partial cds 
NM_130838 UBE3A Homo sapiens ubiquitin protein ligase E3A 4.07 
(human papilloma virus E6-associated protein, 
Angelman syndrome) (UBE3A), transcript variant 
l , n iRNA 
NM_014330 PPP1R15A Homo sapiens protein phosphatase 1, regulatory 4.07 
(inhibitor) subunit 15A(PPP1R15A), mRNA 
NM_018834 MATR3 Homo sapiens matrin 3 (MATR3), mRNA. 4.06 
NM_016545 IER5 Homo sapiens immediate early response 5 (IER5), 4.05 
mRNA. 
NM_032519 HT023 Homo sapiens hypothetical protein HT023 4.05 
(HT023), mRNA 
NM_016652 CRNKLl Homo sapiens Cm, crooked neck-like 1 4.04 
(Drosophila) (CRNKLl) , mRNA 
NM_006444 SMC2L1 Homo sapiens SMC2 structural maintenance of 4.04 
chromosomes 2-like 1 (yeast) (SMC2L1), mRNA. 
NM一004896 VPS26 Homo sapiens vacuolar protein sorting 26 (yeast) 4.03 
(VPS26), mRNA. 
AFO13759 CALU Homo sapiens calumein (Calu) mRNA, complete 4.02 
cds 
AB032953 0 D Z 2 Homo sapiens mRNA for KIAAl 127 protein, 4.00 
partial cds 
NM_022448 RGNEF Homo sapiens hypothetical protein FLJ21817 4.00 
similar to Rhoip2 (FLJ21817), mRNA 
Gene expression induced by lovastatin in M059K glioblastoma cells 
NCBI_ACC Gene Initials DESCRIPTION Fold 
‘ Changes 
NM_016270 KLF2 Homo sapiens Kruppel-like factor (LOC51713), 12.56 
mRNA. 
NM_001353 AKRICI Homo sapiens aldo-keto reductase family 1, 12.27 
member CI (dihydrodiol dehydrogenase 1; 
1 8 5 
20-alpha (3-alpha)-hydroxysteroid 
dehydrogenase) (AKRICI) , mRNA 
NM_004040 ARHB Homo sapiens ras homolog gene family, member 11.42 
B (ARHB), mRNA 
NM_025047 FLJ22595 Homo sapiens hypothetical protein FLJ22595 11.33 
(FU22595), mRNA 
NM_001631 ALPI Homo sapiens alkaline phosphatase, intestinal 9.96 
(ALPI), mRNA. 
NM_002275 KRT15 Homo sapiens keratin 15 (KRT15), mRNA 9.23 
NM_001305 CLDN4 Homo sapiens claudin 4 (CLDN4), mRNA. 8.13 
BC031573 NGEF Homo sapiens, neuronal guanine nucleotide 7.70 
exchange factor, clone MGC:35393 
IMAGE:5186132, mRNA, complete cds 
NM_002587 PCDHl Homo sapiens protocadherin 1 (cadherin-like 1) 6.77 
(PCDHl), transcript variant 1, mRNA. 
K03021 NULL Human tissue plasminogen activator (PLAT) 6.75 
gene, complete cds. 
NM_013230 CD24 Homo sapiens CD24 antigen (small cell lung 6.57 
carcinoma cluster 4 antigen) (CD24), mRNA 
NM_004089 DSIPI Homo sapiens delta sleep inducing peptide, 6.24 
immunoreactor (DSIPI), mRNA. 
NM_002250 KCNN4 Homo sapiens potassium intermediate/small 5.97 
conductance calcium-activated channel, subfamily 
N, member 4 (KCNN4), mRNA. 
NM—004723 ARHGEF2 Homo sapiens rho/rac guanine nucleotide 5.57 
exchange factor (GEF) 2 (ARHGEF2), mRNA. 
NM_007193 ANXAIO Homo sapiens annexin AlO (ANXAIO), mRNA 5.17 
NM_014147 HSPC047 Homo sapiens HSPC047 protein (HSPC047), 5.01 
mRNA 
NM_014509 dJ222E13.1 Homo sapiens serine hydrolase-like (SERHL), 4.60 
mRNA 
BI915338 NULL Human mRNA; cDNADKFZp761C10121 (from 4.44 
- clone DKFZp761C10121); complete cds. 
• NM_015916 LOC51063 Homo sapiens hypothetical protein LOC51063 4.38 
(LOC51063), mRNA 
AF217965 NULL Homo sapiens clone PP102 unknown mRNA 4.31 
NM_003202 TCF7 Homo sapiens transcription factor 7 (T-cell 4.22 
specific, HMG-box) (TCF7), mRNA. 
1 8 6 
AB058719 MAML3 Homo sapiens mRNA for KIAAl816 protein, 4.12 
partial cds 
NM_030657 LIM2 Homo sapiens lens intrinsic membrane protein 2 4.04 
(19kD) (LIM2), mRNA. 
NM_005130 HBP 17 Homo sapiens heparin-binding growth factor 4.01 
binding protein (HBP 17)，mRNA 
NM_000526 KRT14 Homo sapiens keratin 14 (epidermolysis bullosa 4.00 
simplex, Dowling-Meara, Koebner) (KRT14), 
mRNA 
NM_005397 PODXL Homo sapiens podocalyxin-like (PODXL), 3.98 
mRNA. 
NM_005574 L M 0 2 Homo sapiens LIM domain only 2 3.98 
(rhombotin-like 1) (LM02), mRNA 
AF131784 NULL Homo sapiens clone 25194 mRNA sequence 3.91 
NM_001490 GCNTl Homo sapiens glucosaminyl (N-acetyl) 3.84 
t ransferase 1，core 2 
(beta-1,6-N-acetylglucosaminyltransferase) 
(GCNTl) , mRNA 
NM_000527 LDLR Homo sapiens low density lipoprotein receptor 3.74 
(familial hypercholesterolemia) (LDLR), mRNA. 
AK024475 NULL Homo sapiens mRNA for FU00068 protein, 3.74 
partial cds 
NM_002405 MFNG Homo sapiens manic fringe homolog (Drosophila) 3.70 
(MFNG), mRNA. 
AK024270 NULL Homo sapiens cDNA FLJ 14208 fis, clone 3.67 
NT2RP3003264 
NM一005110 GFPT2 Homo sapiens glutamine-fructose-6-phosphate 3.61 
transaminase 2 (GFPT2), mRNA. 
AK024270 NULL Homo sapiens cDNA F U 14208 fis, clone 3.56 
NT2RP3003264 
NM_015916 LOC51063 Homo sapiens hypothetical protein LOC51063 3.46 
(LOC51063), mRNA 
NM_006829 APM2 Homo sapiens adipose specific 2 (APM2), 3.35 
‘ mRNA. 
Y12855 NULL Homo sapiens P2X7 gene, exon 12 and 13 3.33 
AL 157424 NULL Homo sapiens mRNA; cDNA DKFZp761E1512 3.33 
(from clone DKFZp761E1512) 
NM_000362 TIMP3 Homo sapiens tissue inhibitor of 3.30 
1 8 7 
metalloproteinase 3 (Sorsby fundus dystrophy, 
pseudoinflammatory) (TIMP3), mRNA 
NM_006033 LIPG Homo sapiens lipase, endothelial (LIPG), mRNA. 3.25 
NM_002961 S100A4 Homo sapiens SI00 calcium binding protein A4 3.22 
(calcium protein, calvasculin, metastasin, murine 
placental homolog) (S100A4), transcript variant 
l , m R N A 
NM_013974 DDAH2 Homo sapiens dimethylarginine 3.21 
dimethylaminohydrolase 2 (DDAH2), mRNA 
NM_004925 AQP3 Homo sapiens aquaporin 3 (AQP3), mRNA. 3.19 
NM_000104 CYPIBI Homo sapiens cytochrome P450, subfamily I 3.19 
(dioxin-inducible), polypeptide 1 (glaucoma 3， 
primary infantile) (CYPIBI) , mRNA. 
NM一012244 SLC7A8 Homo sapiens solute carrier family 7 (cationic 3.16 
amino acid transporter, y+ system), member 8 
(SLC7A8), mRNA. 
AF113511 NULL Homo sapiens integrin subunit alpha-2 (ITGA2) 3.15 
gene, ITGA2-2 allele, 3'UTR 
NM_003790 TNFRSF12 Homo sapiens tumor necrosis factor receptor 3.15 
superfamily, member 12 (translocating 
chain-association membrane protein) 
(TNFRSF12), mRNA 
NM_024642 FLJ21212 Homo sapiens hypothetical protein F U 2 1 2 1 2 3.14 
(FU21212) , mRNA. 
NM_006096 NDRGl Homo sapiens N-myc downstream regulated gene 3.13 
1 (NDRGl) , mRNA. 
AW888226 NULL MXRAl Homo sapiens cDNA 3.08 
BC032003 NULL Homo sapiens，clone MGC:21394 3.06 
. IMAGE:4754193, mRNA, complete cds 
NM_057179 DERMOl Homo sapiens likely ortholog of mouse and rat 3.04 
twist-related bHLH protein Dermo-1 (DERMOl) , 
mRNA 
BM690053 NULL UI-E-CKl-abr-c-12-O-UI.rl Homo sapiens cDNA 3.04 
> 5' end 
AB037855 KIAA1434 Homo sapiens mRNA for KIAA1434 protein, 3.03 
partial cds 
Gene expression reduced by lovastatin in M059K glioblastoma cells 
NCBI—ACC Gene Initials DESCRIPTION Fold 
1 8 8 
Changes 
NM_001565 SCYBIO Homo sapiens small inducible cytokine subfamily 12.33 
B (Cys-X-Cys), member 10 (SCYBIO), mRNA. 
NM_001901 CTGF Homo sapiens connective tissue growth factor 11.42 
(CTGF), mRNA. 
NM_002667 PLN Homo sapiens phospholamban (PLN), mRNA. 10.50 
NM_015224 RAP140 Homo sapiens KIAAl 105 protein (RAP 140), 9.29 
mRNA. 
NM_003238 TGFB2 Homo sapiens transforming growth factor, beta 2 8.56 
(TGFB2), mRNA 
NM_001554 CYR61 Homo sapiens cysteine-rich, angiogenic inducer, 8.23 
61 (CYR61), mRNA 
NM_013394 GLI0703 Homo sapiens acid fibroblast growth factor-like 7.58 
protein (GLI0703), mRNA 
NM_001485 GBX2 Homo sapiens gastrulation brain homeo box 2 7.51 
(GBX2), mRNA 
NM_002053 GBPl Homo sapiens guanylate binding protein 1, 6.59 
interferon-inducible, 67kD (GBPl) , mRNA 
NM_000173 GPIBA Homo sapiens glycoprotein lb (platelet), alpha 6.25 
polypeptide (GPIBA), mRNA. 
NM一014217 KCNK2 Homo sapiens potassium channel, subfamily K, 6.10 
member 2 (KCNK2), mRNA 
NM_014143 B7-H1 Homo sapiens B7-H1 protein (B7-H1), mRNA. 6.09 
AK026065 NMNAT Homo sapiens cDNA: FLJ22412 fis, clone 6.08 
HRC08458 
NM_006350 FST Homo sapiens follistatin (FST), transcript variant 5.99 
FST317, mRNA. 
NM_001993 F3 Homo sapiens coagulation factor III 5.97 
(thromboplastin, tissue factor) (F3), mRNA. 
NM_004982 KCNJ8 Homo sapiens potassium inwardly-rectifying 5.92 
channel, subfamily J, member 8 (KCNJ8), 
mRNA. 
NM二000692 A L D H I B I Homo sapiens aldehyde dehydrogenase 5 5.84 
’ (ALDH5), mRNA. 
NM_001822 CHN1 Homo sapiens chimerin (chimaerin) 1 (CHN1 )， 5.17 
mRNA 
NM_033274 ADAM 19 Homo sapiens a disintegrin and metalloproteinase 5.16 
domain 19 (meltrin beta) (ADAM 19), transcript 
1 8 9 
variant 2, mRNA. 
NM—031957 KRTAPl-5 Homo sapiens keratin associated protein 1.5 5.05 
(KRTAP1.5), mRNA 
NM_005409 C X C L l l Homo sapiens small inducible cytokine subfamily 5.04 
B (Cys-X-Cys), member 11 (SCYBl l ) , mRNA 
NM_001709 BDNF Homo sapiens brain-derived neurotrophic factor 5.03 
(BDNF), mRNA 
NM_000600 IL6 Homo sapiens interleukin 6 (interferon, beta 2) 4.97 
(IL6), mRNA. 
NM一022648 TNS Homo sapiens tensin (TNS), mRNA. 4.88 
NM_001824 CKM Homo sapiens creatine kinase, muscle (CKM), 4.67 
mRNA. 
NM_032043 BRIPl Homo sapiens BRCAl-interacting protein 1 4.66 
(BRIPl) , mRNA 
BC015417 MGC21981 Homo sapiens，clone MGC:21981 4.63 
IMAGE:4396073, mRNA, complete cds 
NM_002185 IL7R Homo sapiens interleukin 7 receptor (IL7R), 4.59 
mRNA 
NM_000337 SGCD Homo sapiens sarcoglycan, delta (35kD 4.52 
dystrophin-associated glycoprotein) (SGCD), 
mRNA 
NM_024563 FLJ 14054 Homo sapiens hypothetical protein FLJ 14054 4.41 
( F U 14054), mRNA 
AB037812 KIAA1391 Homo sapiens mRNA for KIAA1391 protein, 4.40 
partial cds 
NM_007088 CALB2 Homo sapiens calbindin 2, (29kD, calretinin) 4.40 
(CALB2), transcript variant CALB2c, mRNA. 
NM_001615 ACTG2 Homo sapiens actin, gamma 2, smooth muscle, 4.39 
enteric (ACTG2), mRNA 
BC015134 NULL Homo sapiens, clone IMAGE:3934391, mRNA 4.33 
NM_016147 PME-1 Homo sapiens protein phosphatase 4.31 
methylesterase-1 (PME-1), mRNA 
NM二016931 N 0 X 4 Homo sapiens NADPH oxidase 4 (N0X4) , 4.25 
‘ mRNA. 
NM_000916 OXTR Homo sapiens oxytocin receptor (OXTR), 4.23 
mRNA. 
NM_001175 ARHGDIB Homo sapiens Rho GDP dissociation inhibitor 4.19 
(GDI) beta (ARHGDIB), mRNA. 
1 9 0 
AFO10236 NULL Homo sapiens mRNA from chromosome 5q31-33 4.11 
region 
NM一016147 PME-1 Homo sapiens protein phosphatase 4.09 
methylesterase-1 (PME-1), mRNA 
NM_000800 FGFl Homo sapiens fibroblast growth factor 1 (acidic) 4.04 
(FGFl) , transcript variant 1，mRNA 
NM O 16206 L0C51159 Homo sapiens colon carcinoma related protein 4.03 
(LOC51159), mRNA. 
NM_004137 KCNMBl Homo sapiens potassium large conductance 4.02 
calcium-activated channel, subfamily M, beta 
member 1 (KCNMBl) , mRNA. 
NM_006622 SNK Homo sapiens serum-inducible kinase (SNK), 4.01 
mRNA. 
NM_001461 F M 0 5 Homo sapiens flavin containing monooxygenase 4.00 
5 (FM05) , mRNA. 
NM_025135 KIAA1695 Homo sapiens hypothetical protein FLJ22297 3.97 
(KIAA1695), mRNA. 
NM_002192 INHBA Homo sapiens inhibin, beta A (activin A, activin 3.88 
AB alpha polypeptide) (INHBA)，mRNA. 
NM一006403 HEFl Homo sapiens enhancer of filamentation 1 3.83 
(cas-like docking; Crk-associated substrate 
related) (HEFl) , mRNA. 
NM_003725 RODH Homo sapiens oxidative 3 alpha hydroxysteroid 3.79 
dehydrogenase; retinol dehydrogenase; 
3-hydroxysteroid epimerase (RODH), mRNA. 
NM_002467 MYC Homo sapiens v-myc myelocytomatosis viral 3.79 
oncogene homolog (avian) (MYC), mRNA. 
NM_016201 A M 0 T L 2 Homo sapiens Leman coiled-coil protein (LCCP), 3.76 
mRNA. 
AL049969 NULL Homo sapiens mRNA; cDNA DKFZp564A072 3.74 
(from clone DKFZp564A072) 
NM_006457 LIM Homo sapiens LIM protein (similar to rat protein 3.71 
’ kinase C-binding enigma) (LIM), mRNA. 
‘ NM_004657 SDPR Homo sapiens serum deprivation response 3.65 
(phosphatidylserine binding protein) (SDPR), 
mRNA. 
BCO 13577 CLDN11 Homo sapiens, claudin 11 (oligodendrocyte 3.64 
transmembrane protein), clone MGC:9232 
1 9 1 
IMAGE:3895040, mRNA, complete cds 
NM_002184 IL6ST Homo sapiens interleukin 6 signal transducer 3.62 
(gpl30, oncostatin M receptor) (IL6ST), mRNA. 
NM_014178 HSPC156 Homo sapiens HSPCl 56 protein (HSPC156), 3.62 
mRNA. 
NM_018288 XAP135 Homo sapiens PHD zinc finger protein XAPl 35 3.58 
(XAP135), transcript variant 1, mRNA 
NM_030915 LBH Homo sapiens hypothetical protein 3.57 
DKFZp566J091 (DKFZP566J091), mRNA 
NM_004120 GBP2 Homo sapiens guanylate binding protein 2, 3.47 
interferon-inducible (GBP2), mRNA. 
AK057634 NULL Homo sapiens cDNA FLJ33072 fis, clone 3.46 
TRACH2000243 
NM_005139 ANXA3 Homo sapiens annexin A3 (ANXA3), mRNA. 3.46 
AB033040 KIAAl214 Homo sapiens mRNA for KIAAl214 protein, 3.45 
partial cds 
NM_033138 CALDl Homo sapiens caldesmon 1 (CALDl) , transcript 3.45 
variant 1, mRNA 
NM_032876 JUB Homo sapiens hypothetical protein MGC15563 3.44 
(MGC15563)，mRNA 
NM_001449 FHLl Homo sapiens four and a half LIM domains 1 3.39 
(FHLl) , mRNA 
AK057236 NULL Homo sapiens cDNA FLJ32674 fis, clone 3.33 
TESTI1000142, highly similar to 
TRANSDUCIN-LIKE ENHANCER PROTEIN 4 
NM_031218 FLJ 12488 Homo sapiens hypothetical protein FLJ 12488 3.30 
(FU12488) , mRNA 
NM_031469 SH3BGRL2 Homo sapiens SH3 domain binding glutamic 3.28 
acid-rich protein like 2 (SH3BGRL2), mRNA. 
NM_006851 GLIPR Homo sapiens glioma pathogenesis-related 3.26 
protein (RTVPl) , mRNA 
NM_000237 LPL Homo sapiens lipoprotein lipase (LPL), mRNA 3.25 
NM二031426 FLJ 12783 Homo sapiens hypothetical protein FLJ 12783 3.25 
‘ ( F U 12783), mRNA 
NM_014549 DKFZP434P211 Homo sapiens DKFZp434P211 protein 3.24 
(DKFZP434P211), mRNA 
M24545 CCL2 Human monocyte chemotactic and activating 3.24 
factor (MCAF) mRNA, complete cds 
1 9 2 
NM_001211 BUB IB Homo sapiens BUBl budding uninhibited by 3.24 
benzimidazoles 1 homolog beta (yeast) (BUBIB), 
mRNA. 
AK000996 FLJ10134 Homo sapiens cDNA FLJ 10134 fis, clone 3.22 
HEMBA1003096 
D43639 ADM Human gene for preproadrenomedullin, complete 3.20 
cds (exon 1-4) 
NM_024728 C7orf 10 Homo sapiens chromosome 7 open reading frame 3.20 
10(C7orfl0) , mRNA 
BF089733 NULL CM2-HT0948-070900-368-d08 Homo sapiens 3.18 
cDNA 
NM_013262 MIR Homo sapiens myosin regulatory light chain 3.16 
interacting protein (MIR), mRNA. 
NM_032049 AGTRl Homo sapiens angiotensin receptor 1 (AGTRl) , 3.13 
transcript variant 5，mRNA. 
NM_001110 ADAM 10 Homo sapiens a disintegrin and metalloproteinase 3.12 
domain 10 (ADAM 10), mRNA. 
NM_016179 TRPC4 Homo sapiens transient receptor potential cation 3.11 
channel, subfamily C, member 4 (TRPC4), 
mRNA 
NM一003020 SGNEl Homo sapiens secretory granule, neuroendocrine 3.10 
protein 1 (7B2 protein) (SGNEl) , mRNA. 
NM_016441 CRIMl Homo sapiens cysteine-rich motor neuron 1 3.08 
(CRIMl), mRNA. 
NM_007064 TRAD Homo sapiens serine/threonine kinase with Dbl- 3.07 
and pleckstrin homology domains (TRAD), 
mRNA 
NM_002051 GATA3 Homo sapiens GATA binding protein 3 (GATA3), 3.06 
mRNA. 
» 
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